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Functionally distinct HMGB1 isoforms correlate with physiological 
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Background: Stevens Johnson syndrome (SJS) and toxic epidermal 
necrolysis (TEN) are serious, life threatening severe immune-mediated 
cutaneous reactions with mortality ranging from 10 to 30 %. The com-
monest causes are drugs. SJS/TEN is characterised by widespread epider-
mal detachment due to keratinocyte cell death. Increased concentrations 
of cytotoxic molecules may act as potential serum biomarkers of SJS/TEN. 
However, to date no mechanism based biomarker has been validated for 
diagnostic utility in this field. HMGB1 is a well-validated biomarker of cell 
death and inflammation. This study investigated whether HMGB1 repre-
sents a valid, utilisable biomarkers for drug-induced SJS/TEN.
Materials and methods: Serum samples from nevirapine-treated 
Malawian HIV patients (27 MPE, 12 DRESS, 12 SJS/TEN cases and 
matched tolerant controls) were analysed for total HMGB1 by ELISA. 
Novel mass-spectrometric protocols were also used to analyse post-
translationally modified forms of HMGB1. In addition serum from 20 
Taiwanese SJS patients (five carbamazepine, eight allopurinol, five 
phenytoin, two sulfamethoxazole) both during and post-reaction were 
analysed for HMGB1 isoforms.
Results: There was a significant elevation of mean total serum HMGB1 
at time of reaction in patients with nevirapine-induced MPE (6.0  ng/
ml), HSS (6.3  ng/ml) and SJS/TEN (15.9  ng/ml) compared to tolerant 
controls at weeks (1.3 ng/ml) (p < 0.001). Analysis of post-translationally 
modified isoforms of the HMGB1 in the different phenotypes (Fig.  1) 
showed patients with MPE and DRESS had elevation the acetylated 
form of HMGB1 which is a marker of innate immunity. By contrast, SJS/
TEN patient sera contained comparable levels of acetylated HMGB1, 
but also had very high levels of the non-acetylated form, which is asso-
ciated with cell death/tissue injury. The tolerant control patients had 
low levels of the unacetylated form. This pattern of HMGB1 isoform 
elevation was replicated in the Taiwanese SJS cohort. As patients recov-
ered, the total HMGB1 concentrations went down, although there was 
still significant elevation of the sulphonyl (partially reduced) HMGB1 
isoform which has no known immune function and may represent a 
marker of innate immunity returning to “steady state”.
Conclusions: In conclusion, our data suggest that post-translationally 
modified HMGB1 may represent mechanism-based diagnostic and 
prognostic markers for drug-induced SJS/TEN. This needs to be stud-
ied in more patients.
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Hypersensitivity reactions to beta‑lactams, does the t cell 
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Background: Worldwide, beta-lactam antibiotics can commonly cause 
hypersensitivity reactions (HR) with various clinical pictures from 
minor affections like maculopapular exanthema (MPE) and urticaria to 
severe cutaneous adverse reactions (SCAR) and anaphylaxis. Currently, 
two different concepts provide rational explanations how a drug can 
initiate a drug HR by activating human T cells—the hapten concept 
and the pharmacological interaction with immune receptor (p–i) con-
cept. In this study, we investigated the relationship between the reac-
tivity pattern of drug-reacting T cells found in the peripheral blood of 




Fig. 1 Serum levels of post‑translationally modified isoforms of 
HMGB1 in nevirapine treated patients at time of hypersensitivity reac‑
tion (2 weeks post commencement of treatment for tolerant patients)
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Materials and methods: We expanded beta-lactams reacting T cells 
from drug allergic individuals, including patients with typically IgE 
mediated hypersensitivity reactions such as urticaria or anaphylaxis as 
well as patients with T cell mediated reactions such as MPE and SCAR. 
The drug-reacting T cells were analyzed in terms of their phenotype 
(CD4+/CD8+) and the recognition pattern of AMX, e.g. hapten or p–i.
Results: From patients with type I HR to amoxicillin, T cell clones (TCC) 
could be generated and analysed. They showed amoxicillin reactivity 
according to the hapten mechanism: antigenic complexes were stably 
presented and antigen presentation machinery was essential for T cell 
activation. TCC from patients suffering from MPE showed similar fea-
tures. Three patients with DRESS to amoxicillin or ceftriaxone could be 
included. Drug reacting T cells from those patients showed exclusively 
reactivity according to pi-concept. Stimulatory antigenic complexes 
were not stably presented for T cell activation and addition of drug to 
TCC in the presence of antigenic presenting cells lead to immediate 
activation, measured by calcium intake.
Conclusions: We conclude that T cells from type I HR and MPE patients 
recognize beta-lactams according to the hapten mechanism. In con-
trast, in patients with SCAR, the p–i concept might also be relevant for 
beta-lactams recognition. Consequently, the current preclinical risk 
evaluation of new drugs to cause severe HR, which is solely based on 
their ability to form haptens, might be insufficient.
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Background: Nevirapine (NVP) is a non-nucleoside reverse tran-
scriptase inhibitor (NNRTI) associated with a hypersensitivity syn-
drome (HSR) in approximately 5 % of patients. Multiple class I/II HLA 
associations have been described in association with NVP hypersensi-
tivity reaction (HSR) phenotypes. Based on the established models of 
drug HSR which highlight the significance of the HLA peptide binding 
groove for specific drug interactions, we compared NVP HSR-asso-
ciated alleles across ethnic groups for similarities in peptide binding 
specificities and HLA binding pocket structure.
Materials and methods: HLA typing was performed on DNA from 
ClinicalTrials.gov NCT00310843. Univariate and multivariate analyses 
stratified for race were performed according to HLA class I/II alleles, 
MHCcluster groups and key HLA peptide binding groove amino acids.
Results: Examination of HLA allele peptide binding characteristics, 
together with structure of the B and F pockets in the peptide binding cleft 
identified a group of HLA-C alleles with common binding properties, and 
the same F pocket structure as HLA-C*04:01 that were predictive of cutane-
ous NVP HSR (HLA-C*04:(03/06/07), -C*05:(01/09), -C*18:01) (OR [95 % CI] 
2.9 [1.6–5.23], p = 0.005). Similarly, a group of protective HLA-B alleles with 
a characteristic B pocket was identified (HLA-B*15:(01/12/24/25/27/32/35), 
-B*52:01) (OR [95  % CI]  =  0.2 [0.07–0.5], p  =  0.0003). HLA-DRB1 alleles 
DRB1*01:(01/02/03), DRB1*04:(04/05/08/10), -DRB1*14:02) which share 
the DRB1-P4 pocket were found to associate with cutaneous NVP HSR (OR 
[95 % CI] 2.15 [1.23–3.24], p = 0.0013). Molecular docking suggests that 
NVP is able to bind to the B pocket in both HLA-B and HLA-C as well as the 
P4 residues in HLA-DRB1.
Conclusions: The cutaneous phenotypes of NVP HSR associates with 
different HLA-C, HLA-B and DR-alleles respectively that share peptide 
binding characteristics and binding pocket structure. Models suggest 
that NVP may bind directly to multiple HLA within the antigen binding 
cleft in the site normally occupied by peptide. The identified HLA-NVP 
interactions will have consequences for peptide binding and T cell 
receptor recognition in NVP HSR.
Keywords: Nevirapine; HLA; Peptide binding groove
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Background: Non-specific binding of IgE in in  vitro IgE allergy tests 
contributes to false-positive results. For ImmunoCAP it is stated that 
very low levels of allergen specific IgE (sIgE) should be evaluated with 
caution when total IgE (tIgE) >1000 kU/l. For β-lactams and chlorhex-
idine sIgE the warning limit is 500 kU/l. For 3gAllergy no such alerts are 
known. These warnings imply to measure tIgE for an interpretation of 
analytical results of at least ImmunoCAP sIgE. Goal of this study is to 
verify such warning limits for ImmunoCAP as well as 3gAllergy.
Materials and methods: Relationship between sIgE and tIgE was 
investigated for ImmunoCAP (Thermo Fisher) and 3gAllergy (Siemens) 
penicillin V sIgE as well as for ImmunoCAP chlorhexidine sIgE. Ves 
versus 5 sIgE was taken as the 1000  kU/l limit control. All tests were 
performed according the manufacturers’ instructions. Because Immu-
noCAP and 3gAllergy tIgE have a very strong correlation (r =  0.995), 
sIgE of both tests were graphically plotted against ImmunoCAP tIgE 
only. An iterative polynomial regression procedure, which excluded 
outliers when those after fitting were outside the 95  % confidence 
interval, was applied to check for the nature of a relationship.
Results: For ImmunoCAP penicillin V (r  =  0.900) and chlorhexidine 
(r = 0.888) strong polynomial relations were observed, while for Immu-
noCAP Ves versus five only very weak relations (r < 0.500) were noticed. 
For tIgE > 500 kU/l most of the penicillin V and chlorhexidine sIgE val-
ues were >0.10 kU/l and with increasing tIgE the number of sIgE values 
>0.35 kU/l increased. For 3gAllergy some results were >0.35 kU/l, but the 
majority of results was <0.10  kU/l and consequently insufficient data 
points were obtained for adequate regression. ImmunoCAP is based on 
high-capacity binding cellulose and at relatively high concentrations of 
tIgE, the frequency of possible false-positive results increases, especially 
for penicillin V and chlorhexidine sIgE. 3gAllergy is based on non-speci-
fied polymers attached to a bead, which is also subjected to false-posi-
tive results for penicillin V sIgE, but only at lower levels and frequency.
Conclusions: The warning limit of 500  kU/l of tIgE for ImmunoCAP 
penicillin V and chlorhexidine sIgE is valid and above the limit false-
positive results are likely. For 3gAllergy penicillin V sIgE a limit is also 
needed but at a higher level. Consequently, for the respective tests we 
do need to measure tIgE for any sIgE result >0.10 kU/l.
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Background: Anaphylaxis is a severe systemic allergic reaction that 
can be life-threatening. In about 85 % of cases evidence for the acti-
vation of the classical anaphylaxis pathway involving IgE and IgE 
receptors can be detected. Recently, an alternative pathway involv-
ing IgG and IgG receptors (FcγRs) on neutrophils has been suggested 
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by animal models. We hypothesized that such a mechanism may also 
exist in humans and studied this possibility in a multicentric prospec-
tive cohort of patients suspected of perioperative anaphylaxis to neu-
romuscular blocking agents (NMBA).
Materials and methods: Consecutive patients suspected of periopera-
tive anaphylaxis (n = 86 cases) were recruited and paired with 86 control 
patients. Blood samples were collected for cases and controls promptly 
after anesthesia induction. Extensive allergological testing was per-
formed 6–8 weeks after the reaction for cases. Circulating elastase, neu-
trophil extracellular traps (NETs), tryptase, histamine, and IgG and IgE 
anti-NMBA were measured by ELISA. FcγR expression on the major cell 
populations in the blood was analyzed by flow cytometry.
Results: We found higher circulating NETs and elastase levels during 
an anaphylactic reaction compared to controls. IgG anti-NMBA were 
found in both cases and controls, however for cases the IgG titer was 
associated with anaphylaxis severity. Finally, we show a significant 
decrease of FcγR expression specifically on neutrophils, pointing 
towards their engagement by immune complexes. This decrease not 
only correlated significantly with NET release but also with the severity 
of the anaphylactic reaction. Together, our results strongly suggest an 
activation of neutrophils by NBMA-IgG complexes during anaphylaxis.
Conclusions: We reveal for the first time the existence of an IgG-
dependent neutrophil activation pathway during anaphylaxis in 
human. This additional mechanism opens potential applications in 
anaphylaxis diagnostics and treatment.
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Background: Epidermal growth factor receptor tyrosine kinase inhibi-
tors (EGFR-TKIs) have been widely used to treat non-small-cell lung 
cancer (NSCLC). Skin toxicities related to EGFR-TKIs are common, such 
as acneiform eruptions, pruritus, xerosis, and paronychia. However, 
purpuric eruptions are rarely seen and only few cases reported. We 
conducted this study to classify the purpuric drug eruptions due to 
EGFR-TKIs (gefitinib, erlotinib, or afatinib) for NSCLC with clinic-path-
ological correlations.
Materials and methods: During January 2012 to August 2015, 32 
patients were included in this study. We recorded the characteristic, 
lag period, and also the peripheral platelet counts while biopsy. Skin 
biopsies with tissue culture were undertaken in every patients. DIF 
studies were performed in most of them.
Results: We classified the clinical presentations into four different types: 
purpura only (n = 7, 21.9 %), eczema craquelé-like (n = 5, 15.6 %), pus-
tulosis (n  =  16, 50  %), and necrolytic migratory erythema (NME)-like 
patches (n = 8, 25 %). Different types could be presented on the same 
patient concomitantly. 93 % (15/16) of pustulosis type specimens grew 
Staphylococcus aureus, whereas only 25  % (5/20) among other types. 
Most of the histopathology showed parakeratosis, hypogranulosis, 
perivascular lymphocytic and neutrophilic infiltration, endothelial cell 
swelling and RBC extravasation. Typical leukocytoclastic vasculitis (LCV) 
was found in 13–29  % of patients. Most of the DIF showed negative 
finding. Most of the patients were responsive to one-week systemic 
cefazolin treatment with or without discontinuing the EGFR-TKI.
Conclusions: There are four types of the purpuric drug eruptions due 
to EGFR TKIs: purpura, eczema craquelé-like, pustulosis, and NME-like 
patches. No significant histopathological differences between each 
group, and less than one-third of patients presented typical LCV. 
Staphylococcus aureus was the most common pathogen identified. 
Most of the patients showed dramatic improvement by the treatment 
of systemic antibiotics, especially those with pustulosis type.
Keywords: EGFR-TKIs; Purpura; Vasculitis; Staphylococcus
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Background: Anaphylaxis incidence in the perioperative setting varies 
between 1:10,000 and 1:20,000. Although this value is yet to be deter-
mined in Portugal, an increase in the number of reactions has been 
reported. Clinical evaluation is important in order to identify risk fac-
tors and drugs that cause anaphylaxis, so that alternative options can 
be found.
The aim of this study was to characterize the reactions of patients 
(pts) with perioperative anaphylaxis and for conducting medical tech-
niques requiring sedation.
Materials and methods: Retrospective analysis of medical records 
of 57 pts with perioperative anaphylaxis and anaphylaxis undergo-
ing medical procedures with sedation, observed in the immunoaller-
gologic outpatient clinic (2009–2015).
The diagnostic investigation was carried out 6–8 weeks after the reac-
tion, included detailed medical history, specific IgE assay to betalac-
tams and latex, skin tests (ST) with the culprit drug and evidence of 
provocation when necessary, according to the recommendations of 
the SFAR/ENDA.
Results: We studied 56 pts (41 females) with mean age of 50 ± 18 years.
Regarding the severity of anaphylaxis and according to Mertes classifi-
cation, 24 cases (42.8 %) had stage I reaction and 24 cases (42.8 %) had 
II reaction, 7 cases (12.5 %) grade III and 1 case (1.8 %) grade IV.
An IgE-mediated mechanism has been established in 34 pts (60.7 %). 
The major etiologic agents causing IgE-mediated reactions were mus-
cle relaxants in seven pts (12.5 %), antibiotics in six cases (10.7 %; four 
cefazolin, one aminopenicillin, one ciprofloxacin), metamizole in three 
pts (5.4 %), two pts latex (3.6 %), seven pts (12.5 %) reacted with less 
representative agents.
On 10 pts (17.8 %) drugs responsible for the reactions were associated 
with non-IgE-mediated mechanisms, anti-inflammatory (NSAIDs) are 
the most frequent agents (five pts).
In 14 pts (25  %) it was not possible to determine a pharmacological 
aetiology of the reaction.
Conclusions: More than half of perioperative events (60.7  %) have 
an IgE-mediated mechanism. Muscle relaxants, antibiotics and pat-
ent blue dye were the most frequently identified agents. In 17.8 % of 
the reactions was involved a non-IgE-mediated mechanism, namely 
NSAIDs. It is important to determine the aetiology of perioperative 
reactions for guidance in future surgery, either because the identified 
agents are often used outside the perioperative setting.
Keywords: Anaphylatic reactions; Anaesthesia
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Background: Chlorhexidine (CHX) and its diacetate derivative (CHA) 
are two forms of the same disinfectant for skin and mucosal surfaces 
as well as medical devices. CHX/CHA are bivalent compounds with 
biguanide groups and chlorophenyl endings. CHX/CHA can cause IgE-
mediated anaphylaxis. Alexidine (ALX), a related biguanide without 
aromatic end groups, has similar bactericidal properties and repre-
sents a potential substitute for CHX/CHA. The allergic potential of ALX 
is unknown.
Materials and methods: We investigated whether patients sensitized 
to CHX/CHA also react with ALX. We used blood of CHX/CHA-allergic 
donors for basophil activation testing (BAT for CD63 and CD203a as 
activation markers) with CHA and ALX. In addition, we performed inhi-
bition assays with CHA, chlorguanide (CG) and ALX using a commercial 
IgE assay for CHX (ImmunoCAP, ThermoFisher Scientific, Uppsala).
Results: 13 patients from a single tertiary care center with allergic 
reactions to CHX within the last 8 years were included. 9/13 patients 
had still elevated CHX-specific IgE (>0.35  kU/l), although mostly 
substantially lower compared to the time of anaphylaxis. In 6/13 
patients with CHX-specific IgE >0.7  kU/l CAP inhibition studies were 
performed. CG showed a strong inhibitory effect in 6/6 and CHA in 
3/6 tested sera. ALX induced partial inhibition of CHX positivity in 
2/6 sera but at much higher concentrations compared to CHA. 3/13 
patients showed a positive BAT with CHA, one of them with additional 
positivity to ALX.
Conclusions: Both, CAP inhibition studies as well as BAT analysis show 
that patients with documented CHX/CHA allergy do not or only par-
tially react with ALX in these IgE-based assays. Based on this limited 
cross-reactivity of CHX/CHA and ALX, ALX may be potential alternative 
for CHX-allergic patients. More patients need to be included to sub-
stantiate this assumption. An ALX-specific IgE assay would help to dif-
ferentiate CHX/CHA- and ALX-specific sensitization.
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Background: Anaphylaxis is defined as a serious generalized aller-
gic or hypersensitivity reaction that is rapid in onset and might 
cause death. It is very rare in infancy. In this case report, we present 
a neonate who developed anaphylaxis during infusion of first dose of 
cefotaxime.
Report: A-1  month infant was referred to our Pediatric Emergency 
Department because of anaphylactic reaction with rash, cyanosis and 
respiratory arrest developed after first dose of cefotaxime treatment. 
She was intubated immediately, then extubated after 10 min. Physical 
examination on admission showed prolonged expirium bilaterally, and 
rales at the right lung base. Other findings were unremarkable. She 
was hospitalized and treatment with salbutamol nebules (0.15  mg/
kg/dose, q 6  h) was started. Vital findings were observed closely. On 
the 4th day of admission, before discharge, she was consulted with 
our pediatric allergy department. She was born full term by Cesarean 
delivery, weighing 3180 g. Her personal and family history was unre-
markable, except her mother described rash and swelling of the lips 
and face after spraying cologne. Laboratory investigations on admis-
sion: CBC with white blood cell differential was within normal range; 
C-reactive protein (CRP): 1.35  mg/dl (0–0.34); serum total IgE: 2.4  U/
ml (0–170). Serum tryptase: 17.7 ng/ml (on the 4th day of admission); 
serum tryptase 12.3 ng/ml (after 2 months). Skin prick tests with cefo-
taxime (2 mg/ml), and cefotaxime (10 mg/ml) were both negative. We 
did not perform intradermal tests and drug provocation test with cefo-
taxime. The patient was discharged to be followed with prescription 
of epinephrine autoinjector to use in case of anaphylactic emergency, 
and the family was educated about about signs and symptoms of ana-
phylaxis and about when and how to use the EpiPen.
How this report contributes to current knowledge: Anaphylaxis 
in newborn period is very rare. Our case was interesting that to our 
knowledge this is the first case of anaphylaxis in a newborn induced 
by first dose of an antibiotic. We wished to attract attention that severe 
drug reactions can also be seen in early life. 
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Background: The Auckland Anaesthetic Allergy Clinic is jointly pro-
vided by the Departments of Anaesthesia and Immunology. All 
patients referred following perioperative anaphylaxis are skin prick 
tested with chlorhexidine 2  %. This review describes the clinical fea-
tures of the cases in which a diagnosis of allergic anaphylaxis to chlo-
rhexidine was made during the period January 2012 to December 
2015.
Materials and methods: Patient data and clinic test results were 
archived on a simple Excel spreadsheet. These were reviewed by the 
author and a chart review of the chlorhexidine anaphylaxis cases was 
undertaken.
Results: A total of 14 patients were diagnosed with chlorhexidine 
allergy during the period (11 male and 3 female).
The following manifestations of anaphylaxis were documented: hypo-
tension (12 patients), tachycardia (9), flushing (7), facial swelling (4), 
urticaria (3), bronchospasm (2), piloerection (2), agitation (1), gen-
eralized swelling (1). Four patients had CPR during their anaphylaxis, 
nine patients had a grade 3 reaction and one patient had a grade 1 
reaction. Twelve of the 14 patients received adrenaline. Anaphylaxis 
followed the insertion of a chlorhexidine impregnated central venous 
line in seven cases, urethral catheterization with chlorhexidine con-
taining gel in three and following topical exposure only in four cases.
Skin testing was performed 30–130 days after the anaphylaxis event.
All of the patients diagnosed with chlorhexidine allergy developed 
a wheal >3  mm after a s prick test with 2  % chlorhexidine (range 
3–20 mm). The specific IgE for Chlorhexidine was obtained in 11 of the 
14 cases and in 10 of the 11 it was elevated.
During the same period 219 other patients were seen at our clinic and 
all received skin prick tests for chlorhexidine 2 %. All of these patients 
had completely negative tests with a no wheal and no flare.
Conclusions: This data shows that patients with chlorhexidine ana-
phylaxis demonstrate typical signs but that hypotension is the most 
common manifestation. Convincing skin testing results along with 
specific IgE testing and the clinical history provided the basis of the 
diagnosis. Chlorhexidine is used in our region for skin preparation 
prior to anaesthetic and surgical procedures and four anaphylaxis 
cases resulted from topical exposure to chlorhexidine.
Our data also suggests that a skin prick test with 2 % chlorhexidine in 
alcohol is a satisfactory method of skin testing.
Keywords: Chlorhexidine; Skin prick testing; Specific IgE; Anaphylaxis
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Background: Drug-induced anaphylaxis (DIA) is the most common 
cause of fatal anaphylaxis. Anaphylaxis related to nonsteroidal anti-
inflammatory drugs (NSAID) is typically drug-specific or class-specific, 
as well as with beta-lactams (BL) antibiotics (AB). Although skin testing 
and drug provocation tests (DPT) can confirm the diagnosis, in severe 
cases the diagnosis is mostly based on clinical history. The aim of this 
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study was to characterize patients (pts) with DIA and their drug allergy 
work-up.
Materials and methods: Systematic review of all pts with clinical his-
tory compatible with DIA reported to our drug allergy center in the 
last 5 years. All pts were investigated according to ENDA/EAACI recom-
mendations, through skin testing and in vitro tests (whether standard-
ized tests available) and DPT (when indicated).
Results: A total of 114 pts were included: mean age 41.5 (SD ± 16.8) 
years, 10 % <18 years, 68 % female, 72 % atopic and 23 % had asthma. 
Median age of first anaphylactic episode was 36.5  years [1;74], and 
19 pts had recurrent DIA. The main causes were NSAID (50 pts) [ace-
tylsalicylic acid (15), ibuprofen (13), metamizol (13), diclofenac (9), 
paracetamol (3), etodolac, ketorolac and clonixin (one each)] and AB 
(46 pts) [BL (37), quinolones (4), macrolides (3), fosfomycin (1) and 
minocycline (1)]. Other drug agents found: neuromuscular blocking 
drugs (five pts), proton pump inhibitors (five pts), carboplatin (three 
pts), corticosteroids (two pts), local  anesthetics (two pts), ranitidine, 
midazolam and patent blue (1pt each). There was a predominance 
of mucocutaneous manifestations (96  %), followed by respiratory 
(80 %) and cardiovascular (45 %) symptoms. In 25 % of pts the reac-
tion occurred in hospital setting and 12  % had intraoperative ana-
phylaxis. DIA was supported in 72 pts (63 %), through skin tests in 62 
and the remaining by in vitro tests or DPT. Considering the severity of 
reactions and the lack of standardized tests for some drugs, patients 
whose DIA was based on clinical history were successfully challenged 
with alternative drugs.
Conclusions: NSAID and AB were responsible for the majority of DIA. 
Anaphylactic reactions were reported at any age. The heterogeneity of 
mechanisms involved, the severity of clinical reactions and the lack of 
standardized in vivo and/or in vitro tests do not allow to confirm the 
diagnosis in all cases. Patients with DIA should be evaluated in special-
ized centers in order to perform accurate diagnosis, to prevent recur-
rence and to find safe alternatives.
Keywords: Anaphylaxis; Drug allergy; NSAID; Antibiotics
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Background: Intraoperative anaphylactic reactions are a diagnostic 
challenge. The chronology of the administration of the multiple drugs 
and the beginning of the reaction are important in identifying the cul-
prit drug.
Patent blue V is a well known cause of perioperative anaphylaxis
This dye is a member of the triarylmethane family, which also includes 
isosulfan blue and methylene blue. Is used for staging breast cancer, 
identifying sentinel lymph nodes. The frequency of reactions is around 
0.24–1.1  %. It can be also found in food (food additive E-131) and 
cosmetics.
Report: We describe the case of a woman 65 years-old with a ductal 
carcinoma of the left breast, who suffered hypotension (85/60), 
bronchospasm with hypoxemia, urticaria, angioedema of the face, 
tongue and epiglottis after the administration through the nip-
ple of colorant patent blue V. Anaesthetic induction was done with 
fentanyl, propofol and rocuronium. Adrenaline, bronchodilators, 
antihistamines, corticosteroids and vasopressive drugs were admin-
istered, being admitted in the ICU. The levels of tryptase were 8.5 µg/
ml 20 min after the beginning of the reaction, 16.6 µg/ml at 2 h and 
3.23 µg/ml at 48 h.
One month after the reaction cutaneous tests were done, being posi-
tive for patent blue V (intradermal reaction at 1/10) and negative for 
suxamethonium, cis-atracurium, rocuronium, fentanyl, propofol, mida-
zolam, povidone-iodine and latex.
It was the first time the patient received this dye or any similar dye as 
a drug.
Intraoperative anaphylactic shock due to allergy to patent blue V was 
diagnosed.
The future use of this dye was prohibited and an advise to avoid stuff 
which contains this product was given to the patient.
A suspicion of sensitization through foods or cosmetics is possible as 
the patient reacted the first time she received this drug.
How this report contributes to current knowledge: This case con-
firms previous descriptions of reactions with patent blue V: reaction 
with the first exposition and severe allergic reactions, with hypoten-
sion and raise in tryptase levels. Cutaneous test are useful in the diag-
nostic and standardized concentrations have been described by ENDA.
Consent: Written informed consent was obtained from the patient for 
publication of this abstract and any accompanying images.
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Background: Kounis Syndrome (KS), the occurrence of acute coro-
nary events as consequence of allergic or hypersensitivity reactions 
has been described for years. It is still relatively unknown and conse-
quently underdiagnosed, leading to inadequate treatment and subse-
quent morbidity. There are three subtypes of KS: type I which occurs 
in patients without predisposing cardiovascular factors; type II which 
occurs in patients with cardiovascular risk factors; and type III by stent 
thrombosis.
Report: A 55 year old man, a smoker with type II Diabetes, was admit-
ted to our hospital for myocardial infarction (MI) after taking two pills 
of diclofenac 75 mg for left leg pain. He complained of immediate gen-
eralized pruritus, malaise, constrictive radiating chest pain, dyspnea, 
dizziness and sweating. He was assessed by the mobile medical team 
on site as being agitated, hypotensive (BP: 96/74  mmHg) and with 
generalized wheezing on chest auscultation. Aggressive fluid resuscita-
tion, nebulized salbutamol and IV corticosteroids improved his status 
on route to the ER; he was also treated with acetylsalicylic acid 250 mg 
and sublingual isosorbide dinitrate 5  mg. Epinephrine was not given. 
ECG confirmed NSTEMI with an elevated troponin I (0.59 ng/ml). Serum 
tryptase was not measured. He was admitted to the Coronary ICU 
and cardiac catheterization showed mild coronary artery disease. He 
recalled a previous reaction to diclofenac, with immediate generalized 
pruritus. The patient recovery was uneventful. He was then referred to 
our Drug Allergy Unit. Oral challenge with meloxicam 15 mg was nega-
tive and he was instructed to avoid NSAID’s other than meloxicam.
How this report contributes to current knowledge: MI in the set-
ting of anaphylaxis is underreported. Clinicians should be aware of this 
possible complication even in patients without cardiovascular risk fac-
tors in order to diagnose and treat it early. Also, the WAO Anaphylaxis 
guidelines recommend a minimum 4 h observation period after ana-
phylaxis, 8–10  h if there is respiratory or cardiovascular compromise 
during the reaction. This allows not only for detection and treatment 
of biphasic reactions, but also of secondary cardiovascular events.
Consent: Written informed consent was obtained from the patient for 
publication of this abstract and any accompanying images.
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Background: Perioperative anaphylaxis (PA) is a medical emergency, 
with potential for mortality. Skin testing (ST) of agents used in the 
perioperative period is considered the gold standard for the identifi-
cation of likely causative agents [1]. Neuromuscular blocking agents 
(NMBA) (58 %), antibiotics (12–15 %) and latex (16–19 %) are the most 
commonly implicated causative agents [1, 2]. Chlorhexidine allergy 
is also described although its prevalence is not well established and 
likely underreported [3, 4].
We conducted a retrospective audit of all patients who underwent 
ST and specific IgE testing (SpIgE) for investigation of a perioperative 
allergic event. We sought the proportion of patients who had a likely 
agent detected and the prevalence of likely causative agents in our 
cohort.
Materials and methods: Medical histories were reviewed for all 
patients referred for PA who underwent testing in our centre over a 
2-year period from September 2013 to August 2015. Data collected 
included severity grading [5], acute elevation in Mast cell tryptase 
(MCT) (>12  ng/ml or >135  % basal level), and causative agent indi-
cated by the presence of a positive ST or SpIgE to NMBA, latex, antibi-
otics or chlorhexidine. Results are expressed as n (%) and comparisons 
performed by Fisher’s exact test.
Results: Of 47 patients identified during this period, ST was posi-
tive in 22 (47 %), with NMBA and beta-lactam antibiotics accounting 
for 10 (42  %) and 7 (29  %) of positive results respectively. Of the 27 
patients with MCT results, 14/19 (73  %) patients with an acute MCT 
rise had positive skin or SpIgE tests, compared with only 1 (13  %) of 
8 patients with no reported MCT rise (P < 0.01). Over the same period, 
four patients (18 %) had positive SpIgE to chlorhexidine (range 0.43–
55.8kUa/l). Reactions graded as severe (Grade 3) were associated with 
an increased proportion of positive ST (16/31, 52  %) compared with 
Grades 1 and 2 (6/16, 38 %), however this result did not reach statisti-
cal significance.
Conclusions: The prevalence of causative agents reflects current lit-
erature, with an increased proportion of reactions to antibiotics, and 
decreased proportion to latex. Our audit indicated a significantly 
higher proportion of positive ST in those with acutely elevated MCT. In 
our cohort, chlorhexidine appeared to be a common allergen.
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Background: Allergy work-up to identify the causative agent in 
patients experiencing peri-operative anaphylaxis is challenging. 
Patients have multiple exposures over a short time period; Paper-
based records from remote hospitals are often unavailable to the aller-
gist; and diagnostic testing for many drugs is either unavailable or 
sub-optimal.
Report: A 56-year-old man with debilitating osteoarthritis required 
hip replacements in order to work. He had no chronic medical 
co-morbidities, but labeled penicillin allergy following a child-
hood reaction during prolonged antibiotics for osteomyelitis. He 
was referred for testing after three operations in a remote private 
South African hospital. Peri-operative anaphylaxis, confirmed with 
serial tryptase measurement, occurred in the 1st and 3rd surgeries. 
Possible offending agents included: propofol, midazolam, bupiv-
acaine, fentanyl, clindamycin and cyclokapron. Apparently, in the 
uneventful 2nd surgery, the drugs were the same except cycloka-
pron was omitted. Cleaning agents used were unknown. In vitro 
specific IgE testing was negative to latex but elevated (5.49  kUA/l) 
for chlorhexidine; Skin testing was positive with chlorhexidine and 
intradermal testing generated systemic symptoms and required 
treatment. CAST ELISA testing was negative to propofol and bupi-
vacaine. Clindamycin in  vitro testing was unavailable and in  vivo 
testing is not recommended. The likely offending agent was chlo-
rhexidine, and the patient was anxious to return to work, thus, 
although each anesthetic chart was not available for detailed 
review, repeat surgery proceeded. Unfortunately, he experienced 
recurrent anaphylaxis despite a chlorhexidine free theatre. Several 
months later the anesthetic charts from all four operations were 
acquired, and it was clear that an additional offending agent was 
likely clindamycin. Avoidance of both clindamycin and chlorhex-
idine resulted in a safe surgery. Subsequent testing allowed the 
patient to be ‘de-labeled’ as penicillin allergic.
How this report contributes to current knowledge: Dual sensitiv-
ity is described in about 2 % of peri-operative anaphylaxis cases. Thus, 
even if a possible causative agent is identified, it remains mandatory 
a conduct a detailed review of all anesthetic charts; however, this can 
pose a major challenge in countries were records remain paper-based. 
The use of alternative drugs in patients carrying a penicillin allergy 
label can carry significant morbidity.
Consent: Written informed consent was obtained from the patient for 
publication of this abstract and any accompanying images.
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Background: Fixed drug eruptions (FDE) are characterized by well-
demarcated skin and/or mucosal lesions beginning a few min-
utes to several hours after drug exposure and that reappear at the 
exact location on re-exposure to the offending drug. Aminopenicil-
lins are among those drugs most commonly associated with FDE. 
Non-pigmenting FDE (NPFDE) is an FDE type that leaves no residual 
pigmentation.
Report: The authors report the case of a non-atopic 5  years-old boy, 
presenting two reproducible episodes of cutaneous lesions (erythe-
matous pruritic plaques) located to the genital area, occurring a few 
hours after medication with amoxicillin for upper airways infection. 
The antibiotic was changed to a non-beta-lactam drug with progres-
sive symptoms resolution, leaving no residual skin pigmentation. There 
was a previous exposure to amoxicillin with tolerance. After the second 
episode, the child has already been medicated with a second genera-
tion cephalosporin (cefaclor) and tolerated this drug. Following the first 
evaluation in our Allergy Department, the child was assessed in the 
Drug Allergy Unit. No skin tests (intradermal with late reading) were 
performed due to age-related constraints. A controlled re-challenge 
with oral amoxicillin in the age-recommended intake-dose was per-
formed. Five hours after the end of oral challenge, the child began to 
develop a cutaneous exanthema and returned to the hospital for medi-
cal assessment as it was recommended. On physical examination, we 
observed swelling and erythematous plaques affecting the inferior part 
of penis, the scrotum and the perianal region; the child’s mother con-
firmed that the lesions presented the same location as that of the two 
previous episodes. Taking these findings into account, the final diag-
nosis was multiple fixed drug eruption. The child was treated with oral 
antihistamine and corticosteroid, with complete resolution in 3 days.
How this report contributes to current knowledge: To the authors’ 
knowledge, this is the third case reported of this type of drug eruption 
in the paediatric age.
Consent: Written informed consent was obtained from the patient for 
publication of this abstract and any accompanying images.
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Background: About 10 % of Portuguese children report to have had 
at least one adverse reaction to drugs and 6 % to be allergic to at least 
one drug, being the antibiotics the most frequent medication impli-
cated. The diagnostic investigation reveals that in 90 % of cases drug 
hypersensitivity is not confirmed, what is thought to be related to the 
high prevalence of infectious/viral rashes in childhood. Our aim was 
to evaluate the main reasons for referral to our pediatric drug allergy 
clinic, characterize the reactions mentioned by patients, particularly 
with regard to their sazonality and to analyse the results of the diag-
nostic investigation performed.
Materials and methods: Retrospective analysis of medical records 
from the pediatric patients followed in our department, in the last 
6 years, due to suspected drug hypersensitivity.
Results: We studied 364 children of whom 200 (55  %) were male. 
The median age at the time of the suspected reaction was 3.5 years 
(6 months–17 years). Antibiotics were the suspected drug in 84 % of 
cases (n = 305). In 75 % (n = 274) of patients the symptoms reported 
were only cutaneous (maculopapular eruptions or urticaria) and in 
72 % (n = 262) of cases the reaction was nonimmediate. Drug hyper-
sensivity was confirmed in 10 patients (3 %). The month in which the 
drug reaction occurred was identified by 51 % (n = 184) of patients. 
Sixty percent of the reactions occurred during winter–spring months. 
Viral serologies were performed on 74 patients who reported a 
recent reaction and positive results for at least one of the viruses 
studied were obtained in 14 patients (19  %—IgM) and 48 patients 
(65 %—IgG).
Conclusions: The majority of children studied due to suspected drug 
hypersensitivity reported cutaneous symptoms and nonimmedi-
ate reactions. Most reactions occurred before 3  years of age, which 
according to the literature, concerns the age when infectious rashes 
are more frequent. We verified a seasonal pattern in the occurrence 
of the suspected drug reactions that is similar to that described for 
the most common viral infections in childhood, while the peak for 
antibiotic consumption has been reported in autumn. Confirmation 
of hypersentisitivity to the suspected drug was possible in 10 of 364 
patients, while a possible viral etiology was documented in 14 of 74 
patients. Our findings reinforce the idea that many of the cutaneous 
reactions which motivate the study in our department are probably 
caused by infections and not by drug hypersensitivity.
Keywords: Children; Drug reactions
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Background: Surgery associated allergic reactions have been exten-
sively studied and culprit agents have been pointed on several 
reports. Nevertheless last decade changes in pharmacological proto-
cols resulted in the increase of possible implicated drugs. In the other 
hand, other invasive procedures (diagnostic/therapeutic) have been 
increasing in frequency and are also related to allergic events. Our aim 
was to seek for new agents involved in perioperative allergy as well as 
characterize reactions occurring due to other invasive procedures
Materials and methods: We reviewed the medical records of 28 
patients referred to our clinic for allergic reaction associated to an 
invasive procedure in the last 2  years regarding administered drugs, 
type of reaction and results of the allergological workup.
Results: In our study group, 21 were female and 7 male, mean age was 
54.7 years (2–84).
Fourteen were studied for procedures with general anesthesia related 
adverse events: six anaphylatic reactions, six urticaria/angioedema, 
one bronchospasm and one hypotension. Positive relevant results 
were obtained in 13 patients: one skin prick test (SPT) to metamizol, 
two intradermal skin tests (IDT) to midazolam, one to tramadol, three 
to ondansetron, one to rocuronium, one to atracurium, two to vecu-
ronium, two to metamizol, one basophil activation test (BAT) to meta-
mizol. One patient was positive to both to atracurium and vecuronium 
and one patient had no positive tests.
In nine patients reactions were associated to invasive procedures with 
local anesthesia. Positive results were one IDT and BAT to verapamil 
(anaphylaxis) and one patch test to iodixanol (maculopapular rash) 
in two patients submitted to coronary angiography. Six patients with 
adverse reactions during dental treatment and one during a carpal 
tunnel surgery had no positive tests.
Five patients had been submitted to procedures without use of any 
anesthetic: one with local erythema after an esteroid intra-articular 
infiltration had a positive patch test to betamethasone dipropionate; 
one with an anaphylactic reaction during a colonoscopy had a posi-
tive BAT to metamizol used as analgesic; one with acute urticaria after 
contrast injection for a thyroid TC had IDT positive to iomeprol. Two 
patients had a negative workup.
Conclusions: Comparing to previous published series ondansetron 
seems to be emerging as an important agent in perioperative allergy.
Invasive procedures other than major surgeries are associated to 
allergic reactions both immediate and non-immediate, some of them 
being severe.
Keywords: Perioperative allergy; Invasive medical procedures; Drug 
hypersensitivity
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Background: Beta-lactam antibiotics remain one of the most effective 
treatments of bacterial infections and are the most frequently pre-
scribed antibiotic in children. Allergic reactions to these antibiotics are 
common. Nevertheless, strategies for peadiatric antibiotic allergy test-
ing and management remain poorly defined, including issues around 
the need for skin testing prior to oral provocation challenges (OPC; 
2-dose) and the value of prolonged courses with the culprit antibiotic 
after the successful administration of an initial supervised dose.
Materials and methods: To address these issues, we performed a 
retrospective cross-sectional analysis of children (6 months–16 years) 
with an antibiotic allergy label who presented to a tertiary pediat-
ric hospital in Western Australia from 2006 to 2015. Data collection 
included results of skin prick (SPT), intradermal testing (IDT) and OPCs, 
outcome of 5-day antibiotic courses, type of initial reaction, confound-
ing illnesses and co-existing allergies. The data was analysed using 
Mann–Whitney U for continuous data and Fishers exact test for cat-
egorical data.
Results: We performed 207 beta lactam antibiotic tests in 172 chil-
dren. In 82 (39.6  %) cases OPCs were performed without preceding 
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skin testing (Group 1); three OPCs (3.7 %) were unsuccessful with one 
child with anaphylaxis. In 125 (60.4  %) cases skin testing was per-
formed (Group 2). Of these, 22 cases (17.6 %) were positive by SPT or 
IDT; these children were deemed to have confirmed antibiotic allergy. 
The remaining 103 cases proceeded to OPC; 4 (3.8 %) reacted to OPC, 
including two children with anaphylaxis. Finally, 152 cases (from Group 
1 or 2) received a 5 day course with the culprit antibiotic. This resulted 
in a rash in nine children (5.9 %) during the course. In both groups con-
founding illnesses, initial reaction, gender and co-existing allergies did 
not predict testing outcome.
Conclusions: In our cohort, the rate of allergy confirmed by skin test-
ing was significantly higher than for those who underwent a direct 
challenge (17.6 vs. 3.7 %). The rate of reactivity to OPC was compara-
ble for Group 1 and 2. These data further supports that performing 
direct supervised OPC with the culprit drug in children may be safe 
and potentially may avoid the need for resource intensive skin testing. 
Extended courses with the culprit drug should be considered, allowing 
confirmation of non-immediate reactions such as cutaneous reactions.
Keywords: Allergy; Antibiotic; Anaphylaxis
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Background: Patients or parents reported drug allergy in children is 
more common than the true drug allergy incidence. The aim of our 
study was to evaluate the clinical pattern of patient/parent reported 
drug hypersensitivity reactions and results of diagnostic evaluation.
Materials and methods: 15 children who were tested for drug allergy 
in 2015 were included in the study: eight boys (53.3 %) and seven girls 
(46.7  %), age range 1–15  years. We analysed causes, clinical pattern 
of reported drug hypersensitivity reactions and results of diagnostic 
evaluation.
Results: 26 drug hypersensitivity reactions were reported. Three drug 
hypersensitivity reactions were reported in four children, two reac-
tions—in three children. The main suspected drugs were antibiotics 
17 (65.4 %), NSAIDs—5 (19.2 %) cases, local anaesthetics—4 (15.4 %) 
cases. Amoxicillin was the most frequently suspected drug (six (23.1 %) 
cases). 8 (30.8 %) reactions appeared during 1 h. Skin symptoms were 
reported in 24 (92.3 %) cases: maculopapular rash—20 (76.9 %), angi-
oedema—5 (19.2 %) cases. Respiratory and cardiovascular symptoms 
were reported in two cases (7.7 %). Drug provocation test was positive 
only for one child, who experienced angioedema after nimesulide and 
ibuprofen intake, and drug provocation test was positive to ibuprofen.
Conclusions: The most common suspected drugs were antibiotics, 
especially amoxicillin. Skin was the most frequently affected and mac-
ulopapular rash was the most common symptom. Drug provocation 
test was positive only for one patient.
Keywords: Drug hypersensitivity; Chidren; Clinical pattern; 
Diagnostics
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Background: Delayed urticaria and maculopapular eruptions associ-
ated with antibiotics are the most common reasons for referral to our 
pediatric drug allergy clinic. In this context, several studies point to 
the limited usefulness of skin tests, even to b-lactam antibiotics, with 
some authors advocating the use of drug provocation test without 
the need for other previous diagnostic procedures. Our aim was to 
describe the cases followed in our department in which this diagnostic 
approach was used (exclusive drug provocation test).
Materials and methods: Retrospective analysis of medical records 
from children referred to our drug allergy clinic due to suspected 
hypersensitivity to antibiotics, who reported nonimmediate cutane-
ous reactions (urticaria or maculopapular eruption) without signs of 
severity or systemic involvement. All children underwent provoca-
tion test with the suspected drug without conducting previous skin 
tests. The drug provocation test was extended to include the number 
of days of treatment reported at index reaction. Data was collected 
regarding gender of patients, age at the drug reaction, drug involved, 
symptoms reported on the reaction and results of the drug provoca-
tion test.
Results: We evaluated 213 children of which 50  % (n  =  107) were 
male, with a median age of 3 years (6 months–17 years) at the time 
of reaction. In 97  % (n  =  206) of the cases the involved antibiotics 
were b-lactam (amoxicillin-clavulanic acid in 92 patients, amoxicil-
lin in 89 and cephalosporins in five cases). Only three children had 
positive drug provocations tests. In all cases the symptoms were 
similar to those previously reported and easily controlled with oral 
antihistamine.
Conclusions: Performing an exclusive drug provocation test in chil-
dren with suspected hypersensitivity to antibiotics, who present with 
nonimmediate cutaneous reactions without signs of severity, proved 
to be a safe and effective approach.
Keywords: Skin tests; B-Lactams; Diagnosis
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Background: Patients with a sulfonamide allergy or penicillins (PCN) 
may be at increased risk for reactions to other drugs. However, the 
studies were conducted in adults without PCN skin testing (PST) to 
confirm a PCN allergy. We conducted a study to determine if pediat-
ric patients with a history of PCN allergy and a positive PST were at an 
increased risk for multiple drug allergies.
Materials and methods: Children (<18  years) with a history of PCN 
allergy were evaluated with PST and reviewed for basic demographic, 
PST results, and other medication allergies listed in the allergy module 
in the electronic medical record. A univariate logistic regression analy-
sis was employed to calculate the odds ratio (OR) and the 95 % confi-
dence interval (CI). P value of 0.05 or less was considered statistically 
significant. The Institutional Review Board (IRB) approved the study.
Results: 778 children underwent penicillin skin test. 703 (90.4  %) of 
778 patients had a negative PST, 66 (8.5 %) were positive, and 9 (1.1 %) 
were equivocal. The overall mean  ±  standard deviation (SD) age of 
the study group was 5  ±  3.5  years. Three hundred and sixty-seven 
(47.1  %) were females. 703 children (90.4  %) had a negative PST, 66 
patients (8.5 %) positive PST, and 9 (1.1 %) equivocal PST. 181 (23 %) of 
778 patients reported a history of multiple drug allergies. Among the 
181 patients reporting a history of multiple drug allergies, 81 (45  %) 
were female and 100 (55  %) were male. Males were 1.6 times (95  % 
CI 0.8–1.6, p =  0.5) more likely than females to report multiple drug 
allergies, although not statistically significant. 14 (21 %) of 66 patients 
with a positive PST reported multiple drug allergies compared to 167 
(23 %) of 712 (p = 0.76) patients with a negative PST. Those patients 
with multiple drug allergies and a history of PCN allergy, cephalo-
sporin [15 % (114 of 778)] was the most common medication listed in 
the allergy module. Other medication listed in the medication allergy 
modules were 10 % (79) macrolide antibiotics, 9 % (71) sulfonamides, 
0.4 % (3) quinolones, and 1 % (9) nonsteroidal anti-inflammatory drugs 
(NSAIDS).
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Conclusions: PCN allergic pediatric patients may not be at an 
increased risk for multiple drug allergies. Among patients with a his-
tory of PCN allergy, cephalosporin, macrolide antibiotics and sulfona-
mide antibiotics were the most common drug allergies listed in the 
medication allergy module.
Keywords: Penicillin allergy; Multiple drug allergies; Risk
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Background: Adverse reactions to drugs are common problem, but 
true hypersensitivity to drug is rare.
Aim of the study: to investigate true hypersensitivity reactions 
among female and male with suspicion of drug allergy.
Materials and methods: 755 patients with suspicion of allergic reac-
tions to drugs were addressed to consultations in Pulmonology and 
Allergology center by general practitioners. Patients were divided 
into groups by sex and suspected drugs: I—Antibiotics (AB), II—
NSAID, III—Other. Each category was divided into subcategories: IA 
beta-lactam AB, IB Other AB; IIA ASA, IIB acetaminophen, IIC other 
NSAID; IIIA local anesthetics (LA), IIIB iodine containing contrasts 
(ICC), IIIC Other.
Results: 755 patients with 980 cases of suspected drug allergy were 
investigated: 618(81.85 %) females with average age 48.4(SD ± 15.2) 
and 137(18.15 %) males with average age 47.6(SD ± 18).
Female group had 821(83.8 %) adverse reactions to drugs. 199(24.2 %) 
reactions to I (AB): 151(75.9  %) were to beta-lactams, from all tested 
36(16.9  %) were true hypersensitivity; 46(23.1  %) reactions were 
to other-AB, from all tested reactions  4(9.1  %) were proved. 2(1  %) 
cases were not tested. Accordingly: II (NSAID) had 306(37.3  %) reac-
tions: to aspirin—56(18.3  %), 4(9.6  %) were proved; to acetami-
nophen—47(15.3  %), 12(40  %) were proved; IIC (Other-NSAID)—203 
(66.3  %), 29(19.2  %) were proved. III (Other) had 316(38.5  %) reac-
tions: IIIA (LA)—99(31.3 %), 1(1.5 %) was proved; IIIB (ICC)—20(6.3 %), 
2(15.5 %) were proved; IIIC (Other)—197(24 %), proved—19(15.4 %).
Male group had 159(16.2  %) adverse reactions to drugs. I (AB) had 
30(18.8 %) reactions: IA (beta-lactam)—25(83.3 %), from all tested reac-
tions 7(21.2 %) were proved. Accordingly: IB (other-AB)—5(16.6 %), all 
negatives. II category had 77(48.4 %) reactions: to aspirin—17(22 %), 
2(16.6  %) were proved; IIB (acetaminophen)—18(23.4  %), 2(11.8  %) 
were proved; IIC (other-NSAID)—42(54.5 %), DPTs proved 2(6.9 %). III 
category had 48(30.2 %) reactions: IIIA (LA)—16(33.3 %), 1(7.7 %) was 
proved; IIIB (ICC)—6(12.5, all negatives; IIIC (Other)—26(54.2 %), DPTs 
proved 4(22.2 %). NA—4(2.5 %).
Conclusions: Of all reactions true hypersensitivity were proved for: 
antibiotics—15.6 %, NSAIDs—20.2 %, other drugs—11.1 % in female 
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Background: Drug hypersensitivity reactions (DHR) is defined 
“unwanted and harmful reactions occurring to drugs prescribed dose” 
by World Health Organization (WHO). DHR is an important health 
problem because of causing life-threatening condition, extending the 
length of stay in hospital and increasing the cost of treatment.
The aim of this study was to determine the prevalence of self-reported 
DHR among students at the university.
Materials and methods: A structured questionnaire was carried out 
to students of Celal Bayar University in Manisa, Turkey.
Results: 2086 students have participated in our study. 1217 (58.3 %) 
of them were women, 869 (41.7 %) were male. The mean prevalance 
of self-reported DHR was 5.3 % (111/2086). Drug allergy incidence of 
students (male/female) was 3.5 and 6.7  %, respectively (p  <  0.001). 
The most common allergic reactions were rash 52.2  %, cardiovas-
cular reactions  12.6  % and respiratory reactions  11.7  %. Aforemen-
tioned two systems involvement were 23.4  %. The most frequently 
involved drugs were antibiotics 52.2 % (n: 58) and analgesics 24.3 % 
(n: 27).
Conclusions: The diagnosis of drug allergy is based on a detailed his-
tory of the onset of symptoms/signs’ relationship between the appear-
ance of symptoms and drug use. Misinterpretations just based on the 
DHR story can effect the individual treatment options. A definitive 
diagnosis can be easily reachable with a complete clinical history, 
standardized skin tests and drug provocation tests. Therefore we can 
recommend that doctors should be more informed about the man-
agements of DHR due to self-reported DHR is highly prevalant just like 
shown in this study.
Keywords: Drug hypersensitivity; Prevalence
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Background: Epidemiologic data on drug induced anaphylaxis (DIA) 
in pediatric age is lacking. The aim of this study is to define the actual 
rate of drug induced anaphylactic reactions in childhood together 
with the severity and culprit drug patterns.
Materials and methods: Patients with a history of drug hypersensi-
tivity reaction (DHR) referred between January 2012-December 2015 
were included. After filling out an European Network for Drug Allergy 
(ENDA) questionnaire, initial skin tests and/or provocation tests were 
performed for the offending drug. The severity of anaphylactic reac-
tions was determined as mild, moderate and severe according to 
EAACI guidelines on anaphylaxis in childhood.
Results: Among 627 children and adolescents referred due to a DHR, 
diagnostic work-up was completed in 532 patients. 103 (19.3  %) of 
them [54.4  % male, median age (interquartile range; 9.6  years (5.3–
13.3)] had anaphylaxis in the history and diagnostic tests revealed 
that 75 (14.1 % of all evaluated patients, 72.8 % of all patients with a 
DIA) of them were actually hypersensitive to the offending drug. The 
culprit drugs responsible from actual DIA were antibiotics (36  %), 
NSAIDs (22.7  %), chemotherapeutics (20  %), biologicals (6.7), anes-
thetic agents (5.3  %), enzyme therapy (4  %) and others. Majority of 
the patients with actual DIA reported moderate (38.7  %) and severe 
(37.3  %) drug induced anaphylactic reactions. History of chronic dis-
ease (44 vs. 17.9  %, p  =  0.014), concomitant intake of other drugs 
regularly (40 vs. 7.1  %, p =  0.001), cyanosis (23 vs. 3.6  %, p =  0.022) 
and hospitalization (56.2 vs. 17.9, p = 0.001) due to the suspected DIA 
and use of chemotherapeutics as the culprit drug (20 vs. 0 %, p = 0.01) 
were more frequent, whereas use of antibiotics was less frequent (71.4 
vs. 36 %, p = 0.001) in patients with actual DIA compared to nonhyper-
sensitive patients. Atopic disease, atopy or family history of atopy or 
drug hypersensitivity did not have an impact on actual DIA. It is impor-
tant to note that actual DIA was more frequent in children younger 
than 10 years of age compared to older adolescents (81.5 vs. 63.3 %, 
p = 0.038).
Conclusions: During childhood, any history of DIA reaction may 
not be an actual DHR, however young age, existence of chronic 
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disease and use of chemotherapeutics might point out the actual drug 
induced anaphylaxis in children and adolescents.
Keywords: Drug hypersensitivity; Anaphylaxis; Child; Pediatric
Poster Walk 3: Desensitisation (P20–P28)
P20 
A protocol for desensitisation to valaciclovir
Celia Zubrinich, Bianca Tong, Mittal Patel, Michelle Giles, Robyn O’Hehir, 
Robert Puy
Alfred Health, Melbourne, Australia  
Correspondence: Celia Zubrinich
Clinical and Translational Allergy 2016, 6(Suppl 3):P20
Background: We report a protocol for desensitisation to valaciclovir.
Report: A woman in her 40 s developed generalised urticaria on the 
second or third day of her initial course of acyclovir (administered five 
times daily) for newly diagnosed genital herpes. The urticaria contin-
ued to cause distress despite substitution to valaciclovir for a further 
few days.  Antiviral medication was ceased. The rash resolved over 
2 weeks with the use of anti-histamines. For more than a decade since 
then, she has experienced frequent and prolonged confirmed herpetic 
recurrences, more often present than not. The attacks had a marked 
viral prodrome and significantly affected her lifestyle.
Recurrent genital herpes may be treated with suppressive antiviral ther-
apy if frequent. Supervised direct challenge to valaciclovir was an option 
but desensitisation was favoured because it required a single clinic visit 
and, of relevance to the patient, likely entailed less risk. We identified 
reports of desensitisation to acyclovir but not valaciclovir. The final treat-
ment dose of acyclovir (usually 400 mg) differs from that of valaciclovir 
(500  mg). Acyclovir therapy requires multiple doses per day, whereas 
valaciclovir requires only a single daily dose. We developed and present 
a 14-dose oral desensitisation protocol that was administered over 3.5 h 
(Fig. 1). The first 10 doses were valaciclovir in suspension and the final 
four doses were prepared from a 500 mg tablet. The patient tolerated 
the procedure with no ill effect. There has not been a single herpetic 
recurrence in the 12 months since the treatment commenced.
How this report contributes to current knowledge: Desensitisation 
to valaciclovir may be performed where suppressive therapy for her-
pes is indicated.
Consent: Written informed consent was obtained from the patient for 
publication of this abstract and any accompanying images.
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Background: Modafinil is a 2-benzhydrylsulfinylethanamide mol-
ecule, belonging to a class of medications called wakefulness promot-
ing agents used to treat excessive sleepiness caused by narcolepsy 
(a condition that causes excessive daytime sleepiness) or shift work 
sleep disorder. Another use is to prevent excessive sleepiness caused 
by obstructive sleep apnea/hypopnea syndrome. It acts as a blocker of 
a type of molecule called the dopamine transporter. Rare occurrences 
including severe cutaneous adverse reactions, as erythema multi-
forme, SJS, TEN and DRESS, affecting adults and children and probably 
allergic, have been reported. Rare cases of angioedema and multi-
organ hypersensitivity reactions have also been described.
Report: The authors describe a case of a 27  year-old male with the 
diagnosis of narcolepsy medicated with modafinil 100  mg in an 
increasing dosage. Four days after beginning the medication, he com-
plained of generalized pruritus, maculopapular exanthema and angi-
oedema of upper and lower limbs. No analytical changes were found 
in the acute phase. He was treated with intravenous corticosteroid 
and antihistamines and, 4 days after complete recovery, the drug was 
re-introduced with reproducible signs and symptoms arising 12 h after 
the intake of 100 mg of modafinil. Because this was the only therapeu-
tic option for the patient he was referred to our Allergy Department 
for desensitization. A suspension of 1 mg/ml (100 mg/100 ml) was pre-
pared and a “tailor made” desensitization protocol was started with an 
initial dose of 1 mg, followed by doubling doses, taken with 1 h inter-
vals. The cumulative dose reached on the first day was 15 mg, 85 mg 
on the second and 100 mg on the third and fourth days. For safety rea-
sons, 100 mg/day were taken in the first week followed by an increase, 
to the intended doses (Neurology prescription) in the following weeks: 
100 + 100 mg on the second week, 100 + 200 mg on the third week 
and 200 + 200 mg on the fourth and on, as chronic treatment. After we 
have achieved tolerance to a dose of 100 mg, the slowly increase to the 
targeted dose of 200 mg twice a day was well tolerated. The patient is 
still on the same therapeutic scheme with no further reactions.
How this report contributes to current knowledge: As far as we 
know this is the first case describing a desensitization protocol to 
modafinil.
Consent: Written informed consent was obtained from the patient for 
publication of this abstract and any accompanying images.
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Background: Although desensitization in immediate type hyper-
sensitivity reactions due to chemotherapeutics is well described and 
standardized for many drugs, common protocols in delayed type 
hypersensitivity reactions (DHR) are not standardized. Our aim is to 
evaluate the usefulness of the 16-day desensitization protocol which 
we had recently described for capasitabine in DHRs caused by various 
oral chemotherapeutic drugs.
Materials and methods: We applied our slow desensitization proto-
col which started with 1/100 of the target dose and was completed in 
16 days with slow incremental doses in patients who had experienced 
DHR due to various oral chemotherapeutic drugs.
Results: Four patients (two female, two male) who were referred 
to our clinic for desensitization were included. The mean age was 
55  ±  22.25  years. The culprit drugs were pazopanib, nilotinib and 
lenalidomide. The mean reaction time after the initiation of the drug 
was 7.5 ± 2.08 days and the reaction types were maculopapular rush 
(MPR) in two patients and generalized morbiliform rushes (GMR) in 
two patients. Two patients who had experienced MPR caused by lena-
lidomide completed the protocols without any reactions. However, the 
other two patients developed pruritus and rush on the 9th and the 
15th days of the desensitization protocols. After the reactions were 
treated with methylprednisolone, the doses were decreased to the 
last tolerated doses and gradually increased afterwards. One of them 
completed the desensitization in 28 days. However, the second patient 
could tolerate almost the ¾ of the targeted dose.
Conclusions: This sixteen-day protocol seems to be a useful guide for 
the desensitization in delayed type hypersensitivity reactions espe-
cially in MPR in oral chemotherapeutics. However, the protocol can be 
modified in some patients.
Keywords: Delayed type hypersensitivity reactions; Desensitization
P23 
Desensitization to intravenous etoposide using a 12 and a 13‑step 
protocol. Two cases report
Olga Vega Matute1, Amalia Bernad1, Gabriel Gastaminza1, Roselle 
Madamba1, Carlos Lacasa2, M. J. Goikoetxea1, Carmen D’Amelio1, Jose 
Rifón3, Nicolas Martínez3, Marta Ferrer1
1Departament of Allergy and Immunology Clínica Universidad de Nav‑
arra, Pamplona, Spain; 2Department of Pharmacy Clínica Universidad de 
Page 11 of 35Clin Transl Allergy 2016, 6(Suppl 3):31
Navarra, Pamplona, Spain; 3Departament of Hematology Clínica Universi‑
dad de Navarra, Pamplona, Spain  
Correspondence: Amalia Bernad
Clinical and Translational Allergy 2016, 6(Suppl 3):P23
Background: Etoposide is a chemotherapy agent used to treat malig-
nant conditions. Because of the repeated use of this drug in within 
time intervals for cancer treatment, there is a high chance as with any 
chemotherapeutic agent to induce hypersensitivity reactions (HSR). It 
is reported to induce HSR in 6 % of the patients.
Report: We present two cases. First is a 7  year old female patient 
with acute myeloid leukemia (AML). She had previously received two 
courses of treatment with etoposide. In the second course, with the first 
administration she had a reaction consisted with facial erythema and 
severe dyspnea. When evaluated in our hospital, she needed treatment 
with etoposide for autologous stem-cell transplantation.  The second 
patient was an 8 year old male with refractory acute lymphoid leuke-
mia (ALL-B) that had received six doses of treatment with etoposide. In 
the last dose, he reported pharyngeal obstruction and chest erythema. 
When evaluated in our hospital, he needed salvage chemotherapy con-
taining etoposide followed by allogenic stem-cell transplantation.
We performed skin prick test with Etoposide, using commercially avail-
able drug solution for intravenous use. In both patients the test was 
negative.
Because Etoposide was the most suitable chemotherapeutic option 
for both patients, we decided to administer the drug using a desensi-
tization protocol. Castells (2) developed a protocol for desensitization 
to drugs with a 12 steps infusion of the target dose. In the first case 
we had to add one step to this protocol because of the dose needed. 
She received premedication treatment and 400  mg of Etoposide in 
a 13 steps protocol, twice in consecutive days. She had no HSR, the 
transplantation went well and she is now in complete remission.  In 
the second patient we followed the 12 step protocol with premedi-
cation treatment and the patient was able to receive the target dose 
(150 mg). We did three desensitization protocols with the total dose, in 
three consecutive days. He had no HSR and he continues in follow up 
in our hospital.
How this report contributes to current knowledge: Patients with 
HSR to etoposide, in which this drug is the most adequate chemother-
apeutic option for such a severe disease, the desensitization protocol 
is a treatment that proved to be effective in order to administer the 
treatment.
Consent: Written informed consent was obtained from the patient for 
publication of this abstract and any accompanying images.
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Background: Any cancer drug can potentially trigger a hypersensitiv-
ity reaction (HSR), particularly chemotherapy agents and monoclonal 
antibodies. The more frequent drugs inducing HSR are the platins 
(IgE-mediated reactions) and taxanes (non-immunological reactions). 
Desensitisation protocols must be considered when there is no valid 
and effective alternative treatment. This is especially relevant for can-
cer patients who are thus able to continue their first line treatment. 
The aim was  to describe the experience of an Immunoallergology 
Department with desensitization to chemotherapy agents.
Materials and methods: Retrospective review of charts of oncology 
patients desensitized in the Immunoallergology Department of CHUC 
in the last 5 years.
Results: There were a total of 72 desensitisation procedures cor-
responding to 15 patients treated (11 female) during the period in 
question, with a mean age of 56 years (range 28–73 years). The patients 
had ovarian cancer (eight patients), lung cancer (three patients), colon 
cancer (2), rectal cancer (1) and breast cancer (1). The HSR were all with 
moderate to severe immediate reactions: rash, urticaria, laryngeal stri-
dor, bronchospasm, syncope and anaphylaxis (six patients). Eleven 
patients were desensitized to platins (carboplatin n = 6, cisplatin = 3, 
oxaliplatin n  =  2), three to taxanes (docetaxel n  =  2, nabpaclitaxel 
n = 1) and one to monoclonal antibodies (panitumumab). In the total 
of 72 desensitisation procedures, the range of desensitisation proce-
dures for patient was 17 (maximum) to 2 (minimum) treatmens with 
carboplatin. There were five desensitisation procedures in 2011, 12 in 
2012, 19 in 2013, 18 in 2014 and also in 2015. In the 72 desensitisation 
did not have any reaction in 59 procedures (82 %) and in the others, 
the reactions were milder than the initial HSR (only one patient had 
anaphylaxis in the third desensitization with cisplatin). All patients 
received their daily programmed dose. Five patients discontinued 
the desensitization programme (three patients due to progression of 
the oncological disease, one patient due to neurological toxicity and 
another for anaphylaxis during de desensitization).
Conclusions: In the majority of patients, desensitization procedures 
allowed safe reBackground of chemotherapy agents in Immunoaller-
gology centers with experience. This approach must be considered by 
Oncologic doctors in the treatment of specific oncologic patients with 
previous history of HSR to these drugs.
Keywords: Drug desensitisation; Oncology; Chemotherapy agents; 
Platins; Taxanes
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Background: Filgrastim is a recombinant human granulocyte colony-
stimulating factor (G-CSF) and is used to prevent or treat neutropenia 
that is generally associated with chemotherapy. Anaphylatic reactions 
to filgrastim are rarely reported and there is only one published suc-
cessful desensitization protocol in a patient with immediate hypersen-
sitivity to filgrastim.
Report: We describe a case of a 47-year-old woman with ductal breast 
carcinoma receiving chemotherapy with doxorubicin, cyclophospha-
mide and docetaxel. She developed chemotherapy induced neutro-
penia for which she was started on SC filgrastim [300 mcg] days after 
the chemotherapy cycle, given once a day, for four consecutive days. 
Ten minutes after the 4th dose of filgrastim, she developed facial ery-
thema, labial angioedema, dyspnea and colicky abdominal pain. These 
symptoms quickly reversed spontaneously in 48  h. Subsequently, fil-
grastim was withdrawn and anaphylaxis work-up was done.
A 5-step desensitization protocol was performed using sequential 
doses intravenously: 15, 30, 60, 80, 115 to a cumulative dose of 300 
mcg diluted in 20 ml of saline over approximately 3 h. In the following 
day she received 300 mcg in two steps with success and in 3rd day in 
one without any reaction.
How this report contributes to current knowledge: In summary, we 
present a successful desensitization protocol for filgrastim in a patient 
with a previous life-threatening immediate hypersensitivity reaction.
Consent: Written informed consent was obtained from the patient for 
publication of this abstract and any accompanying images.
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Background: Mucopolysaccharidosis VI or Maroteaux-Lamy Syn-
drome (MPS VI) is a lysosomal storage disorder caused by deficiency of 
arylsulfatase B. The enzyme replacement therapy (ERT) with galsulfase 
is so far the only specific treatment for MPS VI. Infusion-related reac-
tions (IRR) to ERT can occur and can be severe, precluding further ERT. 
However, the interruption of ERT can accelerate the disease progres-
sion and precipitate earlier death. The aim of this study is to report IRR 
to galsulfase in a MPS VI Brazilian patient, and his treatment reestab-
lishiment after desensitization.
Materials and methods: a 7  year-old male started presenting 
symptoms such as dyspnea and itch during his 44th infusion. No 
improvement was observed with premedication (corticosteroids and 
antihistamines) in the folowing infusion. ERT were stopped for 4 weeks 
and the patient underwent skin tests (prick and intradermal). Skin 
prick test was performed using the straight concentration of galsulfase 
and Intradermal tests with progressive dilutions. Skin tests were also 
performed in 10 healthy subjects and in a MPS VI patient without IRR, 
to rule out a skin irritant effect, since skin tests with galsulfase have 
not been standardized.
Results: Patient presented a positive skin prick test, suggesting an 
IgE-mediated reaction. Therefore, a rapid desensitization protocol 
was generated. Three solutions (each 250  ml 0.9  % sodium chlo-
ride—1:100, 1:10 and 1:1 respectively) were delivered in 12 consecu-
tive steps at an increasing infusion rate. Pre-medications were used 
to block different allergy pathways. This protocol has succeeded for 
6 months, when during the 22th infusion he started to present wheals 
in the beginning of the third bag. A new protocol was developed (four 
bags—16 steps), but the patient still had symptoms. A 75 mg omali-
zumab (Omab) monthly was introduced. Ten days after the Omab, a 
new infusion using the same desensitization protocol was performed 
with no reaction.
Conclusions: To our knowledge, we are the first group to use an 
adapted 12-step desensitization protocol to galsufase with omali-
zumab. The protocol has shown to be safe and effective for the patient 
receiving the enzyme in the recommended dose. Management of 
these reactions with desensitization can provide first line therapy and 
permit continued ERT.
Keywords: Omalizumab; Desensitization
Consent: Written informed consent was obtained from the patient for 
publication of this abstract and any accompanying images.
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Background: Rapid drug desensitization (RDD) induces a tempo-
rary tolerance to biological drugs inducing hypersensitivity reactions 
(HSRs) but data are limited regarding use of this outside of the USA. 
Therefore in this study we aimed to report our data with RDD to rituxi-
mab, infliximab, cetuximab and trastuzumab.
Materials and methods: The study was conducted as a retrospective 
chart review of patients with symptoms of HSRs to biological agents to 
which RDD have been performed between January 2012 and January 
2016. HSRs were classified as Grade I, II and III based on their sever-
ity. Skin prick/intradermal tests were performed with implicated bio-
logicals. The 12-step RDD protocol developed at Brigham and Women 
Hospital was used
Results: Study group consisted of 11 female and four men (mean 
age: 54, 21 ± 11 years). Majority of the study subjects (66.6 %) were 
using the biological agents for the treatment of malign diseases. 
Twelve subjects had experienced HSR to rituximab, three had HSR to 
cetuximab, infliximab and trastuzumab respectively. HSR to cetuxi-
mab, infliximab and trastuzumab occurred during first infusion and 
all were Grade III, 11 of 12 subjects with rituximab hypersensitivity 
had reaction during first infusion, nine had Grade II and three had 
Grade III. Of the 15 patients, 86.6  % had respiratory symptoms, 
66.6 % had cardiovascular, 60 % had cutaneous symptoms, and 40 % 
had gastrointestinal symptoms. Skin tests with rituximab were done 
on eight patients, only three resulted in positive in 1/100 dilutions 
of intradermal tests, and skin tests were negative on either prick or 
intradermal tests with other biologicals. Of 88 RDD, 81 desensitiza-
tions with rituximab, five desensitizations with cetuximab, and one 
desensitization with infliximab and one desensitization with trastu-
zumab were done. There were nine breakthrough reactions (10.1 %) 
in seven subjects, which were all associated with rituximab and less 
severe than initial reactions. Of breakthrough reactions, 55.5 % were 
cutaneous, followed by cardiovascular (33  %), respiratory (22.2  %), 
and gastrointestinal (11.1  %) symptoms. Reactions mainly occurred 
at step 12, and all were successfully under-controlled and except sin-
gle desensitization, all desensitization procedures were completed 
with full target dose.
Conclusions: We found RDD is safe and effective, to our knowledge, 
in the largest series of biological including Rituximab in our country.
Keywords: Biologicals; Rituximab; Infliximab; Rapid drug 
desensitization
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Background: Delayed type hypersensitivity reactions are mediated by 
cells rather than by antibodies. They can be life-threatening and classi-
cally constitute a contraindication to desensitization (DZT). However, 
in selected cases of uncomplicated exanthemas, when the culprit drug 
is irreplaceable or more effective, this option might be considered. 
Methotrexate (MTX) is a folic acid antagonist with a major role in the 
treatment of B cell acute lymphoblastic leukemia (ALL). The authors 
describe a successful DZT to a high dose of IV MTX associated to inth-
rathecal administration, following a delayed-type hypersensitivity 
reaction.
Report: We report a case of a 12 year old boy under B cell ALL treat-
ment. He was scheduled to receive four cycles of MTX 8000  mg IV 
perfusion over 24 h (10 % on the 1st hour, 90 % over the remaining 
23 h, with a constant concentration), followed by inthrathecal admin-
istration of MTX 12 mg, cytarabine 30 mg and prednisolone 10 mg. 
He complained of an intensely pruritic morbilliform exanthema in 
his abdomen arising 72 h after completion of the first treatment. The 
rash resolved with anti histamines and oral and topic corticosteroids, 
over a period of 10 days with severe residual hyperpigmentation. No 
renal or liver function analytical changes were found during this epi-
sode. Because no alternative treatment was available for his specific 
type of leukemia, a decision to perform DZT was made.
The patient (60 kg) was pretreated with montelukaste 10 mg, starting 
2  days before chemotherapy (QT); prednisolone 60  mg was started 
the day before QT and maintained over 4  days in decreasing doses. 
He was admitted and a 14 step DZT protocol to MTX was performed. 
The doses administered were doubled in each step until the 14th 
step, with a cumulative dose of 1671 mg of MTX infused over a period 
of 4.5  h. The remaining dose, until the target dose of 8000  mg was 
infused at a small rate during 24.5 h. This procedure was followed by 
triple inthrathecal treatment, including MTX. The patient was able to 
reach the target dose without any reaction. He has now completed 3 
of the 4 scheduled cycles.
How this report contributes to current knowledge: To our knowl-
edge this is the first description of a successful DZT to such a high 
dose of MTX in a delayed type reaction. The IV DZT protocol also made 
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possible the administration of inthrathecal MTX. Our findings support 
that DZT protocols might be suitable in selected cases, allowing these 
patients to safely continue with first line therapy.
Consent: Written informed consent was obtained from the patient for 
publication of this abstract and any accompanying images.
Poster Walk 4: SJS (P29–P38)
P29 
Assessment of impact of infection on drug‑induced severe 
cutaneous adverse reactions and rhabdomyolysis using the 
Japanese adverse drug event report database
Kimie Sai1, Takuya Imatoh1, Ryosuke Nakamura1, Chisato Fukazawa2, 
Yasushi Hinomura2, Yoshiro Saito1
1National Institute of Health Sciences, Tokyo, Japan; 2Japan Pharmaceuti‑
cal Information Center, Tokyo, Japan  
Correspondence: Kimie Sai
Clinical and Translational Allergy 2016, 6(Suppl 3):P29
Background: Involvement of immune-mediated mechanism has 
been demonstrated in a certain type of serious adverse drug reactions 
(ADRs), such as severe cutaneous adverse reactions (SCAR) or rhab-
domyolysis (RM), and thus, a possible potentiation of these ADRs by 
infection via activating immune reactions is postulated. In this study, 
to assess a role of infection in occurrence and severity of SCAR and 
RM in Japanese cases, we analyzed a relation of infection to reporting 
rates of these ADRs and severe outcomes or periods to onsets using 
the Japanese Adverse Drug Event Report database (JADER).
Materials and methods: A total of 302,641 reports regarding primary 
suspected drugs from 2009 to 2013 in JADER were used in our analy-
sis. Of these, a total of 3167 SCAR reports (Stevens–Johnson syndrome, 
toxic epidermal necrolysis (TEN), or mucocutaneous ocular syndrome) 
and 1847 RM reports were included. Infection-Positive (Infect-P) was 
defined if the individual case report included data on anti-infectious 
drugs or infection-related diseases, either as a primary suspected drug 
(PS) or concomitant drugs/diseases (CO). Rates of infections for SCAR 
or RM among total reports, and ratios of severe phenotype (TEN for 
SCAR) and severe outcomes (no recovery, permanent damage and 
death) and period to onset of SCAR or RM were compared between 
Infect-P and Infection-Negative (Infect-N).
Results: The reporting ratios for Infect–P (vs. Infect-N) were signifi-
cantly higher in SCAR (adjusted odds ratio [95 % CI]: 1.8 [1.7–2.0] for PS 
and 2.0 [1.8–2.2] for CO, respectively) and lower in RM (0.6 [0.5–0.7] for 
PS and 0.8 [0.7–0.9] for CO). The rate of TEN in SCAR was significantly 
higher in Infect-P (vs. Infect-N) (1.3[1.1–1.6] for PS and 2.2 [1.8–2.7] for 
CO). Higher rates of severe outcomes by Infect-P (vs. Infect-N) were 
observed for SCAR (1.6 [1.2–2.1] for PS and 1.9[1.4–2.5] for CO) and RM 
(1.3 [0.8–2.2] for PS and 1.7 [1.0–2.3] for CO). The mean period to onset 
of SCAR was shorter for PS (25 days) but marginal for CO (40 days) in 
Infect-P comparing with Infect-N (36  days), and earlier onset of RM 
was evident in Infect-P (47 days for PS and 191 days for CO) comparing 
with Infect-N (250 days).
Conclusions: This study indicated a substantial association between 
infection and occurrence/severity in SCAR as well as RM, showing 
much larger impacts on SCAR.
Keywords: Severe cutaneous adverse reactions; Rhabdomyolysis; 
Infection; Database
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Background: Erythema multiforme (EM) and severe cutaneous 
adverse reactions (SCARs) are immunologically-mediated delayed 
hypersensitivity reactions triggered after exposition to external agents 
such as drugs. We aim to characterize hospitalizations occurring in 
Portuguese public hospitals with associated diagnosis of drug-related 
EM and SCARs concerning patients’ demographic and clinical charac-
teristics, in-hospital mortality and most frequently associated drug 
classes.
Materials and methods: We used a database containing all hospitali-
zations occurred in mainland Portugal public hospitals and analyzed 
all episodes with associated diagnosis of drug-related EM or SCARs—
Stevens–Johnson syndrome (SJS), toxic epidermal necrolysis (TEN) and 
SJS/TEN overlap syndrome. These hospitalizations were compared 
concerning patients’ demographic and clinical characteristics (gender, 
age and comorbidities), length of stay, and in-hospital mortality. We 
also evaluated the drug classes most frequently associated with these 
diagnoses, estimating the number of episodes per million drug pack-
ages sold. A logistic regression was performed to evaluate for factors 
significantly associated with in-hospital mortality among SCARs.
Results: Between 2009 and 2014, there were 122 hospitalizations 
with associated diagnosis of EM and 132 with associated diagno-
sis of SCARs. Most EM (65 %) and SCARs (55 %) episodes occurred in 
women. The median age was 63  years old for both EM and SCARs. 
The frequency of HIV co-infection was higher among SCARs episodes 
(9 vs. 2 %; p = 0.009). In-hospital mortality varied between 7 % (EM) 
and 44  % (TEN). Advanced age (OR 1.06; 95  % CI 1.02–1.45), heart 
failure (OR 4.93; 95  % CI 1.01–23.99), liver disease (OR 7.39; 95  % CI 
1.07–51.02) and TEN diagnosis (OR 14.66; 95 % CI 1.73–124.31) were all 
significantly associated with higher risk of in-hospital mortality among 
SCARs episodes. The highest numbers of EM and SCARs episodes per 
million drug packages sold concerned antiviral (1.5 and 8.7, respec-
tively) and uric acid metabolism drugs (2.4 and 5.0, respectively).
Conclusions: SCARs are associated with higher mortality than EM. 
Advanced age, heart failure, liver disease and TEN diagnoses are 
associated with higher in-hospital mortality among SCARs episodes. 
Antiviral and uric acid metabolism drugs are the drug classes most fre-
quently associated with SCARs hospitalizations.
Keywords: Erythema multiforme; Severe cutaneous adverse reactions; 
Epidemiology; Stevens–Johnson Syndrome; Toxic epidermal necrolysis
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Background: Immunological mechanisms are supposed to be 
involved in the pathogenesis of certain types of serious adverse reac-
tions (ADRs), such as severe cutaneous adverse reactions or rhabdo-
myolysis. Therefore, infection which activates immune system may 
affect incidence and severity of ADRs. In this study, we analyzed an 
association of concomitant infectious diseases with incidence/severity 
of Stevens–Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN) 
and myopathy, based on Japanese voluntary case reports.
Materials and methods: Patients who experienced SJS/TEN (259 
cases) or myopathy (a total of 129 cases) were recruited through 
a nationwide blood sampling network in Japan operated by the 
National Institute of Health Sciences under a cooperation of the Min-
istry of Health, Labour and Welfare, Pharmaceuticals and Medical 
Devices Agency, and Federation of Pharmaceutical Manufacturers’ 
Association of Japan. Written informed consent was obtained from all 
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recruited patients. Using the case report data, we analyzed rates for 
concomitant infectious disease (tuberculosis, hepatitis, AIDS, influenza 
infection, and herpes simplex infection, etc.), and compared the sever-
ity (severe phenotypes or outcomes) and the mean period to onset of 
the ADRs between patients with and without infectios diseases.
Results: For SJS/TEN cases, the rate of infectious diseases was 51 %, of 
which 31  % was the cases caused by a primary suspected drug. The 
rates of severe phenotype TEN, ocular involvement and permanent 
damage were significantly higher (p  <  0.05) and the mean period of 
onset of SJS/TEN was significantly shorter in the infectious patients’ 
group compared with non-infectious group. The rate of infectious dis-
eases in myopathy was 23 %, of which 12 % was the cases caused by 
a primary suspected drug. The rates of severe phenotype and perma-
nent damage were higher and the mean period of onset of myopathy 
was shorter in the myopathy patients with infectious disease than 
those without infection, although these differences were not statisti-
cally significant.
Conclusions: This study indicated that the incidence and the severity 
of SJS/TEN and myopathy are associated with the concomitant infec-
tious disease, especially in the cases of SJS/TEN, which might reflect a 
greater contribution of immune system as a mechanism of occurrence.
Keywords: SJS; TEN; Myopathy; Infection; Adverse reaction
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Background: Stevens–Johnson syndrome (SJS) and toxic epidermal 
necrolysis (TEN) are rare, but life-threatening adverse drug reactions. 
While the clinical manifestations of SJS/TEN are well-defined, the opti-
mal treatment for these diseases remains unavailable. We aim to evalu-
ate the efficacy and safety of etanercept (anti-TNF-α agent) in patients 
with SJS/TEN.
Materials and methods: We enrolled 98 patients with SJS/TEN to per-
form an open, prospective, double-blind and randomized comparison 
trial of etanercept versus corticosteroid. We further investigated the 
immunologic effects of etanercept in SJS/TEN patients.
Results: This study demonstrated that etanercept had clinical 
improvements in patients with SJS/TEN. Etanercept revealed to 
be more decreased the SCORTEN-based predicted mortality rate 
(predicted rate  =  17.47  %; observed rate  =  8.33  %) than in corti-
costeroid use (predicted rate = 20.13 %; observed rate = 15.91 %). 
Compared with corticosteroid, etanercept also showed a shorter 
skin healing time (The median times are 14 days for etanercept and 
17 days for corticosteroid; P < 0.05*) and less side effect for gastroin-
testinal hemorrhage (0 % after etanercept use and 11.8 % after cor-
ticosteroid use; P < 0.05*) in total SJS/TEN patients. For mechanism 
study, etanercept significantly decreased the granulysin and TNF-α 
expression in blister fluids and plasma (In blister fluids: granuly-
sin =  62.5  % and TNF-α =  50.0  % decrease after 2  days treatment; 
in plasma: granulysin = 54.7 % and TNF-α = 69.2 % decrease after 
15 days treatment, all P < 0.05*) and increased Treg cells population 
(twofold percentage increase after 15  days treatment, P  <  0.01**) 
(Fig. 2).
Conclusions: This study indicates that etanercept (anti-TNF-α agent) 
not only has immunosuppressive effects but also serves as an alterna-
tive medicine for SJS/TEN treatment.
Consent: Written informed consent was obtained from the patient for 
publication of this abstract and any accompanying images.
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Background: Stevens–Johnson syndrome (SJS)/toxic epidermal 
necrolysis (TEN) is rare, but the most severe of all adverse drug reac-
tions due to a high mortality, which is almost 50 % in TEN. Good evalu-
ation of risk factors is essential for efficient pharmacovigilance.
Materials and methods: From January 2003 to December 2012 the 
international Registry of Severe Cutaneous Adverse Reactions (RegiS-
CAR) included 1096 cases of SJS/TEN collected in seven countries 
(France, Germany, Israel, Italy, Netherlands, Spain, United Kingdom). 
The diagnoses and dates of onset were validated by an expert group, 
blinded for any information on exposures. Causality was established 
by using the specific algorithm ALDEN that had previously shown a 
good correlation with the results of a case–control analysis in an ear-
lier systematic collection of several hundred cases.
Fig. 2 The clinical improvement in SJS/TEN patients after etanercept 
treatment
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Results: In terms of overall causality assessment, at least one medi-
cation was evaluated as the «probable» or «very probable» cause in 
744/1096 cases (68 %). A medication cause was determined as «pos-
sible» in 209 cases (19  %), as «unlikely» in 68 cases (6.2  %) and “very 
unlikely” in 57 cases (5.2 %). 18 patients (1.6 %) denied any exposure 
to medications. The five medications most often incriminated («proba-
ble» or «very probable» causality) were allopurinol (n = 187; 17 %), sul-
famethoxazole (n = 80), lamotrigine (n = 76), carbamazepine (n = 51), 
phenytoin (n = 42). There were substantial differences between reac-
tions developing among hospitalized and community patients, e.g. 
older age, exposure to a substantially higher number of drugs and a 
noticeable role for metamizole among inhospital cases in Germany. In 
both groups (inhospital and community cases) we identified a signal 
for proton pump inhibitors.
Conclusions: In spite of prior warnings in medical journals and 
towards regulatory agencies, allopurinol is still the principal cause 
of SJS/TEN in Europe, as it was 10 years ago. Off-label prescription of 
allopurinol for asymptomatic hyperuricemia has not decreased. Sul-
famethoxazole and other anti-infective sulfonamides are still frequent 
inducers of SJS/TEN. Lamotrigine is now the third cause and the first 
one among antiepileptic drugs, independent of new indications such 
as bipolar disorder. Finally, it is important to note that at least 13 % of 
SJS/TEN-cases have no drug cause.
Investigation of other possible causes of such «idiopathic cases», e.g. 
infections, should be a priority.
P34 
Long‑term sequelae in patients with Stevens–Johnson syndrome 
and toxic epidermal necrolysis: a 5‑year analysis
Maren Paulmann1, Carmen Kremmler1, Peggy Sekula2, Laurence 
Valeyrie‑Allanore3, Luigi Naldi4, Sylvia Kardaun5, Maja Mockenhaupt1
1Dokumentationszentrum schwerer Hautreaktionen, University Medical 
Center, Freiburg, Germany; 2Institute of Medical Biometry and Medical 
Informatics, University Medical Center, Freiburg, Germany; 3Reference 
Center for Toxic and Autoimmune Blistering Diseases, Hopital Henri 
Modor, University Paris‑Est, Créteil, France; 4Department of Dermatol‑
ogy, Papa Giovanni XXIII Hospital, Bergamo, Italy; 5Reference Center 
for Cutaneous Adverse Reactions, University Medical Center, Groningen, 
The Netherlands  
Correspondence: Maren Paulmann
Clinical and Translational Allergy 2016, 6(Suppl 3):P34
Background: Stevens–Johnson syndrome (SJS) and toxic epidermal 
necrolysis (TEN) are rare, but severe reactions with blisters and ero-
sions of skin and mucosae. Most often SJS/TEN is induced by drugs, 
less frequently by infections, whereas some cases are “idiopathic”. 
Severity is determined by skin detachment related to the body sur-
face area (BSA): SJS < 10 %, TEN >30 %, and SJS/TEN-overlap 10–30 % 
of BSA. The high mortality rate is due to severity as well as age of the 
patient. Survivors frequently suffer from long-term sequelae, particu-
larly of the mucosae.
Materials and methods: In order to evaluate frequency and extent of 
late sequelae in patients with SJS/TEN, a cohort study was performed. 
Patients with a validated diagnosis of SJS/TEN, who were included in 
the international Registry of Severe Cutaneous Adverse Reactions 
(RegiSCAR) between 2003 and 2007, were asked to answer a follow-up 
questionnaire.
Results: 112/233 completed follow-up questionnaires could be ana-
lyzed. 62 patients were diagnosed with SJS, 35 with SJS/TEN-overlap, 
and 15 with TEN. The mean age is 44  years, and approx. 60  % are 
women. More than 90  % of the patients suffer from sequelae after 
5 years, while the percentage increases with severity of the reaction. 
Less than 50  % were able to completely return to their normal daily 
activities. Sequelae mainly affect skin (73 %), mucosa (57 %) and nails 
(52 %). Chronic sequelae of the eyes (67 %) are the main issue for the 
patients. They include increased photosensitivity, dry eyes, ingrowing 
eyelashes (trichiasis), excessive watery eyes (epiphora), inflammatory 
cicatrization up to blindness. Furthermore, patients describe sleep dis-
turbances and nightmares (29 %). In addition, they are afraid of drug 
use (65  %), and 56  % of the patients avoid taking drugs, which may 
have a negative impact on their health. Although many patients con-
sider professional psychological support helpful (54 %), only 9 % had 
received it.
Conclusions: This evaluation shows that the majority of patients who 
survived SJS/TEN suffer from long-term sequelae. An interdisciplinary 
approach is not only important in the acute stage of the disease, but 
also after discharge from the hospital, including regular check-ups by 
specialists for these rare severe reactions.
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Background: Stevens–Johnson Syndrome (SJS) and Toxic Epidermal 
Necrolysis (TEN) are life-threatening mucocutaneous reactions, pre-
dominantly drug-induced. In addition to these high mortality rates, 
early and late physical complications are common. No studies were 
conducted on the emotional status or the general Health-Related 
Quality of Life among survivors of SJS/TEN. We aimed to characterize 
the long-term emotional complications and health-related quality of 
life among SJS/TEN survivors.
Materials and methods: Patients older than 18 years who survived 
SJS/TEN were assessed using various parameters. Emotional assess-
ment was conducted by three validated questionnaires: Impact of 
Events Scale-Revised, General Health Questionnaire, and Hospital 
Anxiety and Depression Scale. Health-Related Quality of Life was 
assessed by three validated questionnaires: Dermatology Life Quality 
Index, EQ-5D, Skindex-29 and one specially designed for the study.
Results: Our cohort consists of 17 patients with mean 
51.6  ±  74.7  months (median  =  9, range 1–228) following SJS/TEN. 
Eleven out of 17 (65  %) were found to have symptoms of post-trau-
matic stress (Impact of Events Scale-Revised, mean = 22.4 ± 19.9) and 
5 (29 %) met the criteria for post-traumatic stress disorder, 12 (71 %) 
had psychological distress (General Health Questionnaire, mean 
total score = 4.6 ± 4.2) and 11 (65 %) had symptoms of a psychiatric 
clinical disorder (Hospital Anxiety and Depression Scale, mean total 
score  =  14.5  ±  8.4). The Dermatology Life Quality Index indicated 
a moderate to extremely large effect on the lives of 9 (53  %) partici-
pants (mean total score  =  6.9  ±  7.6). Skindex-29 indicated a mild-
severe effect on Health-Related Quality of Life in 10 (59 %) participants 
(mean = 24.6 ± 21.5). Participants rated their general health at a mean 
of 66.2/100 ± 18.1 (EQ-5D VAS). Fourteen (82 %) participants reported 
that SJS/TEN decreased their current quality of life. Twelve (71  %) 
reported that SJS/TEN influenced their current emotional status. 
Eleven (65 %) reported that SJS/TEN influenced their current everyday 
activities.
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Conclusions: Survivors of SJS/TEN suffer from severe long-term emo-
tional complications and decreased health-related quality of life.
Keywords: Stevens–Johnson Syndrome; Toxic epidermal necrolysis; 
Emotional complications; SJS/TEN
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Background: Stevens–Johnson syndrome (SJS) and toxic epidermal 
necrolysis (TEN) are rare but severe adverse drug reactions with high 
mortality.
Materials and methods: To present the clinical characteristics of SJS 
and TEN in Japan and evaluate the efficacy of treatments, we retro-
spectively analyzed cases of SJS and TEN treated in Yokohama City 
University Hospital and Yokohama City University Medical Center 
between January 2000 and December 2015.
Results: 60 cases of SJS (24 males and 36 females; average age, 
54.2 years) and 40 cases of TEN (19 males and 21 females; average age, 
56.2 years) were included in this study.
31 cases of SJS (51.6  %) and all cases of TEN were caused by drugs. 
Hepatitis was the most common organ involvement in both SJS and 
TEN. Renal dysfunction, intestinal disorder, and respiratory disorder 
were also involved in some cases. The major complication was pneu-
monia and sepsis. All cases except for four cases were treated systemi-
cally with corticosteroids. In SJS 40 cases (66.6  %) were treated with 
corticosteroid alone, Steroid pulse therapy was performed in 40 % of 
SJS and 90 % of TEN. Plasmapheresis and/or immunoglobulin therapy 
was combined with steroid therapy performed 17 cases in SJS (42 %) 
and 26 cases in TEN (65  %). Average SCORTEN score was 1.13 in SJS 
and 2.32 in TEN. The mortality rate was 6 % and the rates for SJS and 
TEN were 1.7 and 12.5  %, respectively. The mortality rate was 0  % 
treated with combination of corticosteroid, plasmapheresis and 
immunoglobulin therapy in SJS and TEN. These were much lower than 
predicted mortality according to a severity-of-illness scoring system 
for TEN prognosis (SCORTEN) socre.
Conclusions: Treatment with steroid pulse therapy in combination 
with plasmapheresis and/or immunoglobulin therapy seems to have 
contributed to prognostic improvement in SJS/TEN.
Keywords: SJS; TEN
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Background: Stevens–Johnson Syndrome (SJS) and Toxic Epidermal 
Necrolysis (TEN) are considered the most severe types of cutane-
ous adverse reactions to drugs, with high morbidity and mortality 
rates. We aimed to characterize the long-term physical complications 
among SJS/TEN survivors.
Materials and methods: Patients older than 18  years who survived 
SJS/TEN were assessed by an interview and by skin, oral mucous mem-
brane and detailed ophthalmic exam.
Results: Our cohort consists of 17 patients with mean 
51.6  ±  74.7  months (median  =  9, range 1–228) following SJS/TEN. 
The most commonly reported symptom among survivors was chronic 
fatigue/weakness (76  %). The most common cutaneous signs were 
post-inflammatory dyspigmentation in 77  % of participants, scars 
(46  %), and milia (15  %). The most common cutaneous symptoms 
were pruritus (53  %), photosensitivity (35  %), and dry skin (24  %). In 
the ophthalmic exam, dry eyes were the most common finding in 
44 %. Other identified signs were: lid adhesions/symblepharon (33 %), 
chronic ocular surface inflammation (33 %), loss of visual acuity (22 %), 
chronic conjunctivitis (22  %), keratinization of the tarsal conjunctiva 
(22  %), lachrymal duct scarring (22  %), blindness (11  %), photopho-
bia (11  %), ectropian and trichiasis (11  %), corneal abrasions/ulcers 
(11 %), conjunctival synechiae (11 %), and corneal neovascularization 
(11 %). The most commonly reported ocular symptoms were dry eyes 
in 47 % of participants; other symptoms included photophobia (35 %), 
loss of visual acuity (35 %), and ocular pain (24 %). Hair loss and nail 
loss were reported in 53 and 35 % of participants a few months after 
TEN, respectively. Other less common complications included genital 
synechiae in 18 % of female survivors, lupus (12 %), renal dysfunction 
(12  %), and fibromyalgia (6  %). Tinnitus, tenderness on soles of feet, 
abnormal ECG, and vocal cord dysfunction were each reported in 6 % 
of participants.
Conclusions: Survivors of SJS/TEN suffer from severe, long-term physi-
cal complications and require ongoing longitudinal medical follow-up.
Keywords: Physical complications; Stevens–Johnson Syndrome; Toxic 
epidermal necrolysis; Long-term complications
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Background: The combination of Stevens–Johnson syndrome/toxic 
epidermal necrolysis (SJS/TEN) with haemophagocytic lymphohistio-
cytosis (HLH) is life-threatening and usually fatal in adults. We report 
a rare case of a 36  year old male who survived these concomitant 
illnesses.
Report: The patient presented with a 1  week history of fevers and 
flu-like symptoms, with onset of a mucocutaneous rash on day five. 
He was admitted to a tertiary intensive care unit (ICU) with a diagno-
sis of SJS/TEN (20–25  % of total body surface area). The potentially 
implicated drugs (ibuprofen, codeine and amoxicillin) were promptly 
withdrawn, and he received immunosuppressive therapy with 
methylprednisolone, intravenous immunoglobulin and cyclosporin 
combined with supportive ICU care. He continued to systemically 
deteriorate at a time when his skin lesions stabilised. Recognition of 
hyperferritinemia (40,900 µg/l), unremitting fevers and pancytopenia 
in a critically ill patient, clinched the diagnosis of HLH which was con-
firmed on bone marrow biopsy. He received treatment with the HLH-
94 chemotherapy protocol (including etoposide and dexamethasone). 
Sequential skin patch tests to ibuprofen and amoxicillin, performed 
6  months post-discharge, were negative (codeine patches were not 
available). The patient’s negative patch tests were interpreted with 
caution, due to previous chemotherapy and the unavoidable delays 
to testing, both of which may have led to T lymphocyte depletion and 
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false negative patch test results. The patient was advised to strictly 
avoid all non-steroidal anti-inflammatories, aspirin, codeine and amox-
icillin (he had tolerated other opiates and beta-lactams in hospital).
How this report contributes to current knowledge: To our knowl-
edge, this is the first report of an adult surviving a severe episode of 
HLH and SJS/TEN overlap (rather than SJS alone). This case highlights 
(1) the potential for HLH to coexist with SJS/TEN and the importance 
of early recognition and treatment, (2) the difficulties in interpreting 
patch tests in patients who have received marrow ablative therapies, 
and (3) the complexities of providing recommendations on drug 
avoidance to patients with severe cutaneous adverse drug reac-
tions and negative patch test results. In  vitro lymphocyte prolifera-
tion assays may be a useful alternative diagnostic tool in this clinical 
setting.
Consent: Written informed consent was obtained from the patient for 
publication of this abstract and any accompanying images.
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Background: Exposure to anti-tuberculosis drugs (ATDs) isoniazid 
(INH), ethambutol (ETB), pyrazinamide (PZA) and/or rifampicin (RIF) 
is associated with a mild elevation of liver enzymes that occasionally 
develops into severe liver injury. We have reported that INH-specific 
CD4+ T-cell clones circulate in patients with ATD-related liver injury, 
which suggests that the adaptive immune system is involved in the 
disease pathogenesis. This study details the nature of the drug anti-
gen-specific T-cell response that develops in a fatal case of ATD-related 
liver failure.
Materials and methods: Peripheral blood mononuclear cells were 
isolated from a patient who had a severe liver reaction to ATD medica-
tions, ALT 514  IU/l and Bilirubin 30 mg/dl. A lymphocyte transforma-
tion test (LTT) and IFNγ-ELISPOT assay using ATDs were performed 
and clones were generated from ATDs by serial dilution. Drug-specific 
clones were identified in terms of cross-reactivity and dose-respon-
siveness and then characterized in terms of CD phenotype and 
cytokine secretion.
Results: Positive LTT against multiple drugs (INH, ETB, PZA, RIF, and 
activated ester of isonicotinic acid which forms isonicotinic amide 
adducts in the cell culture system) was observed. Over 700 T-cell 
clones were generated from INH, ETB, PZA, RIF or activated ester of 
isonicotinic acid treated peripheral blood mononuclear cells. Antigen-
specific proliferative responses of CD4 +/CD8+ clones were identified 
with only ETB and RIF. Clones were highly specific and did not cross-
react with other ATDs. Clones are activated to proliferate and secrete 
cytotoxic mediators (granzyme B, perforin) and effector cytokines 
(IFN-γ, Il-13).
Conclusions: In conclusion, cytotoxic ETB and RIF-specific T-cell clones 
have been identified in patient with ATD-related severe liver failure.
Keywords: Isoniazid; Drug-induced liver injury
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Background: Acute Interstitial Nephritis (AIN) is often drug induced 
and the most frequently implicated drugs are Non-steroidal anti-
inflamatory drugs (NSAIDs) and antibiotics. We report the case of a 
patient with AIN induced by Ibuprofen.
Report: A 74 year-old-female was admitted at emergency department 
with a 10-day history of malaise, anorexia, nausea, diffuse myalgias, 
fever (38 °C) and flank pain, treated with Paracetamol, Ibuprofen and 
Ciprofloxacin for suspected Pyelonephritis, by her attending physician. 
At admission she was febrile (38 °C) and prostrated. Laboratory studies 
revealed: leukocytosis, acute kidney injury (serum creatinine 5.8  mg/
dl, blood urea nitrogen 178 mg/dl) and positive C-reactive Protein; uri-
nalysis with leucocituria, proteinuria and hematuria; negative blood 
culture. Chest X-ray and ultra sound of kidneys were normal. Treat-
ment with Paracetamol, Ibuprofen and Ciprofloxacin was discontinued 
and she started Meropenem and intravenous fluids. Renal function 
improved and she was discharged after 3 days. One year later she was 
admitted to hospital with similar clinical presentation and diagnosed 
with AIN. Ten days prior to this admission she was treated with Cipro-
floxacin and Ibuprofen for Phlebitis. After these two episodes she was 
again treated with Ciprofloxacin with good tolerance. She was then 
referred to our Drug Allergy Clinic for suspected hypersensitivity to 
Ibuprofen. Lymphocyte transformation test (LTT) with Ibuprofen was 
positive (stimulation index of 13.4 at 10 µg/ml). Drug provocation test 
(DPT) with the suspected drug was not performed. DPT and long-term 
challenge with alternative drugs (Paracetamol and Etoricoxib) were 
both negative.
How this report contributes to current knowledge: Renal biopsy is 
the only definitive method to establish the diagnosis of AIN. However, 
when diagnosis seems likely, a probable precipitating drug can be eas-
ily withdrawn or patient improves readily after withdrawal of the sus-
pected drug, biopsy can be avoidable. Challenge with the suspected 
drug remains the gold standard for diagnosis of drug hypersensitivity. 
Since AIN is a severe hypersensitivity reaction, DPT with the suspected 
drug is contra-indicated. The obvious time relationship between Ibu-
profen treatment and reaction development in both episodes, the 
reproducible clinical presentation and positive LTT, suggests Ibuprofen 
has been the culprit drug. In cases of severe reactions LTT seems to be 
a valuable diagnostic tool.
Consent: Written informed consent was obtained from the patient for 
publication of this abstract and any accompanying images.
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Background: Epidermal growth factor receptor inhibitors (EGFRIs) are 
used for treatment of advanced lung, pancreatic, colorectal, and head 
and neck cancers. Cetuximab is a monoclonal antibody that competi-
tively binds to the extracellular domain of EGFR and blocks cytoplas-
mic-domain phosphorilation. It is characterized by frequent cutaneous 
adverse reactions (CARs) including acneiform rash (AR), desquama-
tion, xerosis, pruritus, hair abnormalities, paronychia, changes in nails, 
mucositis, increased growth of facial hair and eyelashes, and teleangi-
ectasias. AR usually appears between day 2 and week 6 after cetuxi-
mab Background. According to the National Cancer Institute Common 
Toxicity Criteria, severity of toxicity of AR is graded into five grades, and 
according to EGFRI-induced AR severity score into mild, moderate and 
severe toxicity.
Prophylactic antibiotic treatment with doxycycline 100 mg bid for the 
first 6 weeks is recommended. Therapeutic plan includes use of grade-
based skin treatment algorithm: (a) mild toxicity—local therapy with 
corticosteroids or antibiotics, (b) moderate toxicity—local therapy 
with addition of oral antibiotic, and (c) severe toxicity—cetuximab 
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dose lowering and therapy for moderate toxicity with an addition 
of a methyprednisolone dose pack. If therapy is ineffective within 
2–4 weeks, it is necessary to discontinue cetuximab treatment.
Report: We present two male patients with metastatic colorectal can-
cer who developed papulopustular lesions on the sebum-rich areas of 
the face, scalp and trunk accompanied by pruritus and burning sensa-
tions (grade 2/3 or moderate toxicity), 1–3 weeks after Background of 
cetuximab. One patient developed desquamation of the palms. Come-
dones, primary acne lesions, were lacking. There was no sign of super-
infection. Patients were treated with doxycycline 2 × 100 mg bid for 
2 weeks, followed by 1 × 100 mg, until the end of cetuximab therapy. 
Local therapy included clindamycin lotion, hydrocortisone/oxytetra-
cycline ointment, benzoyl peroxide suspension and emollients. After 
3  weeks of treatment, significant improvement of AR severity was 
achieved and there was no need for cetuximab dose reduction.
How this report contributes to current knowledge: Studies have 
demonstrated positive correlation between treatment efficacy and 
CARs for EGFRI. Since frequency and severity of skin lesions are dose-
dependent, a gradual increase in dose until CARs develop might be a 
good strategy to maximize the efficacy of EGFRI.
Consent: Written informed consent was obtained from the patient for 
publication of this abstract and any accompanying images.
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Background: On August 2012 Rubio-Tapia et al. reported an associa-
tion of olmesartan therapy with an unexplained enteropathy symp-
tomatically resembling celiac disease or sprue. Olmesartan is an 
Angiotensin II Receptor Antagonist (ARA II) widely used in high blood 
pressure, heart disease and diabetics. On July 2013 the Food Drug 
Administration (FDA) approves label changes to include intestinal 
problems, Severe Spruelike Enteropathy (SSE) linked to blood pressure 
medicine olmesartan.
Losartan was the first ARA II commercialized in 1995 and it seems to 
produce similar Adverse Drug Reactions (ADR) that olmesartan.
Report: Method
Desing: Case report of enteropathy associated with losartan
Scope: Allergy Service, Hospital Central de la Defensa, Madrid.
Period: May 2015
Main variables assessed: demographic and clinical variables, diagnos-
tic criteria, treatment, evolution, causal relationship between drug and 
enteropathy according to the modified Karch Lasagna algorithm.
The patient has given written informed consent for the publication 
research.
Results: A 81 years old woman, diagnosed of hypertension, treated 
for 3 years with losartan 100 mg/d. After starting treatment she refers 
chronic diarrhea and since 2 years ago worsening diarrhea, abdomi-
nal pain and weight loss. The patient was treated at the emergency 
service twice for 3–4 daily episodes of watery, nonbloody diarrhea 
associated with abdominal bloating. The patient failed conservative 
management including gluten-free diet, oral antibiotic and corti-
costeroid. Additionally to diarrheal syndrome, the patient showed 
hoarseness and cough.
Allergologic study: immediate and delayed prick test and specific IgE 
were negative for food.
A colonoscopy with colonic biopsies revealed evidence of microscopic 
colitis.
Treatment: Losartan withdrawal, achieving complete remission in 
4 weeks.
The case has been reported to Spanish Postmarketing Surveillance 
System.
How this report contributes to current knowledge: The allergist 
should keep in mind this possible and rare ADR in patients treated 
with losartan (ARA II) showing enteropathy, as discontinuing losartan 
leads to clinical improvement.
This enteropathy case is very similar to SSE described in 2012 related 
to olmesartan.
Consent: Written informed consent was obtained from the patient for 
publication of this abstract and any accompanying images.
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Background: Granuloma annulare (GA) is a benign inflammatory der-
matosis affecting predominantly females. The disease etiology and 
pathophysiology remain unclear. Trauma, association with diabetes 
mellitus and medicamentous genesis have been suspected. Patho-
genic mechanisms include cell-mediated immunity (type IV), mac-
rophage activation, and cytokine-mediated degradation of connective 
tissue.
Report: Herein we present a 56-years-old male Caucasian patient who 
developed skin lesions on the back of the hand 3 months after initia-
tion of therapy with canakinumab as a part of a clinical trail for treat-
ment of coronary artery disease. Upon admission the skin changes 
involved the dorsum of the hand and were presented by annular pap-
ules and plaques, the largest 3 cm in diameter with depressed center 
and elevated and infiltrated borders. The patient had no other relevant 
history of present or past disease beyond the coronary artery diseases 
and elevated serum cholesterol levels. He took no other medication 
prior or during the disease onset.
Based on the clinical findings the diagnosis of GA was coined. Cryo-
therapy with liquid nitrogen was performed. Canakinumab was with-
drawn. Skin lesions resolved within the 2 weeks later. No new lesions 
appeared during the 6 months follow up.
How this report contributes to current knowledge: Canakinumab is 
a IL-1 beta monoclonal antibody used in rheumatology and in the treat-
ment of autoinflammatory syndrome. Recently it was tested in coronary 
artery disease, gout and COPD. As a new drug, its safety profile and 
unwanted adverse events are still to be challenged. In the described 
case we present the development of cutaneous reaction coinciding with 
the drug Background. Drug-induced GA has been described in the liter-
ature, e.g. after allopurinol, amlodipine, TNF-alpha inhibitors, gold, and 
interferon therapy. As far as we are aware no previous reports exist on 
the association between canakinumab therapy and GA.
Consent: Written informed consent was obtained from the patient for 
publication of this abstract and any accompanying images.
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Background: Eosinophilic myocarditis (EM) is a potentially fatal dis-
ease if left untreated. There are numerous drugs that have been impli-
cated in causing the hypersensitivity (HS) form of EM but frequently 
the cause of the disease remains unknown as it could have a delayed 
presentation for up to 2 years. In this case report we present an atypi-
cal clinical presentation of HS EM, possibly caused by hydrochlorothi-
azide (HCT), and significant coronary artery disease (CAD).
Report: A 63-year-old man presented to the emergency department 
with flu-like symptoms. He had a history of chronic bronchitis and 
arterial hypertension treated with budesonide/formoterol and HCT. 
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His general physical examination was unremarkable, without any signs 
of heart failure. Complete blood count (CBC) revealed leucocytosis 
with slightly eosinophilia and elevated troponin and CRP. ECG showed 
no changes in ST/T segment. Echocardiography revealed minimal peri-
cardial effusion for up to 4 mm. Initial right pneumonia was observed 
on X-ray. He was treated with amoxicillin/clavulanic acid, azithromy-
cin and ibuprofen. Fifth day of hospitalization the signs of disease 
became more prominent: CBC revealed 19.2 ×  109/l leucocytes with 
11.2 × 109/l eosinophils and troponin level was doubled. Pulse doses 
of corticosteroids (CS) (methylprednisolone 500  mg i.v.) were started 
and other therapy was discontinued. Seven hours later patient was 
asymptomatic, leucocytes were normal with slightly eosinophilia. 
Pulse doses of CS were continued up to 3  days when converted to 
oral CS. Endomyocardial biopsy showed no inflammation. Coronarog-
raphy revealed two-vessel CAD, treated with percutaneous coronary 
intervention.
How this report contributes to current knowledge: One of the most 
common cause of EM reported in literature is drug HS. In our patient 
HCT is a potential cause. Symptoms, levels of troponin, ECG and echo-
cardiographic changes were more suggestive for EM than CAD. Endo-
myocardial biopsy revealed no EM but it was performed third day 
after pulse dosage of intra-venous CS, when symptoms completely 
vanished. It should be also noted that EM is a focal disease and biopsy 
doesn’t have to prove the diagnosis. It is more obvious that CAD was 
co-finding, as symptoms of CAD could not be resolved using CS, and 
troponin levels would not fall second day after initiating therapy. CBC 
with eosinophilic drop powers that hypothesis. Early administration of 
systemic CS is necessary regardless of underlying causes, as delayed 
treatment may result in fatal outcomes.
Consent: Written informed consent was obtained from the patient for 
publication of this abstract and any accompanying images.
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Background: Two mechanisms of drug-induced haemolysis have 
been described. Usually both, extravascular and intravascular hae-
molysis, are caused by drug dependent antibodies (ddAb). Extravas-
cular haemolysis presents with mild and less severe clinical symptoms 
of anaemia, whereas intravascular haemolysis usually manifests with 
a rapid destruction of red blood cells caused by antibody-mediated 
complement activation leading to acute clinical symptoms. Interest-
ingly more than 50  % of all piperacillin-induced immune haemolytic 
anaemia (PIHA) cases investigated at a reference laboratory in Ger-
many were patients with cystic fibrosis (CF). Therefore the investigated 
hypothesis of this study is a higher prevalence for PIHA in patients 
with CF as for the general population. Additionally risk factors for PIHA 
are systematically assessed.
Materials and methods: Included were all patients with CF older 
than 12 years who were admitted to the hospital for antibiotic treat-
ment. Past transplantation was an exclusion criterion. Blood samples 
were obtained in the beginning and at the end of a given intravenous 
treatment. Direct antiglobulin test (DAT) and indirect antiglobulin test 
(IAT) were performed using standard techniques. For positive samples 
an antibody differentiation was done. DdAb were investigated using 
gel technique. Thus we prepared a 1  mg/ml drug solution or used 
ex vivo antigens, respectively and incubated it for 30 min in presence 
of patients’ plasma and group O RBCs. The individual prior exposure 
to piperacillin and information concerning atopy and microbiology are 
documented.
Results: In the ongoing trial 2 out of 20 patients developed a PIHA. 
This is a high prevalence compared to the general expectation of 
approximately 1:1,000,000. Both had ddAb but no complement activa-
tion. This is typical for extravascular haemolysis. Clinical symptoms of 
haemolysis were mild but there was a drop of haemoglobin by 4 mg/
dl. The study will be finished by April 2016.
Conclusions: These results suggest a higher prevalence of PIHA in 
patients with CF than expected in the general population. This is 
backed by several case reports. Possibly this is due to the exposure 
to piperacillin. Therefore PIHA should be considered when treating 
patients with CF.
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P46 
Progesterone triggered pemphigus foliaceus: case report
Sandra Jerkovic Gulin1, Caius Solovan2, Anca Chiriac3
1Department of Dermatology and Venereology, General Hospital Sibenik, 
Sibenik, Croatia; 2Department of Dermatology, University of Medicine 
and Pharmacy, Tamisoara, Romania; 3Dermatology Department, Nicolina 
Medical Centre, Apollonia University, “P.Poni” Research Institute of Macro‑
molecular Chemistry, Iasi, Romania  
Correspondence: Sandra Jerkovic Gulin
Clinical and Translational Allergy 2016, 6(Suppl 3):P46
Background: Pemphigus foliaceus (PF) is a benign variety of pemphi-
gus (P) characterized by acantholysis in the upper part of epidermis, 
induced by immunoglobulin G (IgG) autoantibodies (mainly IgG4 
subclass) targeting desmoglein -1 (dsg-1). Clinical expression of PF is 
based on the presence of scaly and crusted erosions on an erythema-
tous base, flaccid blisters, minor or no involvement of mucous mem-
branes and with seborrheic distribution and aspect of the lesions in 
early stages of the disease. PF is classified into four types: endemic 
(fogo selvagem), idiopathic, erythematosus (Senear-Usher syndrome) 
and drug-induced. Drugs triggering or inducing PF reported in litera-
ture are penicillamine, bucilamine, captopril, lisinopril, enalapril, fos-
inopril, candesartan, tipronin and rifampicin.
Report: A 45-year-old woman presented with facial erythema, mul-
tiple erythematous papules and plaques, few scaly plaques, shallow 
erosions and superficial blisters on an erythematous base localized 
on the upper chest and upper back in “V” distribution, acompanied by 
pain and burning sensation. Mucous membranes were spared. Lesions 
appeared 2 months after initiating systemic therapy with medroxypro-
gesterone acetate 10  mg daily for 14  days per month for metrorrha-
gia. Biopsy revealed subcorneal cleft within the upper epidermis with 
acantholytic keratynocytes. Direct immunofluorescence (DIF) of perile-
sional skin showed intercellular, intraepithelial IgG. Indirect immuno-
fluorescence (IIF) showed intercellular, intraepithelial IgG, with higher 
fluorescent intensity in the upper dermis. The diagnosis of possible 
drug induced PF was presumed based on clinical, histological and 
immunological grounds. The suspected culprit drug—progesterone 
was discontinued. Treatment with high-potency topical corticoster-
oid (betamethasone) in combination with gentamicin ointment twice 
daily was started. After 4 weeks of treatment, lesions resolved almost 
completely. Close follow-up was recommended.
How this report contributes to current knowledge: Although PF 
often occurs spontaneously, it may be triggered by certain medica-
tions. A case of localized PF induced by topical imiquimod treatment 
has been recently reported, based on an unknown mechanism of 
acantholysis, probably due to antibodies to dsg-1. Drug as a trigger 
must be suspected in every newly diagnosed P. Indentification and 
elimination of triggering drug may soothe the clinical symptoms and 
shorten the treatment.
Consent: Written informed consent was obtained from the patient for 
publication of this abstract and any accompanying images.
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Background: Generalized pustular psoriasis (GPP) is an extreme and 
serious form of psoriasis (P) with tiny, sterile, yellow pustules on an ery-
thematous base. The clinical presentation of drug-provoked P include 
more often generalized plaque P and erythroderma, and rarely pal-
moplantar pustulosis or GGP. Drugs can cause (a) precipitation of P de 
novo in predisposed or nonpredisposed individuals; (b) exacerbation 
of pre-existing psoriatic lesions; (c) induction of lesions in clinically 
normal skin in patients with P; and (d) development of treatment-
resistant P. Angiotensin-converting enzyme inhibitors (ACEIs) are 
widely used to control hypertension and are considered to be possi-
ble triggering, exacerbating or inducing agents of P. Rarely, ACEIs have 
been reported in the literature as inductors of GPP. We present our first 
case of ramipril-triggered GPP.
Report: 46-year-old women presented with low-grade fever, ery-
thema, small pustules 1–2  mm in size and exfoliation involving skin 
on trunk, extremities, palms and soles. She had no previous history of 
P or family history of P. She began taking the new antihypertensive—
ramipril 2  months before the onset of symptoms. Laboratory find-
ings showed elevated erythrocyte sedimentation rate and C-reactive 
peptide with other biochemical findings within normal limits. Gram 
stained smear examination of pustules were negative and the pus cul-
ture was sterile. We set up a working diagnosis of GPP based on his-
tory, laboratory findings and clinical picture and the main differential 
diagnosis was acute generalized exanthematous pustulosis. Biopsy 
was performed. Ramipril as suspected culprit drug was discontinued 
and replaced with valsartan. We started the treatment with acitretin 
50 mg/day which resulted in good initial therapeutic response. On the 
basis of clinical picture, biopsy and satisfactory therapeutic outcome, 
the diagnosis of GPP was confirmed.
How this report contributes to current knowledge: Only one case 
of  ramipril-induced  GPP in patient with psoriatic arthritis has been 
published in the literature. According to our knowledge, we present a 
first case of ramipril-triggered GPP in an individual without personal 
and family history of P. As P is a common skin disorder, knowledge of 
the factors that are inducers, triggers, or aggravators of the disease is 
of utmost importance for clinicians. Drug cessation or replacement 
may play a crucial role in the treatment outcome so taking a detailed 
history is decisive.
Consent: Written informed consent was obtained from the patient for 
publication of this abstract and any accompanying images.
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Background: Several studies have demonstrated a reduction in 
adverse cardiovascular events with the administration of dual anti-
platelet therapy (aspirin and clopidogrel) to patients (pts) with coro-
nary artery disease, especially in the prevention of thrombosis after 
implantation of bare-metal and drug-eluting stents. However, when 
pts have aspirin hypersensitivity (AH) this treatment is limited, and 
they are maintained on monotherapy with clopidogrel. Aspirin desen-
sitization (AD) is the alternative for these individuals. The aim is to 
describe the experience of a Portuguese Allergy Department in AD on 
cardiovascular pts, between April 2006 and January 2016.
Materials and methods: Thirty pts with previous history of AH who 
needed dual antiplatelet therapy due to cardiovascular disease 
(female-14, male-16), mean age 64  years-old, were desensitized to 
aspirin. The clinical presentation of AH was asthma (six pts), anaphy-
laxis (four pts), cutaneous rash (seven pts), angioedema (13 pts), in 
some cases with very remote reactions (>20  years ago). In most pts 
(22 out of 30), AD was performed immediately after percutaneous 
coronary intervention (PCI). Most AD were performed in Cardiology 
Department (27); three pts with planned AD were desensitized at the 
Allergy Day-Care Unit; oral doses were increased every 30–60 min (tar-
get dose 152.5  mg) under a 4.5-h protocol. Pre-medication was not 
administered.
Results: All pts successfully completed AD, although there were two 
reactions  30  min after the procedure: a 63  year-old man who devel-
oped acute rhinitis and conjuntivitis, eyelid angioedema and dry 
cough; and a 75 year-old man who developed acute generalized urti-
caria. All pts were monitored after AD, and are still on daily aspirin 
100 mg (there were neither hypersensitivity reactions nor drop-outs).
Conclusions: Despite positive clinical history of AH, some pts had a 
remote reaction, and due to the emergency of the procedure we were 
not able to confirm their AH. This fact could in part explain the low 
incidence of reactions during AD; another reason could be the smaller 
dose of aspirin used as antiplatelet (100–150 mg) compared with the 
dose to which they previously reacted (>500 mg). Some authors advo-
cate that AD should be performed before PCI, but PCI could provide 
greater hemodynamic stability and therefore allow a safer AD. Based 
on our experience, AD is safe and efficacious, even when performed 
after PCI, with all pts responding to the desensitization procedure.
Keywords: Aspirin hypersensitivity; Drug desensitization; Anaphylaxis
Consent: Written informed consent was obtained from the patient for 
publication of this abstract and any accompanying images.
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Background: Subjects with hypersensitivity reactions to NSAIDs with 
airways involvement can develop rhinitis and or asthma after the 
intake of ASA and other NSAIDs that are strong COX-1 inhibitors. Some 
cases may also respond to weak COX-1 and selective COX-2 inhibitors. 
The hallmark characteristic is that symptoms are triggered by asthma 
and that in most instances subjects have a pre-existing respiratory 
disease. We studied if subjects can be selective responders to some 
NSAIDs including weak COX-1 or selective COX-2 inhibitors having 
good tolerance to ASA.
Materials and methods: Subjects reporting rhinitis and/or asthma to 
a single NSAID with good tolerance to ASA were evaluated. An aller-
gological evaluation was carried out plus a controlled challenge with 
ASA for verifying tolerance. In a second step we proceed to a con-
trolled challenge with the culprit drug involved. FEV1 and acoustic 
nasal rhynomanometry were measured with values lower that 12 and 
30  % respectively considered as a positive response. Also nasal and 
bronchial symptoms were recorded.
Results: We confirmed in 21 cases the appearance of nasal and/or 
bronchial symptoms by objective parameters (decrease in FEV1 and/or 
decrease in nasal volume cavity) after the administration of the drug. 
The drugs involved were ibuprofen in four cases, paracetamol in four 
cases, desketoprofen in one and etoricoxib in another.
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Conclusions: Selective respiratory responses to a single NSAID with 
good tolerance to ASA occur. Although the underlying mechanism 
is not known, the classical involvement of the leukotriene’s pathway 
occurring is aspirin exacerbated respiratory disease seems to be dis-
carded. This constitutes a new phenotype within the category of 
hypersensitivity reactions to NSAIDs.
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Background: Nonsteroidal antiinflammatory drugs (NSAIDs) as the 
most frequently prescribed classes of drugs have been reported to 
be the second most common cause of drug hypersensitivity reactions 
after beta-lactam antibiotics. In this study we aimed to evaluate the 
clinical characteristics of NSAID hypersensitivity based on European 
Network for Drug Allergy (ENDA)’s classification.
Materials and methods: 196 patients diagnosed as NSAIDs hyper-
sensitivity between the years of 2013–2014 were enrolled to the 
study. The patients were questioned about the other allergic diseases 
(rhinitis, asthma, urticarial, personal and familial drug allergy) besides 
the demographic features. NSAID reactions were classified as follow: 
NSAID induced urticaria/angioedema (NIUA), single NSAID induced 
urticaria/angioedema, anaphylaxis or both (SNIUAA), NSAID exacer-
bated cutaneous disease (NECD), NSAIDs exacerbated respiratory dis-
ease (NERD), single NSAID induced delayed hypersensitivity reactions 
(SNIDR). Acetylsalicylic acid, diclofenac, paracetamol and meloxicam 
were the most frequently preferred drugs for oral provocation test to 
distinguish of cross-reactive and IgE-mediated reactions.
Results: Hypersensitivity to NSAIDs was three times common in 
female (77 %) than male (23 %). The patients with NERD had atopic his-
tory the most frequently (50  %). 6.6  % of patients have drug allergy 
in their family. The frequency of hypersensitivities was found respec-
tively as follows: NIUA (46 %), SNIUAA (24 %), NECD (15 %), NERD (8 %), 
SNIRD (7  %). The patients who had cross-reactive hypersensitivity 
to many of NSAIDs could be tolerated paracetamol, meloxicam and 
nimesulid. Diclofenac (11 cases 23 %), Flurbiprofen (seven cases 15 %), 
Metamizol (seven cases 15 %) were induced SNIUAA respectively, But 
according to their chemical structure propionic acid derivatives had 
been caused severe anaphylaxis mostly. Commonly seen delayed 
reactions due to NSAIDs are maculopapular eruptions and fixed drug 
eruption.
Conclusions: NSAIDs were caused NIUA, SNIUAA and NECD most fre-
quently (85 %) although NERD and delayed reactions were quite rare. 
There are still unexplained points in these cases. Therefore there are 
needed more clinical studies.
Keywords: Non-steroidal anti-inflammatory drug hypersensitivity
P51 
Development of immediate hypersensitivity to several NSAIDs 
maintaining good tolerance to ASA
Natalia Pérez‑Sánchez1, Natalia Blanca‑López2, Diana Pérez‑Alzate2, 
Gador Bogas1, Inmaculada Doña1, María Salas1, María José Torres1, Miguel 
Blanca1, Gabriela Canto2
1Allergy Unit, Malaga Regional University Hospital‑IBIMA, Malaga, Spain; 
2Allergy Service, Infanta Leonor Hospital, Madrid, Spain  
Correspondence: Natalia Pérez‑Sánchez
Clinical and Translational Allergy 2016, 6(Suppl 3):P51
Background: Subjects responding to several NSAIDs including 
ASA are considered cross-hypersensitive, whereas those respond-
ing to only one NSAID with tolerance to other chemically unrelated 
NSAIDs are considered selective responders. However, in some 
cases, patients that develop immediate reactions to several NSAIDs 
are classified as cross-hypersensitive without assessing ASA 
tolerance.
Report: A 70 year-old woman, without allergic history, referred that in 
1996 she developed two episodes of urticaria less than an hour after 
paracetamol intake. Three years after, she had developed three epi-
sodes of urticaria 90 min after dipyrone intake. At that time she was 
allergologically evaluated: intradermal test (ID) with dipyrone (2 mg/
ml) and paracetamol (0.1 mg/ml) were positive. She was challenged 
with ASA showing tolerance at full therapeutic doses (500  mg). In 
2012, she suffered from an episode of facial angioedema and pruritus 
in the tongue after celecoxib intake. She reported previous tolerance 
to this drug on many occasions. In September 2014, she was re-eval-
uated: ID to paracetamol was negative (0.1 mg/ml), and ID and baso-
phil activation test (BAT) to dipyrone were positive. Drug challenges: 
60 min after achieving a cumulative dose of paracetamol 300 mg, she 
developed generalized pruritus and urticaria. Two weeks later, she 
presented pruritus in the tongue and ears, nasal itching and obstruc-
tion, and wheals in the neck after provocation with a cumulative dose 
of 100 mg of celecoxib, with no changes in FEV1 values. After another 
interval of 2 weeks tolerance to etoricoxib was observed at full thera-
peutic doses. Two weeks later the patient tolerated ASA and ibupro-
fen during controlled challenge until therapeutic doses. In addition, 
around 2 months later the patient received two independent 2 days 
treatment courses with these drugs, separated by a 2  weeks time 
interval.
How this report contributes to current knowledge: Subjects may 
develop an immediate response to a number of different NSAIDs, 
including some COX-1 and/or selective COX-2 inhibitors but tolerate 
strong COX-1 inhibitors. This case shows the importance of testing for 
ASA tolerance when confronted by a patient who responds to several 
chemically unrelated NSAIDs.
Consent: Written informed consent was obtained from the patient for 
publication of this abstract and any accompanying images.
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Background: The most important drug involved in hypersensitiv-
ity drug reactions (HDR) are NSAIDs. Two mechanisms are involved: 
immunological sensitization (specific IgE or T-cell) and pharmaco-
logical (COX-1 inhibition). Paracetamol, one of the drug most highly 
consumed all over the world, has been implicated in HDR. The contri-
bution these mechanisms in HDR to paracetamol is not well known. 
We studied a large group of patients who developed one/several epi-
sodes indicative HDR to paracetamol.
Materials and methods: Patients with reactions to paracetamol were 
classified as cross-hypersensitivity (CH) if they responded to two oth-
ers NSAIDS not chemically related including ASA. If only paracetamol 
was implicated, drug provocation test (DPT) with ASA was required: 
if positive, they were included as CH and if negative, as selective 
responders (SR). In cases who reported respiratory symptoms, nasal 
provocation test with L-ASA were performed. Atopy status was also 
assessed with prick test to inhalant allergens.
Results: A total of 350 patients with confirmed diagnosis of HDR to 
paracetamol were included: 288 (82.28 %) resulted to be CH and 62 
SR (17.71 %). Within the CH group, following the ENDA classification, 
181 (62.84 %) were NIUA, 25 (8.68 %) NERD, 16 (5.55 %) NECD, and 
in 60 (20.83  %) blended reactions. A total of 46 (25.41  %) patients 
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required a positive DPT for diagnosis. Nasal challenge with L-ASA 
was positive in 19 (82.6 %) patients with clinical history suggestive 
of NERD. Within SR group, 56 cases (90.32 %) were SNIUAA (reaction 
less than 24), being anaphylaxis the most frequent clinical entity 
(29 (51.78 %), followed by urticaria/angioedema (16; 28.57 %), angi-
oedema (6; 10.71  %), urticaria (4; 7.14  %) and fixed drug eruption 
(1; 1.78 %). A total of 18 (32.14 %) patients required a positive DPT 
to paracetamol for diagnosis. The remaining six (9.67 %) cases were 
SNIDHR as they had the reaction more than 24 h after paracetamol 
administration: four (66.66  %) maculopapular exanthema and two 
(33.33 %) exanthema with desquamation. One patient had respira-
tory symptoms and was confirmed as SR.
Conclusions: These data indicate that when patients develop a HDR 
to paracetamol after carried out the allergological work-up, the 80 % 
of patients who developed a positive response were CH with a lower 
proportion being SR. DPT was needed in more than 20 % of cases to 
achieve the diagnosis.
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Background: Paracetamol is often proposed as a safe alternative 
to the patients with hypersensitivity to NSAIDs. However, reactions 
induced by this drug can manifest in a wide variety of symptoms.
Aim: To evaluate hypersensitivity to paracetamol in Lithuanian adult 
population according to the new classification of hypersensitivity to 
NSAIDS.
Materials and methods: We followed 183 adult patients (211 clini-
cal histories) of suspected hypersensitivity to paracetamol in the 
Pulmonology and Allergology Centre of Vilnius University Hospital 
Santariskiu Klinikos. The median age of patients was 42.5 [32.75–53.25] 
years. Most of the patients were females 144 (78.7 %). 14 medications 
containing paracetamol were reported. ENDA questionnaires were 
completed, patch and drug provocation tests (DPTs) were performed 
to confirm the diagnosis.
Results: We adapted our clinical cases to the new classification of hyper-
sensitivity to NSAIDs and divided our patients into five categories. 53 
cases (47 patients) were nonimmunologically mediated (cross-reactive) 
hypersensitivity reactions to NSAIDs: four cases of “NSAIDs-exacerbated 
respiratory disease”, four cases of “NSAIDs-exacerbated cutaneous dis-
ease” and other 45 cases (39 patients) of “NSAIDs-induced urticaria/
angioedema (NIUA)”. 86 cases (75 patients) were immunologically medi-
ated (non-cross-reactive) hypersensitivity reactions to NSAIDs: 63 cases 
(55 patients) of “Single-NSAID-induced urticaria/angioedema or ana-
phylaxis (SNIUAA)” and 23 cases (20 patients) of “Single-NSAID-induced 
delayed hypersensitivity reactions (SNIRD)”. 10 cases of bronchospasm 
without underlying chronic airway respiratory diseases and 62 cases of 
anaphylaxis, maculopapular rash and other hypersensitivity reactions 
induced not only by paracetamol but also by other NSAIDs could not be 
classified according to the criteria of this classification.
Only 25 (13.7  %) patients (mostly SNIUAA (ten patients) and SNIRD 
(seven patients)) underwent further allergological work-up with sus-
pected causative drug. Only seven (28 %) of them (three SNIUAA, two 
NIUA and two SNIRD), had true paracetamol hypersensitivity. For one 
patient hypersensitivity was demonstrated by patch test, and for six by 
DPTs. 6 out of 7 positive test results occurred as skin reactions.
Conclusions: True hypersensitivity to paracetamol is rare. In our 
research, only patients with skin reactions in their clinical history, 
mostly SNIUAA, were confirmed to be hypersensitive to this drug.
Keywords: Paracetamol; Diagnostics; Provocation tests; Drug 
hypersensitivity
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Background: Arylpropionic acid derivatives are the most commonly 
prescribed and consumed NSAIDs and very often obtained without 
medical prescription. From these the most common is ibuprofen. 
Within the group of hypersensitivity reactions to NSAIDs, these drugs 
are progressively involved and include those mediated by specific 
immunological mechanisms and those classically classified as cross-
intolerance reactions. Within the first category, IgE mediates or T cell 
specific responses may occur. We present a series of cases with an 
immediate selective response to ibuprofen and other arylpropionic 
derivatives confirmed by drug provocation tests (DPT). In addition to 
demonstrate selectivity of the response to these drugs we assessed 
cross-reactivity between them.
Materials and methods: Subjects who reported symptoms indicative 
of an hypersensitivity reaction to an NSAIDs were evaluated. A DPT 
with ASA was carried out to rule out cross-intolerance (non allergic 
hypersensitivity). Imputability of the different aryl propionic deriva-
tives and assessment of cross-reactivity was carried out by drug prov-
ocation tests. Serum tryptase was quantized in peripheral blood at 2 
and 24 h post episode and in the affected skin by immunohistochem-
istry at the moment of the appearance of the reaction.
Results: All subjects included had good tolerance to ASA. After proceed-
ing with the aryl propionic acid derivative challenge, 42 cases were clas-
sified as selective immediate responders. Ibuprofen was the drug most 
frequently involved, followed by naproxen and desketoprofen. We found 
cases than only responded to one single drug and others who responded 
to several, confirming cross-reactivity. Quantitation of tryptase levels 
in peripheral blood and skin biopsies were indicative of an immediate 
selective response with the involvement of mast cell activation.
Conclusions: Ibuprofen and other aryl propionic acid derivatives 
can induce selective responses in subjects with NSAIDs hypersen-
sitivity. Further studies are in progress for identifying the possible 
adducts (hapten-carrier complexes) implicated and the existence of 
cross-reactivity.
Keywords: Aryl-propionic derivates; Ibuprofen; Immediate selective 
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Background: Exposure to acetylsalicylic acid (ASA) and other non-
steroidal anti-inflammatory drugs (NSAID) may exacerbate respira-
tory disease (asthma, rhinitis), cutaneous diseases (urticaria and 
angioedema in patients with chronic urticaria, trigger urticaria, angi-
oedema and anaphylaxis in patients without underlying diseases.
We made a hypothesis that alternate regulation of cyclooxigenase-2 
(COX-2) mRNA expression may predispose patients to ASA-induced 
exacerbations.
Materials and cons: We performed a prospective study of 40 subjects 
(mean age 49  years, 27 women) who had suspected hypersensitivity 
to ASA or other NSAID. 20 subjects had asthma (10 of them also nasal 
polyposis). We performed provocation tests (nasal and/or oral) with 
ASA in all of them. In 14 subjects tests were positive (eight nasal). Gene 
expression was analyzed in whole blood sample using real-time RT 
PCR just before ASA provocation and 4  h after provocation. We also 
included six Hymenoptera venom allergic patients which were fol-
lowed after systemic reaction (SR) during VIT failure and four healthy 
control subjects.
Results: We found significantly important increase of COX-2 mRNA 
expression in patients with ASA provocation test (p  =  0.004). There 
was no difference in ASA tolerant patients. COX-1 expression was 
comparable between ASA tolerant and hypersensitive patients and 
showed no dynamic during provocation. There were no changes in 
COX-2 expression in subjects with SR during VIT or in healthy control 
subjects.
Conclusions: Main findings in our study are: (1) after provocation with 
ASA COX-2 expression is increased in subjects with Aspirin intolerance 
in comparison with subjects who tolerate Aspirin; (2) during allergic 
reaction like SR in VIT failure we found no difference in COX-2 expres-
sion; (3) all subjects that were positive on ASA provocation test had 
asthma and/or nasal polyposis.
Keywords: Asthma/rhinitis; Hypersensitivity to acetylsalicylic acid; 
COX-2 MRNA expression
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Background: Diclofenac is a phenylacetic acid derivative belonging to 
the group of arylcarboxylic acids. NSAIDs have been reported as the 
2nd most frequent cause of drug-induced anaphylaxis and diclofenac 
was the only NSAID significantly associated with anaphylaxis. How-
ever, some doubts remain about the pathophysiology of these reac-
tions. Here we describe a case series of anaphylaxis probably induced 
by diclofenac.
Materials and methods: Retrospective analysis of patients with sus-
pected anaphylaxis to diclofenac studied in our DAU, who underwent 
skin tests (ST). Records were analyzed for clinical signs and symptoms, 
severity of reactions, ST and oral challenges (OC). ST were performed 
with commercially available IV formulation of diclofenac, in a concentra-
tion of 25 mg/ml, diluted from 1 × 10−4 to 1/1 for IDT and 1/1 for SPT.
Results: A total of 33 patients were enrolled in the final analysis. 
Mean age was 50(±  12.75) years, 22(68.8  %) were women, 6(18.2  %) 
were atopic. The time elapsed until the reaction was less than 1 h in 
26(83.2 %) cases. Seventeen patients had grade 4 anaphylaxis and ten 
had history of re-exposure with reproducible symptoms.
Nineteen patients (62.7 %) reported reactions only to diclofenac (sin-
gle-reactors) and 12 to other NSAIDs (multiple reactors) (eight to ace-
tylsalicylic acid, two to aceclofenac). Twelve single-reactors (63.2  %) 
had positive ST (two with systemic symptoms during the procedure). 
Only four multiple reactors (33.3 %) had positive tests.
Only one diagnostic OC was performed in order to clarify a doubtful 
history and it was positive. OC with alternative drugs were performed 
in 29 patients, with meloxicam in 17 and etoricoxib in 9. Two patients 
had skin symptoms during the alternative OC and both were from the 
multiple reactors group.
Conclusions: We report a large series of anaphylaxis to diclofenac 
assessed by skin tests. As the majority of NSAIDs hypersensitivity reac-
tions are considered to be due to a non-immunologic mechanism, 
non-irritative concentrations to IDT and specific IgE’s are not available. 
Characteristics such as the severity and time of reaction, single-reactor 
status and systemic symptoms during skin tests suggest IgE-depend-
ent hypersensitivity in this study. The value of intradermal tests and 
their non-irritative concentrations remain to be determined doubtful 
history and it was positive.
Keywords: Diclofenac anaphylaxis mechanism
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Background: Nonsteroidal anti-inflammatory drugs (NSAID) are 
one of the most frequent causes of drug-induced hypersensitivity 
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reactions worldwide. It is generally assumed that inhibition of cycloox-
ygenase 1 (COX-1) enzyme by the offending drugs plays a relevant 
pathogenic role in multiple NSAID reactors. It is generally expected 
tolerability to preferential/selective COX-2 inhibitors among patients 
with NSAIDs hypersensitivity.
Materials and methods: We reviewed the medical records and 
selected patients referred to our drug allergy unit in the past 5 years, 
with history of reproducible hypersensitivity reactions to NSAIDs COX-1 
inhibitors and positive oral challenge (OC) with etoricoxib, a selective 
COX-2 inhibitor, and/or to meloxicam, a preferential COX-2 inhibitor.
Results: Inclusion criteria were met in 15 patients, aged 28–68 
(47  ±  13  years-old), 12 females. Seven patients were atopic. Eight 
patients had asthma, five chronic rhinosinusitis and nasal polyposis 
and three patients had chronic urticaria. The primary NSAIDs hyper-
sensitivity reactions were: eight urticaria and angioedema; four ana-
phylaxis and three asthma exacerbation. Eight patients presented 
a positive OC with meloxicam: four with immediate urticaria and 
angioedema; three with late-onset of angioedema and one with 
asthma exacerbation. One patient with late-onset angioedema to 
meloxicam also had a late-onset of angioedema with etoricoxib. 
Eight subjects had positive OC with etoricoxib: five with immediate 
urticarial, two with late-onset angioedema and one with anaphylac-
tic reaction.
Conclusions: Based on the results of previous studies, it could be 
tempting to prescribe COX-2 inhibitors in cases of multiple reactors to 
NSAIDs COX-1 inhibitors, without establishing its tolerance in a proper 
setting. However, these data strongly suggest that, before prescribing 
an alternative NSAIDs, a provocation test should always be performed.
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Background: History of NSAIDs hypersensitivity is common in some 
patients with coronary artery disease who are in need for coronary 
angioplasty. These patients require dual antiplatelet therapy to avoid 
in-stent thrombosis, and full evaluation of NSAIDs allergy. We present 
a cohort of patients with acute coronary syndrome undergoing aspi-
rin desensitization to evaluate the short- and long-term efficacy and 
safety
Materials and methods: We developed a dynamic protocol that is 
based on both the patient characteristics and onset of reaction after 
NSAIDs. This challenge/desensitization protocol is shorter than previ-
ously published ones. The objective is to asses short and long-term 
efficacy and safety prior to stent placement
Results: A total of 19 patients with history of NSAIDs allergy were chal-
lenged with different doses of Aspirin. All patients tolerated the oral pro-
tocol at different timings of 30–45–90–120 min. The dosage given ranges 
between (21, 41, 81 and 162 mg) of aspirin given by mouth after premedi-
cation with montelukast. We had two patients reacting during the pro-
cedure and one during a 6 h-follow-up. All reactions were limited to the 
skin. All patients tolerated the required dose of aspirin within 60–150 min. 
Those requiring urgent catheterization were desensitized within 90 min.
Conclusions: Our protocol provide an effective and safe short and 
long-time administration of Aspirin 81  mg dose in patients with his-
tory of NSAIDs allergy
Keywords: Aspirin; Desensitization; Coronary
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Background: Oral drug challenge (ODC) is the gold standard for the 
diagnosis of hypersensitivity reactions to non-steroidal anti-inflam-
matory (NSAIDs). If suspicion of respiratory symptoms, the ODC might 
include a lung function evaluation (LFE). Aim: To evaluate the lung 
function volumes during ODC to NSAIDs performed in our depart-
ment between 2010 and 2015.
Materials and methods: One-hundred and ten ODCs with NSAIDs 
under LFE were performed. An alternative drug was tested in 77 of 
the patients (70  %) whereas 33 were diagnostic tests (30  %). The 
drugs tested were meloxicam (n = 46, 41.8 %); acetylsalicylic acid (19, 
17.4 %); etoricoxib (16, 14.6 %); nimesulide (15, 13.6 %); ibuprofen (4, 
3.6  %); celecoxib (3, 2.7  %); metamizol (3, 2.7  %); acetaminophen (3, 
2.7 %) and diclofenac (1, 0.9 %). The criteria for a positive ODC were: a 
decrease in FEV1 ≥ 20 % of baseline, a decrease of MMEF75/25 ≥ 25 % 
of baseline or when major symptoms occurred. Statistical analysis 
based on independent sample t test and paired t test.
Results: Seventy-nine patients were female (71.8 %) (44.8 ± 15.6 years) 
and 31 were male (28.2 %) (40.5 ± 16.4 years). Sixty-two patients had 
a previous diagnosis of asthma (56.4 %), 18 of which with diagnosis of 
NSAID-exacerbated respiratory disease (NERD) (16.4 %).
ODC was positive in seven cases (four by decrease of volumes and 
three by reported symptoms): five alternatives and two diagnostic 
(four with meloxicam; one ibuprofen, one metamizol; one etoricoxib), 
two patients with no previous asthma diagnosis.
Taking into consideration the whole population tested, we observed sta-
tistically significant decreases in FEV1 and FVC values at 30 and 120 min 
after medication versus baseline; and also a decrease in volumes at 30, 
60, 120, 180 and 240 min after the second dose vs baseline (p < 0.05).
When comparing alternative versus diagnostic ODCs, we found statis-
tically significant differences in the measurement of FEV1 at 1 h after 
the second dose (p < 0.05).
Conclusions: The number of positive ODCs was low (6.36 %). Patients 
with asthma have an increased risk of reaction even with alternative 
NSAIDs. There was a statistically significant decrease in FEV1 at almost 
all timepoints after NSAIDs compared to baseline, even including neg-
ative challenges in the analysis. This suggests that NSAIDs might have 
a general effect to reduce FEV1.
Keywords: NSAID; NSAID-exacerbated respiratory disease; Asthma
P62 
Prevalence and incidence of analgesic hypersensitivity reactions 
in Colombia
Pablo Andrés Miranda1, Bautista De La Cruz Hoyos2
1Universidad Nacional de Colombia, Cartagena, Colombia; 2Centro de 
Especialistas Santo Domingo ‑ Alergologia, Cartagena, Colombia  
Correspondence: Pablo Andrés Miranda
Clinical and Translational Allergy 2016, 6(Suppl 3):P62
Background: The most common drug hypersensitivity reactions 
(DHR) involve analgesic such as aspirin and other non steroidal anti-
inflammatory drugs.
Materials and methods: Records with personal history of allergy anal-
gesics diagnosis (ICD-10 code Z886) of Information System of Social 
Protection (SISPRO) between 2010 and 2014 were included. To deter-
mine the prevalence and incidence of AHR, population estimates from 
the National Statistics Department of Colombia (DANE) were used.
Results: 1657 cases with personal history of AHR between 2010 and 
2015 were identified. 223 cases were confirmed news diagnoses in the 
same period. On average 331 cases of AHR per year were estimated. 
The estimated annual prevalence AHR were seven cases per million 
(2010 = 6; 2011 = 7.1; 2012 = 8.1; 2013 = 6.8 and 2014 = 7.2). The esti-
mated annual incidence AHR were 0.9 cases per million (2010 =  0.8; 
2011 = 1.1; 2012 = 0.9; 2013 = 0.8 and 2014 = 1). Most cases range 
between 19 and 59 years age (Table 1).
Conclusions: Both under-diagnosis and over-diagnosis AHR are com-
mon in the world. Population studies with confirmatory tests AHR in 
Colombia are required.
Keywords: Analgesic; Allergy; Hipersensitivity
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Background: Aspirin-exacerbated respiratory disease (AERD) is diag-
nosed clinically through a positive oral graded aspirin challenge. 
Upon confirming aspirin hypersensitivity, aspirin desensitization and 
treatment has been proven to reduce recurrence of nasal polyposis 
and asthma symptoms. However, negative aspirin challenges have 
been reported to occur in otherwise aspirin allergic individuals (“silent 
challenges”) after intake of antihistamines, leukotriene blockers, or 
oral corticosteroids. We sought to determine whether recent endo-
scopic sinus surgery (ESS) also affects reactions to aspirin challenge in 
patients with AERD.
Materials and methods: 19 AERD patients underwent two aspirin 
challenges: one before and the other after (within 8 weeks) their most 
recent ESS. Reactions to aspirin were evaluated by changes in forced 
expiratory volume in 1  s (FEVl, percent predicted), nasal peak flow 
(NPF), and fraction of exhaled nitric oxide (FeNO).
Results: Decreased time between ESS and challenge was associ-
ated with decreased frequency of positive reactions: all 19 patients 
with a history averaging 32 months (IQR 9–72) since last ESS, reacted 
to aspirin. In contrast, only 10 (52.6  %) of these patients, challenged 
on average of 1.1  months (IQR 0.8–1.4) after ESS, reacted to aspirin. 
Nine patients (47.4  %) had no clinically apparent reaction to aspi-
rin challenge after recent ESS. In the 10 patients who had a positive 
challenge after recent ESS, the decrease in FEV1 during this challenge 
was less than during the baseline challenge before ESS: −8.9  ±  1.2 
vs. −19.7  ±  3.7  % (p  <  0.01), respectively. NPF decrease was also 
smaller during the challenge after recent ESS than before recent ESS, 
−11.1 ±  5.1 vs. −25.5 ±  6.2  % (p  <  0.01), respectively. FeNO signifi-
cantly decreased in all patients during the first challenge (−22.2  % 
(IQR −50.6 to −20.9)) and decreased only in those who had positive 
challenges after recent ESS (−32.5 % (IQR −35.1 to −22.6; p = 0.3).
Conclusions: Recent ESS could contribute to a false-negative aspirin 
challenge. Patients who reacted to aspirin during the challenge after 
recent ESS had milder reactions comparing to the challenge before 
ESS. This presents a clinical dilemma: while appearing safer, aspirin 
challenges after a recent ESS may have a decreased diagnostic sen-
sitivity so that some AERD patients could be misclassified as aspirin-
tolerant. Clinicians should consider the possibility of false-negative 
challenges after recent ESS.
Keywords: Aspirin exacerbated respiratory disease; Oral graded aspi-
rin challenge; Endoscopic sinus surgery; Silent challenge
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Background: Hypersensitivity to non-steroidal anti-inflammatory 
drugs (NSAIDs) has been classified by Ayuso et al. into different pheno-
types. Multiple NSAID-induced urticaria-angioedema (MNSAID-UA) is 
presumably related to cyclo-oxygenase 1 (COX -1) inhibition. Patients 
with MNSAID-UA have reactions to multiple chemically unrelated mol-
ecules while usually they tolerate low COX-1 inhibitors.
Report: We report the case of a 32  years old man who expe-
rienced several episodes of angioedema of lips and face after 
intake of acetylsalicylic acid (ASA), in one occasion associated 
to the intake of paracetamol. Diagnosis of MNSAID-UA was con-
firmed by oral drug provocation test (DPT) to ibuprofen, a strong 
COX-1 inhibitor chemically unrelated to ASA, that induced labial 
angioedema. DPT with alternative drugs, defined as low COX-1 
inhibitors, was then performed. Angioedema also appeared with 
nimesulide and paracetamol. Instead, the patient tolerated imida-
zole salicylate.
How this report contributes to current knowledge: Low COX-1 
inhibitors as paracetamol and nimesulide not always are tolerated by 
patients with MNSAID-UA. This report confirms the safe use of imida-
zol salicylate in patients with hypersensitivity to ASA presumably due 
to non-interference with the cyclo-oxygenase pathway.
Consent: Written informed consent was obtained from the patient for 
publication of this abstract and any accompanying images.
P65 
Selective hypersensitivity reactions to ibuprofen—seven years 
experience
Marta Ferreira Neto
CHLN‑HSM, Lisbon, Portugal  
Correspondence: Marta Ferreira Neto
Clinical and Translational Allergy 2016, 6(Suppl 3):P65
Background: Immunologically mediated (non cross-reactive) 
hypersensitivity reactions to nonsteroidal anti-inflammatory drugs 
(NSAIDs) are classified in two groups: Single NSAID-induced urti-
caria/angioedema or anaphylaxis and Single NSAID-induced delayed 












 1–5 años 0.4 (1) 5.1 (17) 2.4 (9) 5.2 (17) 3.8 (13)
 6–9 años 5.4 (15) 6.9 (23) 4 (15) 5.2 (17) 3.2 (11)
 10–14 
años
8 (22) 6.3 (21) 9.2 (35) 10.8 (35) 12.1 (42)
 15–18 
años
8.3 (23) 6.9 (23) 7.4 (28) 7.7 (25) 10.8 (37)
 19–26 
años
14.9 (41) 13.9 (46) 19.8 (75) 18.8 (61) 16.8 (58)
 27–44 
años
34.8 (96) 32 (106) 29.8 (113) 26.2 (85) 27.7 (96)
 45–59 
años
19.2 (53) 19 (63) 16.4 (62) 16.6 (54) 14.5 (50)
 >60 años 9.1 (25) 9.7 (32) 11.1 (42) 9.5 (31) 11.3 (39)
 Total 100 (276) 100 (331) 100 (379) 100 (325) 100 (346)
Incidence AHR Colombia
Cases per million
 1–5 años 0 (0) 0 (0) 0 (0) 2.5 (1) 8.2 (4)
 6–9 años 5.4 (3) 0 (0) 2.4 (1) 5 (2) 10.2 (5)
 10–14 
años
8 (4) 9.3 (5) 9.5 (4) 2.5 (1) 10.2 (5)
 15–18 
años
8.3 (2) 7.4 (4) 7.1 (3) 10 (4) 18.4 (9)
 19–26 
años
14.9 (4) 20.4 (11) 21.4 (9) 22.5 (9) 20.4 (10)
 27–44 
años
34.8 (10) 35.2 (19) 26.2 (11) 25 (10) 16.3 (8)
 45–59 
años
19.2 (8) 18.5 (10) 23.8 (10) 22.5 (9) 8.2 (4)
 >60 años 9.1 (7) 9.3 (5) 9.5 (4) 10 (4) 8.2 (4)
 Total 100 (38) 100 (54) 100 (42) 100 (40) 100 (49)
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hypersensitivity reactions. In these entities patients have hypersensi-
tivity to NSAIDS belonging to the same chemical group and tolerate 
chemically nonrelated ones. Usually there isn’t an underlying chronic 
disease like asthma or urticaria. Ibuprofen (Ib), belonging to Propi-
onic acid derivatives (Pad) group, is one of the most frequently used 
NSAIDs, with frequent hypersensitivity drug reactions reports.
Materials and methods: We retrospectively analysed all patients (Pt) 
referred to our drug outpatient visit, from January 2008 to Decem-
ber 2015, with a selective history of hypersensitivity reaction to Ib. 
Oral drug challenges (ODC) were performed, in order to establish the 
diagnosis.
Results: A total of 10 Pt, aged between 18 and 79, 90 % female were 
included. After intake of Ib, 10(100  %) Pt reported cutaneous symp-
toms: 2(20  %) Urticaria (U) and 8(80  %) U/Angioedema. Besides Ib, 
Flurbiprofen, Dexcetoprofen and Naproxen were also the culprit drugs 
in three different Pt. All 10 Pt tolerated Acetaminophen after the reac-
tion. Hypersensitivity reactions were immediate in 3(30  %) Pt (<1  h), 
late (1–6 h) in 1(10 %) and accelerated (8–24 h) in 6(60 %). ODC were 
performed with Ibuprofen, Acetylsalicylic acid (ASA) and Nimesulide 
(N)  in 6(60  %) patients, and in the remaining  4(40  %) only with  ASA 
and N. All ODC (100 %) with Ib were positive, with reproductible symp-
toms, even in the non immediate reactions. All Pt (100 %) had nega-
tive ODC with ASA and N.
Conclusions: Single NSAID-induced urticaria/angioedema to Ib was 
established in 10 (100 %) Pt and to chemically related compounds of 
Pad group in three (30 %) Pt. Women represent the majority, cutane-
ous symptoms are the only clinical presentation and 70  % are non-
immediate reactions. Other strong Cox1 inhibitors (except Pad group), 
Nimesulida and Acetaminophen are the alternatives in the 10 patients.
Keywords: Selective; Ibuprofen; Oral challenges
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Background: Allopurinol, an antihyperuricaemic agent, is used as first-
line treatment of chronic gout. Allopurinol hypersensitivity (AH) is a 
rare but important cause of hypersensitivity reactions, ranging from 
mild cutaneous manifestations to life-threatening severe cutaneous 
adverse reactions (SCAR). Despite several risk factors have been pro-
posed, the underlying mechanisms remain unknown. Our aim was 
to characterize a series of patients with suspected AH referred to our 
drug allergy department during a 7-year period (2009–2015).
Materials and methods: A retrospective analysis was performed, 
assessing demographic and clinical data. AH was confirmed by a posi-
tive drug provocation test (DPT), positive lymphocyte transformation 
test (LTT) or reaction upon desensitization, and considered probable 
based only on a suggestive clinical history.
Results: Among a total of 954 patients, 29 (3  %) had suspected AH. 
The mean age was 69 ± 10 years and 16 (55 %) were male. Allopuri-
nol was prescribed for gout in 14 (48  %), asymptomatic hyperurice-
mia in 12 (41 %) and malignancies in 3 (10 %) patients; 20 (69 %) were 
polymedicated (≥4 drugs). Cutaneous reactions were reported by 27 
(93  %) subjects (14 exanthema, 5 urticaria/angioedema, 2 fixed drug 
eruption, 3 vasculitis and 3 DRESS). Twenty-six (90 %) reported delayed 
reactions (DR), 1 reported immediate reaction and 2 were unable to 
recall onset. SPT (3) and patch tests (25) were negative in all patients 
tested. LTT performed in 12 patients (five exanthema, one urticaria/
angioedema, three vasculitis and three DRESS) was positive in four, 
negative in five, doubtful in two and undetermined in one. DPT was 
positive in 2 out of 11 and long term challenge in 2 out of 8. Four 
patients were submitted to desensitization: three developed reaction 
during the procedure, confirming diagnosis; two were able to toler-
ate treatment. AH was confirmed in 10 (35 %), considered probable in 
six (21  %), excluded in seven (24  %) and inconclusive in six patients. 
Among confirmed AH patients, all were DR and 80  % had started 
Allopurinol recently (≤10 days).
Conclusions: As previously described in the literature, our study sug-
gests that AH is rare, usually presents with delayed cutaneous symp-
toms and can be related to recent Background of Allopurinol. In the 
diagnostic workup of suspected AH, DPT remains the gold-standard 
while patch tests appear to be unhelpful. We discuss the useful-
ness of TTL, which seems promising, especially in SCAR where DPT is 
contraindicated.
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Background: Patients frequently report antibiotic allergies, however 
only about 10  % of labelled patients have a true allergy. This study 
investigates the documentation of antibiotic “allergy” labels (AALs) 
and the effect of labelling on clinical outcomes in an adult tertiary hos-
pital in Australia.
Materials and methods: We performed a retrospective single-centre 
cross-sectional analysis of 737 inpatients in a major teaching hospital 
in Western Australia. All patients were captured in the 2013 and 2014 
National Antimicrobial Prescribing Surveys (NAPS). NAPS is an annual 
audit of Australian health services, led by The Australian Commission 
on Safety and Quality in Health Care, to assess volume and appropri-
ateness of antimicrobial prescribing. Data collected by detailed chart 
review, included antibiotic adverse drug reactions (ADRs), antibiotic 
cost, prescribing appropriateness, prevalence of multi-drug resistant 
organisms, length of stay, intensive care admission and readmissions.
Results: Complete data were captured for 687 patients. 278 (40  %) 
were aged 70 or above, 322 (47 %) were female and 279 (41 %) were 
prescribed antibiotics at the time of audit. AALs were recorded in 
122 (18 %) of all patients. The majority of AALs were penicillin labels 
(n = 87; 71 %). Details of the clinical reactions to the culprit antibi-
otic were documented for 80 of 141 (57 %) individual allergy labels: 
61 described symptoms consistent with drug allergies and 19 were 
non-specific symptoms. Five patients were receiving an antibiotic 
that would be considered contraindicated according to their docu-
mented allergy status. Females and older patients were significantly 
more likely to have an AAL (gender: OR 2.54, 95  % CI =  1.69–3.82, 
p < 0.001; for a one standard deviation (19.6 years) increase in age: 
OR 1.31, 95  % CI  =  1.06–1.60, p  =  0.007). Patients with AALs had 
significantly more hospital readmissions within 4 weeks (p = 0.001) 
and 6  months (p  =  0.025) of discharge, compared with unlabelled 
patients independent of age and gender. The majority of patients 
with AALs (84  %) who were readmitted had a diagnosis of an 
infection.
Conclusions: This first Australian study shows that purported AALs 
are common but poorly documented in hospital records. Patients with 
AALs are significantly more likely to require readmissions. There may 
be a role for antibiotic allergy delabelling to mitigate the clinical and 
associated economic burdens for patients with invalid allergy labels.
Keywords: Antibiotic; Allergy; Adverse drug reactions; Delabelling
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Background: On June 8th, 2015, the 9th International Congress on 
Cutaneous Adverse Drug Reactions (cADR) was held at the 23rd World 
Congress of Dermatology. Eighty participants attended the congress 
from 23 countries; a variety of specialists with different areas of exper-
tise included dermatology, regulatory agencies and public health, 
clinical pharmacology, immunology, infectious disease, oncology, 
pediatrics, etc. During the Congress, surveys were conducted to learn 
about the participants’ experiences and perspectives regarding four 
major topics: pharmacogenomics and severe cutaneous adverse drug 
reactions (SCAR), drug reaction with eosinophilia and systemic symp-
toms (DRESS)/drug-induced hypersensitivity syndrome (DIHS), Ste-
vens–Johnson syndrome and toxic epidermal necrolysis (SJS/TEN), and 
acute generalized exanthematous pustulosis (AGEP).
Materials and methods: Participants answered survey questions 
anonymously through an electronic voting system.
Results: In a survey of the pharmacogenomics of SCAR, 21 % of partic-
ipants regularly conducted genetic screening prior to treatment with 
carbamazepine (N = 53) and 15 % of participants regularly conducted 
genetic screening prior to administration with allopurinol (N  =  52). 
Seventy-eight percent reported that there is a lack of knowledge 
among physicians regarding genetic screening for Human Leukocyte 
Antigens (HLAs) for preventing SCAR in their country (N = 51). In a sur-
vey of SJS/TEN, systemic corticosteroids was the preferred treatment 
in 45  % followed by only supportive treatment in 18  %, intravenous 
immunoglobulin in 16 %, and cyclosporine in 14 % (N = 51). In a sur-
vey of DRESS/DIHS, 36 % regularly assess reactivation of human her-
pesvirus-6 (HHV-6) in their management of patients with DRESS/DIHS 
(N = 53), and 33 % monitor late autoimmune complications in these 
patients (N = 54). In a survey of AGEP, 67 % of participants always con-
duct assessment for systemic involvement (N = 47).
Conclusions: There is a lack of implementation of regulatory agen-
cies recommendations’ regarding genetic screening prior to treat-
ment with carbamazepine or allopurinol. There is still no international 
consensus for the management of patients with SJS/TEN. Assessing 
reactivation of HHV-6 and monitoring late autoimmune complications 
in patients with DRESS/DIHS is not commonly done. Assessing sys-
temic involvement in patients with AGEP was found to be commonly 
conducted.
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Background: Pharmacovigilance (PV) programs based on spontane-
ous reporting of adverse drug reactions (ADRs) are compromised by 
underreporting and inconstant data quality. Underreporting of severe 
adverse drug reactions by hospitals is in the range of 95 % (Drug Saf 
2006;29:385–96). This study aims to assess underreporting and to 
evaluate the potential of electronic chart screening for SCARs in two 
departments (dermatology and allergology) as a proactive case detec-
tion method regarding detection rate and data quality.
Materials and methods: Electronic reports from January 2014 to 
December 2015 of the allergology and dermatology units at the 
Inselspital Bern (Switzerland) were reviewed monthly for diagnosis of 
SCARs (AGEP, SJS/TEN, DRESS) and compared to SCARs reported to the 
PV service of the clinical pharmacology unit. Cases were evaluated for 
standard PV parameters and results of allergologic and HLA testing if 
available.
Results: During this 2-year period, 27 SCARs were registered at our 
PV unit. 2 SCAR cases were reported spontaneously (one DRESS, one 
SJS), while 25 SCARs were detected proactively (13 AGEP, 9 DRESS, 3 
SJS). Interestingly, among the screened charts, a patient with carba-
mazepine-induced AGEP was a carrier for HLA-A*31 (HLA-A*3101 to 
be confirmed), possibly associated with carbamazepine-induced AGEP 
(Epilepsia 2014;55:496–506).
Conclusions: Spontaneous reporting is insufficient, even for severe 
ADRs with well-established causality. Combination of chart screening 
with standard PV programs is a promising method to enhance detec-
tion rate and signal quality for rare idiosyncratic ADRs.
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Background: There are several studies demonstrating an important 
association between allergic diseases and the psychological charac-
teristics of the patients. The majority involves skin or respiratory dis-
eases and only a few drug allergy (DA). Patients with adverse reactions 
to drugs appear to have more psychological disturbances than those 
with asthma/rhinitis.
Materials and methods: We evaluated psychological characteristics 
of 115 consecutively patients >16  years-old, studied in our Depart-
ment for suspected DA. Four self-completed validated questionnaires 
(anxiety, depression, alexithymia, personality type) were used. Evalu-
ation of patient emotions at the time of the reaction was also per-
formed based on a numerical scale to quantify fear/panic and an open 
question. The control group included 55 patients from the outpatient 
clinic without any history of DA. Description of variables was done 
through absolute and relative frequencies. Chi square and Fisher test 
were used to evaluate the association between variables and groups. 
The magnitude of the associations was measured by the Odds Ratios. 
The significance of the difference between the medium intensity of 
fear/panic at the time of the reaction by gender was evaluated by a 
student t-test for independent samples. All the variables with a proof 
value <=0.20 in the univariate analysis were considered for the multi-
variate analysis. The level of significance was considered 5 %. Statisti-
cal analysis used the SPSS, version 20.0.
Results: There were no significant differences between the two 
groups concerning demographic or social characteristics, except 
for age (p =  0.025). Allergic diseases were significantly more preva-
lent in the control group (51.1 vs. 87.3  %; p  <  0.001) but other dis-
eases were significantly higher in the patient group (67.5 vs. 27.8 %; 
p  <  0.001). The majority of the controls were on regular medication 
(68.4 vs. 94.2 %; p < 0.001), although psychiatric medication was more 
frequently used in the case group (32.0 vs. 5.8  %; p  <  0.001). After 
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adjustment for age, allergic disease, other diseases and daily medica-
tion, the suspicion of DA did not show any association with psycho-
logical characteristics. The differences between the medium intensity 
of fear/panic at the time of the reaction by gender were statistically 
significant (p =  0.022), with males having a lower result (2.7 points 
vs. 3.6).
Conclusions: The suspicion of DA did not show any association with 
psychological characteristics of the patients. The analysis of those with 
confirmed DA is still ongoing.
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Background: Challenge test (CT) is the gold-standard for the diagno-
sis of drug allergy. Its implementation involves a high consumption 
of time and resources and implies the risk of severe adverse reactions 
apparence.
Currently there is not a diagnostic tool able to perform an early detec-
tion of the allergic reactions, thus reducing the length of the challenge 
test and decreasing the onset of severe allergic reactions.
Heart rate variability has been used for help to the diagnosis of several 
illnesses. It has been recently used for the detection of allergic reac-
tions. We explore the use of a heart rate variability monitoring device 
to detect in real time the allergic reactions in patients undergoing a 
CT.
Materials and methods: Patients, older than 12 years, with suspected 
drug allergy that, following the normal diagnostic protocol, were 
undergoing a CT and agreed to participate. A remote monitoring 
device called Shimmer was placed from 10 min before the star of the 
test until Its completion. Increasing doses of the drug were adminis-
tered at 30 or 60 min interval until the end of the test or until the onset 
of allergic symptoms. Heart rate variability was analysed by the pro-
posed mathematic algorithm, and Its results were compared to the CT 
results.
Results: One hundred and twenty thee patients were studied: 81 
women, 42 men, mean age 41.8 years (14–92). Drugs tested included 
NSAID (50), Betalactamics (40), other antibiotics (8) and others (25). 
The drug CT was positive in seven of them (5.6 %).
The algorithm detection showed a positive result in nineteen patients 
and a negative one in 104. Its sensitivity and specificity were 57 
and 87  % respectively. When NSAIDs CT were ruled out the results 
improved reaching 100 % sensitivity and 96 % specificity. The global 
negative predictive value was 97 %.
The detection took place at least 90 min before the onset of symptoms.
Conclusions: The use of a heart rate variability device with a mathe-
matic algorithm can be a useful tool in drug allergy diagnosis. Further 
studies are needed.
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Background: Abacavir (ABC) binds non-covalently to the floor of the 
peptide-binding groove of HLA-B*57:01, altering the chemistry and 
shape of the antigen binding cleft. This allows previously untolerized 
self-peptides to be presented by HLA-B*57:01 to T cells. Endoplasmic 
reticulum aminopeptidases (ERAPs) trim peptides for MHC Class I pres-
entation, influencing the degree and specificity of the CD8+ T-cell 
response. Genetic variation within ERAP adds to the positive predic-
tive value (PPV) of the HLA class I risk allele in autoimmune diseases 
such as HLA-B27 positive ankylosing spondylitis. Considering the 
altered peptide repertoire mechanism of ABC HSR we hypothesize 
that variation in ERAP may help explain why 45 % of patients carrying 
HLA-B*57:01 can tolerate ABC.
Materials and methods: 3′UTR, intron and exon encoded SNPs which 
characterise gene haplotypes were examined for ERAP1 in HLA-
B*57:01 + ABC patch test positive (PT +) patients [n = 53] and HLA-
B*57:01 + ABC tolerant controls [n = 22] with sequence-based typing. 
Rs2248374, a tag SNP for functional ERAP2 haplotypes was also exam-
ined. Haplotype A is tagged by the (A) allele, while haplotype B is 
tagged by rs2248374(G). Fisher exact tests and multiple logistic regres-
sions were used to compare genotypes between ABC HSR PT+ and 
tolerant groups.
Results: HLA-B*57:01  +  ABC tolerance was associated with 
rs27434(GG) (18/22(82 %) vs 24/53(45 %) in ABC HSR PT+, p = 0.005). 
This SNP maps to the active site within ERAP1 (AA356). For an HLA-
B*57:01 positive population, with 45  % of cases tolerant to abacavir, 
the estimated chances of tolerance given rs27434 genotype are 
AA (0  %), AG (13  %) and GG (43  %). A missense mutation within the 
domain junction (rs30187(C)) important in conformational change of 
ERAP1 (AA528), was overrepresented in HLA-B*57:01 +  ABC tolerant 
individuals (p  =  0.04). Analysis indicated linkage between rs27044 
and rs30187, rs17482078 and rs2287987, and between rs30187 and 
rs27434 (all p  <  0.0001). In a multivariable model with rs27434(GG), 
the ERAP2 SNP (rs2248374(G)) that tags haplotype B, characterized by 
a truncated protein, was decreased in tolerant individuals (p = 0.005).
Conclusions: ERAP variants are important in the development of ABC 
HSR. ERAP activity may influence the repertoire of peptides presented 
by HLA-B*57:01 or influence early changes in immunodominant 
epitope selection. This provides a potential pathogenic mechanism for 
the development of ABC HSR or ABC tolerance in HLA-B*57:01 carriers.
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Background: Drug rash with eosinophilia and systemic symptoms 
(DRESS) syndrome is an uncommon but serious hypersensitivity drug 
reaction. It is characterized by a polymorphic disseminated eruption 
with fever and multiple organ dysfunction. DRESS syndrome is a rare 
entity in children.
The authors describe a case of a children admitted to our hospital for 
amoxicillin-clavulanate induced DRESS syndrome.
Materials and methods: case report: Male, 31 months-old, presented 
to the emergency department with diffuse erythema involving trunk 
and extremities, sparing palms of hands and feet, angioedema of the 
tongue and fever after treatment with amoxicillin/clavulanate for cuta-
neous infection.
Laboratory findings revealed lymphocytosis, eosinophilia (600/µl), and 
elevated serum transaminases AST 139 U/l, ALT 440 U/l, LDH 976 U/l. 
No previous drug allergies were reported at the time of presentation.
On the second day of hospitalization, the patient’s rash was still persis-
tent ant it appeared petechiae and hemorrhagic suffusion suggestive 
of vasculitis on the face, forehead and periorbital without worsening 
throughout the hospitalization.
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Infectious markers and serological tests were negative. Corticosteroid 
treatment was started after exclusion of other potentially serious condi-
tions including infections and hematologic malignancies. The results of 
the skin biopsy taken from the lesions revealed superficial perivascular 
dermatitis involving spongiotic eosinophils compatible with spongiotic 
drug eruption. A dramatic improvement was observed and his clinical and 
laboratory findings were recovered on the 5th day of the treatment.
The high fever, lymphocytosis and eosinophilia were resolved (eosino-
philia rate was 1.8 %). ALT 114, AST 57, without changes of cholesta-
sis (GGT 28, LDH 567, total bilirubin 0.2 mg/dl). Abdominal ultrasound 
unchanged.
Specific IgE β-lactams were negative.
Patch tests with β-lactams revealed positive reaction to amoxicillin.
Conclusions: Given the significant morbidity early recognition of drug 
reaction with eosinophilia and systemic symptoms syndrome and ini-
tiation of appropriate therapy are imperative in limiting morbidity.
In this study, patch testing was a safe and useful method in confirm-
ing the culprit drug in DRESS induced β-lactam. The pathogenesis of 
DRESS is not yet entirely clarified, but positive patch tests suggest a 
drug-dependent delayed hypersensitivity mechanism.
Keywords: DRESS Syndrome; Amoxicillin-clavulanate; Patch testing
Consent: Written informed consent was obtained from the patient for 
publication of this abstract and any accompanying images.
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Background: Acute generalized exanthematous pustulosis (AGEP) is 
a rare eruption characterized by acute, extensive formation of sterile 
nonfollicular pustules on edematous- erythematous skin. It is accom-
panied by fever, peripheral blood leucocytosis neutrophilia, and some-
times by facial edema, hepatitis and eosinophilia. Most cases of AGEP 
(90 %) is caused by drugs and acute infections.
Report: 34 year- old female patient with ulserative colitis had been taken 
mesalazine tablets 2400 mg per day for 1 month. After 1 month therapy, 
a cutaneous reaction characterized by disseminated pustules on an ery-
thematous base happened and mesalazine was stopped. During the 
period, lesions was localised to extremities, so topical therapy used. After 
the reaction was recovered, because of severe ulserative colitis, 15 days 
later mesalazine was restarted. Due to the second therapy, after the first 
dosage, she developed multiple disseminated sterile pustules on an 
erythematous background, associated with fever and neutrophilia. Lab-
oratory examinations showed the elevation of white blood cells, neutro-
phils, erythrocyte sedimentation rate and C-reactive protein (white blood 
cells, 9110/mm3; (64.2 % neutrophils, 21.4 % lymphocytes, 2.7 % eosin-
ophils, 11.4  % monocytes), erythrocyte sedimentation rate 13  mm/h, 
C-reactive protein level 3.27 mg/dl). Punch biopsy from pustules revealed 
subcorneal pustular formation, perivascular infiltration rich in leukocyte 
in dermis and acanthosis in epidermis. No accumulation was detected 
in immunofluorescence analyses. Clinical and histopathological find-
ings were considered as AGEP. She was treated with intravenous corti-
costeroids, oral antihistamines and topical corticosteroids. The patient’s 
rashes decreased within the following 7 days and then diminished with 
desquamation.
How this report contributes to current knowledge: We report a 
patient with AGEP after the use of mesalazine. It’s important to con-
sider AGEP in the differential diagnosis of acute pustular rashes and 
drugs should be investigated as causative agents. Knowledge of the 
clinical features are necessary to be distinguished from other entities. 
It’s the first AGEP case due to 5-ASA derived mesalazine in the litera-
ture. As mesalazine has been oftenly using for inflammatory bowel 
diseases, clinicians should be aware of its potential about developing 
AGEP and be careful about it. 
Consent: Written informed consent was obtained from the patient.
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Background: Drug reaction with eosinophilia and systemic symptoms 
(DRESS) is a severe cutaneous drug reaction characterized by exan-
thematous skin rash, fever, lymphadenopathies, eosinophilia, atypical 
lymphocytosis and internal organ involvement. Reactivation of human 
herpes virus (HHV)-6 and decreased plasmacytoid dendritic cell (pDC) 
in the peripheral blood were putatively related to the disease, though 
the causality remained inconclusive.
Materials and methods: We recruited 18 patients from July 2013 to 
May 2014 with the diagnosis of drug eruptions including maculopapu-
lar eruptions (MPE), Stevens–Johnson syndrome (SJS), fixed drug erup-
tion (FDE) and DRESS. The peripheral blood pDC (lin−CD123+CD11c−), 
myeloid DC (mDC, lin−CD123−CD11c+) and basophils (lin−HLA-
DR−CD123+CD11c+) were simultaneously labeled and processed by 
4-color assay method, with the frequencies of such cells counted by 
flow cytometry. HHV-6 reactivation was determined by the presence 
of viral DNA in the whole blood sample or the elevation of anti-HHV-6 
IgG in the serum during the convalescent stage.
Results: Decreased frequencies of pDC were significantly associ-
ated with the diagnosis of DRESS (p =  0.004), presence of atypical 
lymphocytosis (p = 0.023) and HHV-6 reactivation (p = 0.043), while 
those of mDC and basophils were unrelated to the type of drug erup-
tion, presence of atypical lymphocytosis, eosinophilia or HHV-6 reac-
tivation. The reactivation of HHV-6 was only found in DRESS patients, 
in which the pDC frequencies consistently showed a decreasing 
trend.
Conclusions: In this study, we found that decreased pDC in the 
peripheral blood during the acute stage is more common in DRESS 
patients than the other drug eruptions, while only part of the patients 
demonstrated measurable HHV-6 reactivation. mDC and basophils did 
not show remarkable trend among different drug eruptions. The dec-
rement of peripheral blood pDC might be the preceding, or might be 
the causative, event before HHV-6 reactivation.
Keywords: Drug reaction with eosinophilia and systemic symptoms; 
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Background: Antituberculosis drugs (ATDs) including isoniazid, 
rifampicin, pyrazinamide and ethambutol are commonly used for 
the treatment of tuberculosis, but occasionally associated with drug- 
induced hypersensitive reactions such as drug  rash with  eosino-
philia  and systemic symptoms (DRESS) syndrome and hepatitis. The 
culprit drug and mechanistic basis of the hypersensitive reaction has 
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not been defined.  The aim of this study was to find whether drug-
responsive T cell response was detectable in patients with ATD-related 
DRESS and characterize the mechanistic features of the T-cell response.
Materials and methods: A lymphocyte transformation test (LTT) 
was performed using peripheral blood mononuclear cells (PBMCs) 
from ATD-induced DRESS patients. Subsequently, drug-specific T-cell 
clones were generated from the hypersensitive patients. We measured 
the drug-specific proliferative responses and interferon-gamma (IFN-
γ) secretion. Anti-human class I and class II blocking antibodies were 
used to analyze HLA-restricted T-cell response.
Results: Strong proliferative responses to isoniazid or rifampicin were 
detectable in the patient with DRESS by LTT. Isoniazid/rifampicin- 
specific T-cell clones were generated from blood of the patients, but 
not pyrazinamide or ethambutol. The T cell clones proliferated and 
secreted IFNγ when stimulated with isoniazid or rifampicin. They did 
not cross-react with each other. T-cell responses were blocked in the 
presence of anti-human class II antibodies.
Conclusions: This study identifies isoniazid/rifampicin- responsive 
T-cells in peripheral blood of certain patients with ATD-induced DRESS. 
It highlights an important role of drug-responsive T-cell immune 
responses in ATD-induced DRESS syndrome.
Keywords: Antituberculosis drugs; Drug rash with eosinophilia and 
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Background: Drug reaction with eosinophilia and systemic symptoms 
(DRESS) is a rare and potentially life threatening condition. DRESS pre-
ceding toxic epidermal necrolysis (TEN) has only been reported with 
three cases to date.
Report: A 31  year old lady presented with a 3  day history of fever, 
morbilliform rash, cervical lymphadenopathy and facial oedema. 
5 weeks prior she had been diagnosed with rheumatoid arthritis (RA) 
and commenced on hydroxychloroquine and sulfasalazine. Investiga-
tions showed an eosinophilia, elevated liver function tests (LFTs) and 
high inflammatory markers. Infectious screen including viral tests was 
negative. A clinical diagnosis of DRESS was made, all RA drugs were 
ceased and she was started on high dose oral corticosteroids. During 
admission she developed a marked lymphocytosis, neutrophilia and 
eosinophilia with worsening LFTs and coagulopathy. The rash, LFTs 
and leukocytosis gradually improved and she was discharged on day 9 
to continue on high dose oral steroids.
She presented 3 days later with worsening of her rash, high fevers and 
right upper quadrant abdominal pain associated with worsening of LFTs, 
anaemia and thrombocytopenia. 3 doses of IV methylprednisolone were 
administered. Haemophagocytic lymphohistiocytosis was considered 
given a high ferritin and hypofibrinogenaemia although bone marrow 
examination showed reactive changes but no evidence of haemophago-
cytosis. There was again improvement in rash, facial swelling and labora-
tory markers, and she was discharged to continue high dose steroids.
She re-presented 7  days later with return of fevers, rash, jaundice 
and deterioration in her LFTs. Cyclosporin was added but ceased 
after 4 days due to concerns regarding worsening LFTs. Liver biopsy 
showed submassive central necrosis and prominent bile duct dam-
age. Ganciclovir was added following an equivocal PCR for HHV-6 on 
the liver biopsy tissue and she was considered for liver transplant 
if her liver failure worsened. On day 40 her LFTs had improved but 
she developed mucosal ulceration involving the mouth, eyes and 
genitals with bullous skin lesions involving 80 % of the body surface 
which was Nikolsky sign positive. Skin biopsy was consistent with 
TEN. She was transferred to the ICU for aggressive management and 
intravenous immunoglobulin but deteriorated and passed away the 
next day.
How this report contributes to current knowledge: Here, we pre-
sent a fatal case of DRESS with fulminant liver failure followed by 
extensive TEN despite immunosuppression and broad anti-microbial 
cover.
Consent: Written informed consent was obtained from the patient for 
publication of this abstract and any accompanying images.
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Background: The aim of this study was to evaluate the clinical and 
chronological Drug Rash with Eosinophilia and Systemic Symptoms 
(DRESS) characteristics according to the culprit drug.
Materials and methods: We carried out a retrospective study includ-
ing all cases of DRESS notified to the Pharmacovigilance Unit of 
Monastir during 11  years. Diagnosis of DRESS was based on Euro-
pean RegiSCAR criteria. Imputability was established according 
to Begaud’s method. Skin tests were performed according ENDA 
recommendations.
Results: Fourty seven cases of DRESS were included in our study: 
27 men and 20 women, with a mean age of 47  years ±  19. Antie-
pileptics drugs (18 cases: 15 carbamazepine, 2 phenobarbital, and 1 
lamorigine) were the most frequent responsible drugs in our study 
followed by antibiotics (12: 6 betalactams, 4 glycopeptides, 1 cot-
rimoxazole and 1 ethambutol), allopurinol (10) and salazopyrin (7). 
All patients had pruritic maculopapular rash involving more than 
50 % of their body surface area. Mucosal involvement was observed 
mainly with antiepileptics drugs (five cases) and allopurinol (four 
cases). Lymphadenopathy was more frequent with salazopyrin 
and antiepileptics drugs (55  % each). Eosinophilia was observed 
in 90  % of cases with allopurinol, 66  % with antibiotics and antie-
pileptics drugs, and 57  % with salazopyrin. Atypical lymphocyto-
sis was observed only in eight cases. Liver was the most common 
organ affected (74.5 %) in our series. The most frequent type of liver 
injury was: cytolytic with antibiotics and allopurinol (58 and 30  % 
respectively) and mixed with salazopyrin and allopurinol (57 and 
50  % respectively). Renal failure was observed in all cases induced 
by allopurinol. Pulmonary involvement was observed in five cases 
(three with salazopyrin and two with antiepileptic drugs). The mean 
incubation period was similar in the four groups of incriminated 
drugs. The outcome was favorable after drug withdrawal in 95.7 % 
of cases. Two patients with DRESS induced by allopurinol died 
because of multiple organ failure. Skin tests (patch or intradermal 
tests) were done in 33 cases. 75  % of skin tests with antiepileptics 
drugs and antibiotics were positive. Skin tests with salazopyrin and 
allopurinol were all negative.
Conclusions: Throughout this study, we point out the variability of 
DRESS clinical characteristics according to the culprit drug in one hand 
and the usefulness of skin tests with salazopyrin and allopurinol in the 
other hand.
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Background: DRESS is a life threatening hypersensitivity reaction. 
Allopurinol is a frequent cause. Lymphocyte transformation test 
(LTT) and epicutaneous tests with allopurinol are usually negative. 
We report a case with positive LTT to allopurinol and its metabolite, 
oxypurinol.
Materials and methods: A 37-year-old female attended the emer-
gency room complaining of asthenia, cough, and generalized 
edema. She had a history chronic renal insufficiency stage 4 sec-
ondary to focal segmental glomerulosclerosis, high blood pressure 
and migraine. She was admitted with respiratory infection, acute 
kidney injury, and desquamative skin lesions that had appeared 
20  days before. Initially she had erythema and face swelling, diffi-
culty swallowing, painful papular lesions on face, scalp and upper 
trunk, abdomen and thighs. She had been treated with antihista-
mines, topical and systemic low dose corticosteroids with clinical 
improvement. She was on treatment with omeprazole, valsartan, 
prednisone, acetazolamide, allopurinol and ezetimibe/simvastatin. 
DRESS was suspected. A team of specialists (dermatologist, aller-
gologist, pharmacologist, nephrologist) evaluated the patient. 
Laboratory tests and herpes virus serology were performed. After 
discharge she was evaluated on Allergy Unit. LTT was performed 
2 months later according to Pichler et al. LTT is positive if stimula-
tion index (SI) ≥2
Results: Tests revealed WBC 11,400, 700  eosinophils/mm3 (6.2  %), 
creatinine 4.38 mg/dl (baseline 2.8 mg/dl), CRP 498, GPT 483, GGT 
1264 and hyperamilasemia. Serology was only positive for herpes 
6(1/320). According to Kardaun score, “probable” DRESS diagno-
sis was established (four points). She was included in Piel en Red 
Registry. Causality assessment according the Spanish Pharmacovig-
ilance System Algorithm (SFEV) results were: allopurinol +7(prob-
able) and Conditional (Unrelated) the other drugs.  Allopurinol 
treatment was stopped. She received a bolus of metylprednisolone 
intravenously three consecutive days, antihistamines and antibiot-
ics with improvement. She was discharged 15 days later with corti-
costeroid treatment (reducing dose) during 14  weeks. Patch tests 
were negative with allopurinol, ezetimibe and simvastatine. LTT 
was positive to allopurinol and to its metabolite oxypurinol at dif-
ferent concentrations with the highest stimulation index for oxypu-
rinol (SI 14.84)
Conclusions: We report a case of DRESS by allopurinol in which the 
diagnosis was difficult to establish. LTT has been useful to identify the 
etiological agent.
Keywords: DRESS; Allopurinol; Oxypurinol; LTT
Consent: Written informed consent was obtained from the patient for 
publication of this abstract and any accompanying images.
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Background: Drug reaction with eosinophylia and systemic symp-
toms (DRESS) is a severe potentially life-threatening drug hypersensi-
tivity reaction with delayed onset (2–8 weeks after beginning a drug 
intake). It is characterized by rash, fever, blood abnormalities and/
or internal organ involvement. Most frequently implicated drugs in 
DRESS are anti-epileptic drugs. We present a case of DRESS induced by 
carbamzepine and paracetamol simultaneously.
Report: A 84 year-old Caucasian woman with no previous drug hyper-
sensitivity history, complained of generalized maculopapular itchy 
purplish rash (trunk, abdomen, upper and lower extremities), peeling 
skin, fever and general weakness. A month before she was diagnosed 
of trigeminal neuralgia and started a treatment with pregabalin, car-
bamazepine and paracetamol. Previously the patient had used par-
acetamol without adverse reactions. Pregabalin and carbamazepine 
were used for the first time. Symptoms disappeared when the three 
drugs were interrupted and oral corticoid treatment was established.
Peripheral blood test was done when patient was symptomatic. Skin 
patch test and lymphocyte activation test (LAT)with paracetamol, car-
bamazepine and pregabalin were performed 4 weeks after complete 
recovering. In blood test was observed eosinophylia (1000/mm3) and 
leucocytosis (>11,000/mm3).  Kidney  and liver function  were normal. 
Skin patch test (interpretation in 48 and 96 h) and lymphocyte activa-
tion test were positive to paracetamol and carbamazepine, and nega-
tive to pregabalin.
Pregabalin treatment was continued without adverse reactions. A 
few months later our patient took a pill of paracetamol and experi-
enced eosinophylia and maculopapular rush in abdomen and lower 
extremities.
How this report contributes to current knowledge: DRESS is a 
type IV drug hypersensitivity reaction and is commonly induced by 
aromatic anticonvulsants as carbamazepine. Nevertheless any drug 
intake could induce this severe reaction, including “innocuous” drugs 
as paracetamol. The allergy work-out should be carried out 4–6 weeks 
after the complete recovering and should include all involved drugs.
Consent: Written informed consent was obtained from the patient for 
publication of this abstract and any accompanying images.
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Background: Drug reaction with eosinophilia and systemic symp-
toms (DRESS) is a severe drug-induced reaction that involves both 
skin and viscera. Antiepileptic agents, allopurinol and sulfonamides 
are the most frequently reported causes. Other causal factors such as 
drug metabolites, genetic factors and viral infections have been also 
reported.
Report: 31-year-old female was admitted to the hospital for the treat-
ment of multidrug-resistant pulmonary tuberculosis. She was treated 
with second-line antituberculosis drugs: moxifloxacin, kanamycin, 
cycloserine, prothionamide, para-aminosalicylic acid. After 3  weeks 
of therapy she developed high fever (>39  °C), lymphadenopathy in 
the cervical and axillary regions and pruritic maculopapular eruption 
all over the body. Hematologic abnormalities such as leukocytosis 
with eosinophilia (1.81 ×  109/l) and monocytosis (1.85 ×  109/l) were 
detected in peripheral blood of the patient. Hepatitis was asymp-
tomatic and detected using the liver function tests: serum aspartate 
aminotransferase (AST 1379  IU/l) and alanine aminotransferase (ALT 
1221  IU/l) levels were increased by approximately 30–40-fold above 
the normal limits. The positive diagnosis of Epstein–Barr infection 
was based on an increase in the anti Epstein–Barr immunoglobulin G 
titer, implicating an Epstein–Barr virus reactivation. Based on the clinic 
and laboratory findings diagnosis of DRESS was suspected, and all the 
drugs were discontinued. Patient’s condition improved after 8 weeks. 
The skin patch tests with moxifloxacin, kanamycin, cycloserine, pro-
thionamide and para-aminosalicylic acid were done 2  months after 
the hypersensitivity syndrome resolved. The patch tests showed a pos-
itive reaction to prothionamide and para-aminosalicylic acid.
How this report contributes to current knowledge: This case reports 
the development of DRESS caused by late type of hypersensitivity to 
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second-line antituberculosis drugs (prothionamide and para-amino-
salicylic acid) in association with Epstein–Barr virus infection.
Consent: Written informed consent was obtained from the patient for 
publication of this abstract and any accompanying images.
Poster Walk 10: Miscellaneous drug hypersensitivity (P82–P91)
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Background: LDE (Lichenoid drug eruption) is a rare form of delayed 
type drug eruptions. Among anti-Tb (antituberculosis) drugs, etham-
butol is one of the most common causative drugs to induce LDEs and 
cycloserine has been reported known as a rare causative drug of the 
LDEs.
Report: 38  years old man presented with pururitus, lichenoid skin 
lesion on whole body, and blood eosinophilia (16,824/µl). He had been 
treated with isoniazid, rifampicin, ethambutol, and pyrazinamide for 
2 months and then with ethambutol, levofloxacin, cycloserine for next 
2 months because of elevated liver enzymes. Mild pruritus developed 
at the start of anti-Tb medications and aggravated with develop-
ment of lichenoid skin lesion 1  month ago. Pruritus, skin lesions, and 
eosinophilia were improved since  anti-Tb medications were stopped. 
Patch test showed mild reaction for ethambutol and strong reaction 
for cycloserine. Then we performed an LTT (lymphocyte transformation 
test) and successfully confirmed cycloserine as the offending drug.
How this report contributes to current knowledge: This suggests 
that the cycloserine should be considered as a possible causative drug 
of LDE and an LTT could be an option for the diagnosis of lichenoid 
drug eruption due to cycloserine.
Consent: Written informed consent was obtained from the patient for 
publication of this abstract and any accompanying images.
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Background: Ophthalmic products are widely used and long-term 
application is frequently needed. This might lead to ocular surface 
changes and increase the frequency of adverse reactions. However, 
the underlying mechanisms and the causal agent are usually difficult 
to ascertain. We aimed to evaluate the patients referred to our drug 
allergy unit with suspected hypersensitivity reaction to topical eye 
drops.
Materials and methods: A cross-sectional, retrospective analysis of 
the clinical files of all patients studied in the Drug Allergy Unit of a Uni-
versity Hospital, in the last 5 years (January 2010 to December 2015) 
was made. Those with a suspected hypersensitivity reaction to topical 
eye drops were selected. Demographic, clinical history and diagnostic 
procedures data were collected.
Results: Four patients, two children (2 and 11  years of age) and 
two adults (49 and 72  years), were referred due to a suspicion of 
hypersensitivity reaction to topical eye drops. Both children reacted 
after atropine conjunctival application. The two adults reacted with 
each of the following topical drugs: timolol and moxifloxacin with 
tobramycin. All showed local symptoms of conjunctival erythema 
and ocular/facial edema immediately after drug administration. 
The patient who reacted to timolol presented dyspnea. For diag-
nostic study, the 2-year-old child performed conjunctival provoca-
tion test (CPT) with increasing doses of atropine (1; 5 and 10  mg/
ml), with positive reaction with facial erythema at 10 mg/ml dose; 
the 11-year-old child was submitted to skin prick and intradermal 
tests with atropine, which were negative, and waits for CPT to com-
plete the study. The two adult patients performed only diagnostic 
CPT. The 49-year-old woman, which reacted with timolol, did CPT 
with spirometry control, without a significant change in FEV1 or 
any clinical symptoms; the 72-year-old male performed two sepa-
rate CPT with moxifloxacin and tobramycin, both with negative 
results.
Conclusions: Hypersensitivity reactions to topical eye drops are prob-
ably underreported in our clinical practice. In three out of four patient’s 
hypersensitivity reaction was excluded after diagnostic work-up. Facial 
erythema is a frequent dose-dependent adverse effect to topical atro-
pine, graded conjunctival challenge is important for establishing the 
diagnosis. Awareness should be increased for unneeded avoidance of 
topical eye drops.
Keywords: Drug allergy; Ocular allergy
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Background: Allopurinol, a xanthine oxidase inhibitor, is the most 
widely administered urate lowering drug in the long-term manage-
ment of chronic hyperuricemia and gout. In 2 % of the treated patients 
adverse drug reactions, life-threatening cutaneous and systemic 
symptoms can develop. Human leukocyte antigen (HLA) genes play 
central role in immune reactions. Important association between HLA-
B*5801 allele and allopurinol-induced severe cutaneous adverse drug 
reactions have been reported.
Materials and methods: In the past few years an increase in allopu-
rinol-induced adverse drug reaction have been experienced among 
patients at our clinic (University of Szeged). Therefore we decided to 
investigate the clinical characteristics of these patients.
Results: Between 2002 and 2008, 81 patients were sent to our labo-
ratory center with suspected allopurinol hypersensitivity for Lympho-
cyte Transformation Test (LTT). This number rose to 222 between 2009 
and 2015. LTT was positive in four cases out of the 81 patients and in 
20 cases out of the 222 patients respectively, indicating 4.9 and 9  % 
sensitivity. Of all these patients we were able to obtain a complete 
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clinical history of 35 patients (mean age 68 years), 4 patients in the first 
period and 31 patients in the second period. They presented general-
ized maculopapular exanthems in 37.14 %, drug reaction with eosino-
philia and systemic symptoms in 31.43 %, Stevens–Johnson syndrome 
in 8.57 %, erythema multiforme in 5.71 %, vasculitis in 5.71 %, bullous 
drug exanthems in 2.86 %, toxic epidermal necrolysis in 2.86 %, acute 
generalized exanthematous pustulosis in 2.86  % and erythroderma 
in 2.86 %. The primary indication of the treatment was asymptomatic 
hyperuricemia in 88.6 % of the patients. We concluded that the con-
comitant use of allopurinol and certain diuretics, furosemide and/or 
hydrochlorothiazide in 28 cases of our 35 patients, and impaired renal 
function enhance allopurinol toxicity increasing the risk of adverse 
drug reaction developments. Evaluation of the HLA-B*5801 studies are 
in progress.
Conclusions: Our data show that the use of allopurinol and thus the 
number of the resulting hypersensitivity reactions is increasing. The 
more and more common hypersensitivity reactions may be the result 
of the improper drug prescription, indication and advanced age. 
Based on our results LTT is not sensitive enough in proving allopurinol-
induced adverse drug reactions.
Keywords: Allopurinol; Adverse reactions; Clinical characteristics
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Background: Due to their anti-inflammatory and immunomodula-
tory properties, corticosteroids are highly prescribed. The prevalence 
of hypersensitivity (HS) reactions is estimated at <1 %. The aim of our 
study was to characterize a population of patients referred to our out-
patient clinic for suspected immediate HS to corticosteroids.
Materials and methods: Retrospective analysis including 61 patients 
sent to our Drug Allergy consultation for suspected corticosteroid HS, 
from January 2005 to December 2015. We proceeded to the patients’ 
clinical evaluation and analysis of the results of skin prick (SPT) and 
intradermal tests (IDT) of the following drugs: prednisolone succi-
nate 125 mg/ml, dexamethasone sodium phosphate 5 mg/ml, meth-
ylprednisolone sodium succinate 40  mg/ml, hydrocortisone 100  mg/
ml, betamethasone dipropionate 5  mg/ml. IDT were performed with 
the following dilutions: 1:1000, 1:100 and 1:10. The tests were read at 
20 min, and at 24–48 h.
Results: We analysed 61 patients with suspected immediate HS to cor-
ticosteroids, in which 77 % was female, with a median age of 47 years. 
Twelve patients had positive tests results (19  %). The population 
with positive results was mainly female, 58  %, with a median age of 
39 (± 16 years). Half of this population had associated atopic disease 
(asthma and/or rhinitis). The clinical manifestations after the drug 
administration were: anaphylactic reactions in 50  %, urticaria and/
or angioedema in 41 % and syncope in 8 %. In these 12 patients we 
obtained 6 % of positive SPT, and 12 % of positive IDT. Thirty percent of 
positive reactions occurred with methylprednisolone, followed by dex-
amethasone (26  %), prednisolone (17  %), hydrocortisone (13  %) and 
betamethasone (13  %). Eight patients (66  %) presented HS to more 
than one corticosteroid.
Conclusions: We obtained 19 % positive prick and intradermal tests to 
corticosteroids, being anaphylaxis the most common reaction in these 
patients. There was a high frequency of sensitization to methylpredni-
solone and dexamethasone. 66 % of patients had HS to more than one 
corticosteroid, which probably correlates with the presence of cross-
reactivity among these drugs.
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Background: Since sensitization against an allergen is an important 
requirement for the development of anaphylaxis, drug hypersensitiv-
ity reactions are very uncommon in infants. We report on a 12-months 
old boy who experienced a severe anaphylactic reaction during perio-
perative anaesthesia.
Materials and methods: About 5 min after receiving fentanyl, propo-
fol and mivacurium for the induction of anaesthesia, a persistent rush 
was noticed, followed by a fall of blood pressure down to 70/40 mm 
Hg, tachycardia (f  =  150/min) and respiratory distress. Emergency 
treatment was initiated by i.v.-application of epinephrine, after which 
the little boy fully recovered. Two months later he was referred to our 
department for allergological evaluation, including both laboratory 
analysis and skin tests with different drugs.
Results: Total IgE was 25.5  kU/l with no allergen-specific IgE-antibodies 
detectable against pholcodine, latex, egg white and soja, and basal serum 
mast cell tryptase was 2.77 µg/l (Thermo Fisher, Germany). Skin prick tests 
revealed a positive result to mivacurium but showed negative reactions 
against fentanyl, remifentanyl, propofol, rocuronium, and cis-atracurium. 
Thus, diagnosis of drug allergy against mivacurium was  established, 
together with cross-reactive sensitization against another neuromuscular 
blocking agent (NMBA), cis-atracurium. Surgery was rescheduled utilizing 
rocuronium for muscle relaxation, which was well tolerated.
Conclusions: NMBAs are the major cause of perioperative anaphylaxis, 
accounting for about 70  % of all cases, with IgE-antibodies directed 
against quaternary ammonium compounds (QAC). Hypersensitiv-
ity reactions against NMBAs without prior exposure to this drug class 
have been reported previously, suggesting sensitization induced by 
other QAM-containing substances like disinfectants, food or industrial 
materials. However, we are not aware about reports of anaphylaxis 
against NMBAs in  infants of such a young age. Thus, this case under-
lines both the risk of allergic reactions against NMBAs at first exposure 
and the necessity of comprehensively testing these drugs even in very 
small children with the history of perioperative anaphylaxis.
Keywords: Anaphylaxis; Mivacurium; Infant; Anaesthesia
Consent: Written informed consent was obtained from the patient for 
publication of this abstract and any accompanying images.
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Background: Histamine released from mast cells plays a key role in 
the pathogenesis of chronic spontaneous urticaria (CSU). However, 
it is unlikely that histamine alone is the only mediator of the disease. 
From clinical experience we know that H1-antihistamines, even at high 
doses, are ineffective in at least 30 % of patients. Antihistamine hyper-
sensitivity has been reported in the literature but CSU exacerbation by 
multiple antihistamines in the same patient is rare.
Report: A 38-year old female patient presented with a 1-year history 
of recurrent itchy hives. The clinical history was suggestive of CSU. 
She was prescribed various antihistamines including chlorphenamine, 
loratadine, fexofenadine, and cetirizine. The patient noticed significant 
worsening of her urticaria within an hour of taking any antihistamine. 
Her urticaria exacerbations responded well to systemic steroids. The 
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patient was re-challenged with cetirizine when her CSU was in remis-
sion. Within 90  min, she developed generalized itchy wheals which 
lasted several days. A skin biopsy showed typical urticaria with unusual 
prominence of eosinophils suggestive of urticaria with superimposed 
drug reaction (Figure  1). The patient was subsequently challenged 
with oral acrivastine and a similar reaction was observed.
How this report contributes to current knowledge: The underly-
ing mechanism of antihistamine hypersensitivity remains unclear. Our 
patient had a positive oral challenge to multiple antihistamines with at 
least a 90-min delay which suggests that the underlying mechanism is 
likely non-immunological. In one case report it was suggested that, in 
some patients, antihistamines could paradoxically shift the H1 hista-
mine receptor to the active confirmation leading to adverse reactions 
after dosing [*]. Our case highlights the rare possibility of a drug most 
commonly used to treat urticaria acting as the causal agent itself.
*Urticaria induced by antihistamines. González de Olano D, et  al. J 
Investig Allergol Clin Immunol. (2006)
Consent: Written informed consent was obtained from the patient for 
publication of this abstract and any accompanying images.
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Background: New medications such as bisphosphonates and stron-
tium ranelate (a strontium salt of ranelic acid) have been introduced 
in the market for the treatment of osteoporosis and there are few case 
reports of severe cutaneous adverse reactions (SCAR) related to anti-
osteoporotic agents. Therefore, we tried to identify the association 
between anti-osteoporotic agents and cutaneous adverse drug reac-
tion (cADR) and the appropriate selection of alternative drugs.
Materials and methods: We retrospectively analyzed cADRs, includ-
ing maculopapular exanthema (MPE),Stevens–Johnson syndrome 
(SJS), drug rash with eosinophilia and systemic symptoms (DRESS), 
related to use of anti-osteoporotic agents in Taiwan and Hong Kong 
from 2011 to 2015. We analyzed the causative anti-osteoporotic 
agents, clinical characteristics, outcomes and further assessed 
patients’ tolerability to alternative anti-osteoporotic agents after 
the development of anti-osteoporotic agents-related cADRs. We 
also review the literatures of anti-osteoporotic agents-related SCAR 
(Table 2; Fig. 3).
Results: There were 14 cases of anti-osteoporotic agents-related 
cADRs, including 6 SJS, 1 DRESS and 7 MPE. The most common causa-
tive agents were strontium ranelate and bisphosphonates. Strontium 
ranelate was found to be related to most SCAR cases, including six 
SJS and one DRESS. For MPE, there were three cases caused by bis-
phosphonates, three cases caused by strontium ranelate and one 
case caused by teriparatide. There was no mortality and long-term 
sequelae of all SCAR cases. There was no cross hypersensitivity among 
strontium ranelate, bisphosphonates, and denosumab (a monoclonal 
antibody). Patients with strontium ranelate-related cADRs were toler-
ant of alternative bisphosphonates and denosumab. One case of bis-
phosphonate-induced MPE was also tolerant of denosumab.
Conclusions: Most of the anti-osteoporotic agents-related cADRs 
are usually mild. In Asia, strontium ranelate seems to cause more SJS/
TEN than DRESS in comparison with that in Europe. No mortality was 
reported among patient with SCARs. Owing to the structural difference 
in anti-osteoporotic agents, denosumab was well tolerated in patients 
Table 2 Strontium ranelate–induced severe cutaneous 
adverse reactions
Abbreviations: 1SR Strontium ranelate, 2PM OPO postmenopausal osteoporosis, 
3SJS/TEN Stevens–Johnson syndrome/toxic epidermal necrolysis, 4DRESS drug 
rash with eosinophilia and systemic symptoms
*data are n(%) of patients unless otherwise specified
a Eye involvement: corneal ulcer or symblepharon, b Liver involvement: 
twofold increase from normal or baseline levels of serum glutamic oxaloacetic 
transaminase (GOT),glutamic pyruvate transaminase (GPT) or total bilirubin
c Kidney involvement: >1.5-fold elevation of serum creatinine from the normal range
d Eosinophilia: eosinophils count >500/μL
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Region Asia Europe
Case series This study Tan et al. [1]/
Lee et al. [2]
Cacoub et al. 
[3]









OPO PM OPO2 OPO
Patients’ profile
 Ethnicity Chinese Chinese Caucasian
 Gender F (83.3) F (100.0) F (100.0)
 Average age (year) 64.7 69.5 68.7 (in DRESS 
group)
No. of SCARs patients 7 2 52
Phenotype
 SJS/TEN3
  Total case no. 6 (85.7) 2 (100.0) 5 (9.6)
  Average latent period 
(days)
29.2 16 Not men‑
tioned
  Eye involvementa 1 (16.7) 1 (50) Not men‑
tioned
  Orogenital involvement 5 (83.3) 2 (100.0) Not men‑
tioned
 DRESS4
  Total case No. 1 (14.3) 0 47(90.4)
  Average latent period 
(days)
90.0 0 33.5
  Liver involvementb 0 (0) 0 (0) 37 (79.0)
  Kidney involvementc 0 (0) 0 (0) 12 (25.0)
  Eosinophiliad 1 (100.0) 0 (0) 43 (91.0)






Mortality rate 0 % 0 % 8.5 % (in 
DRESS 
group)
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allergic to either strontium ranelate or bisphosphonates as alternative 
drug.
Keywords: Severe cutaneous adverse reactions; Anti-osteoporotic 
agents; Bisphosphonates; Strontium ranelate; Denosumab
Consent: Written informed consent was obtained from the patient for 
publication of this abstract and any accompanying images.
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Background: Hypersensitivity reactions (HSR) to corticosteroids (CS) 
are rare although there are a growing number of reports both to sys-
temic and topical CS. There are no standardized procedures for diag-
nostic skin testing with these drugs but a panel is recommended to 
assess cross-reactivity between steroids. Incremental drug challenge is 
still necessary for diagnostic or tolerance assessment purposes, but in 
this point safety issues may overcome.
Materials and methods: Retrospective analysis of consecutive 
patients evaluated in our Drug Allergy Unit for suspected CS HSR, dur-
ing a 5-years-period. Skin prick tests (SPT) and intradermal tests (IDT) 
were performed with commercially available sterile CS formulations—
betamethasone (7  mg/ml), budesonide (0.5  mg/ml), dexamethasone 
(4 mg/ml), hydrocortisone (100 mg/ml), methylprednisolone (62.5 mg/
ml) and/or prednisolone (25  mg/ml). Oral solution of deflazacort 
(22.75  mg/ml) and nasal-spray suspension of fluticasone (27.5  μg/
dose) were also used for SPT. Patch tests (PT) with a standard and/or 
complementary CS series were performed. Drug challenges (DC) used 
a selected-CS dose ranging between approximately 0.5 and 1.5  mg/
kg/day.
Results: A total of 31 patients were assessed (74.2  % females, 
mean  ±  SDage 36.8  ±  23.2  years) for suspected CS HSR. The main 
implicated CS were oral deflazacort (n = 11) and oral betamethasone 
(n = 5). 45.2 % had immediate reactions and 38.2 % late-onset symp-
toms; 51.6  % presented skin/mucosal manifestations. IDT were per-
formed in 12 patients and were positive to at least one of the tested 
drugs in four (two with anaphylaxis and two with late-onset skin/
mucosal involvement); two patients tested positively in IDT for more 
than one CS (dexamethasone/hydrocortisone and methylpredniso-
lone/hydrocortisone). IDT were also performed in non-atopic controls. 
Patch tests in 10 patients revealed positive results (including the sus-
pected CS) in two of them. DC was undertaken with the suspected sys-
temic CS in eight patients (no positive challenges and two doubtful); 
the remaining patients were tested for an alternative CS.
Conclusions: Proper validated skin tests may provide the necessary 
diagnostic evidence in drug allergy. They are particularly useful in 
more severe index reactions when re-challenging is not an option. 
The accuracy of skin tests needs to be further established with larger 
studies.
Keywords: Drug hypersensitivity; Corticosteroids; Skin tests
Fig. 3 Clinical presentations of strontium ranelate‑induced severe 
cutaneour adverse drug reactions. A case of Stevens–Johnson 
syndrome (SJS) had necrotic erosive lesions on the lips and scattered 
dusky red macules over the face and neck (a), and close up view of 
the nape and back with dusky macules/patches and some necrotic 
epidermal detachment (b). Another case of drug reaction with 
eosinophilia and systems symptom presented with facial edema (c), 
and extensive confluent infiltrative erythematous eruption dissemi‑
nated to the truck (d)
